{"matching_results": 33072, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1466, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1267}, {"key": "negative", "matching_results": 186}, {"key": "neutral", "matching_results": 13}]}]}, {"key": "tickerreport.com", "matching_results": 800, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 719}, {"key": "negative", "matching_results": 81}]}]}, {"key": "freelancer.com.co", "matching_results": 778, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 720}, {"key": "negative", "matching_results": 45}, {"key": "neutral", "matching_results": 11}]}]}, {"key": "watchlistnews.com", "matching_results": 762, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 687}, {"key": "negative", "matching_results": 74}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 732, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 658}, {"key": "negative", "matching_results": 73}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 725, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 649}, {"key": "negative", "matching_results": 76}]}]}, {"key": "zolmax.com", "matching_results": 675, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 602}, {"key": "negative", "matching_results": 72}]}]}, {"key": "dailypolitical.com", "matching_results": 601, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 523}, {"key": "negative", "matching_results": 77}]}]}, {"key": "marketscreener.com", "matching_results": 515, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 357}, {"key": "negative", "matching_results": 155}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "theolympiareport.com", "matching_results": 505, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 454}, {"key": "negative", "matching_results": 51}]}]}]}], "results": [{"id": "qSW2jWPPjRqzNcpJCie36BydKCUgLzyLskxuwnDwR9KDbKB1nSxsqWX2J7cn0xw7", "result_metadata": {"score": 39.198093}, "author": "seekingalpha.com", "enriched_title": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.265197, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.251104, "label": "/science/medicine/oncology"}, {"score": 0.210378, "label": "/business and industrial"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.974029}, {"text": "Earnings Call Slides", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.717517}, {"text": "Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362716}, {"text": "Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342977}, {"text": "OTCMKTS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339584}, {"text": "TKPHF", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338736}]}, "crawl_date": "2018-10-31T16:26:27Z", "url": "https://seekingalpha.com/article/4216461-takeda-pharmaceutical-co-ltd-2019-q2-results-earnings-call-slides", "host": "seekingalpha.com", "text": "The following slide deck was published by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings call. 1 29 Click to enlarge Notes:", "main_image_url": "https://static3.seekingalpha.com/uploads/sa_presentations/225/35225/slides/1.jpg?0", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-10-31T12:21:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.964752, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "The following slide deck", "keywords": [{"text": "following slide deck"}]}, "sentence": "The following slide deck was published by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings call.", "object": {"text": "published by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings call", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "Q2 earnings"}, {"text": "conjunction"}, {"text": "Ltd."}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings call", "keywords": [{"text": "Takeda Pharmaceutical Co."}, {"text": "Q2 earnings"}, {"text": "conjunction"}, {"text": "Ltd."}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "The following slide deck was published by Takeda Pharmaceutical Co., Ltd. in conjunction with their 2019 Q2 earnings call.", "object": {"text": "The following slide deck", "keywords": [{"text": "following slide deck"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "was published", "normalized": "be publish"}}], "concepts": [{"text": "English-language films", "relevance": 0.912416, "dbpedia_resource": "http://dbpedia.org/resource/English-language_films"}], "categories": [{"score": 0.707135, "label": "/technology and computing/hardware/computer/portable computer/laptop"}, {"score": 0.115394, "label": "/business and industrial"}, {"score": 0.098988, "label": "/technology and computing/consumer electronics/tv and video equipment/projectors"}], "relations": [], "keywords": [{"text": "following slide deck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.934205}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.849618}, {"text": "Q2 earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.712433}, {"text": "conjunction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.328363}, {"text": "Click", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302836}, {"text": "Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235328}, {"text": "Notes", "sentiment": {"score": 0.439857, "label": "positive"}, "relevance": 0.233318}]}, "extracted_metadata": {"sha1": "4b7f86b87f053e40a7622bec571fca53f63f2d2f", "filename": "1541003187383.zip-e105fe6c374ac453e25418fb9e63be35.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical Co., Ltd. 2019 Q2 - Results - Earnings Call Slides - Takeda Pharmaceutical Co., Ltd. (OTCMKTS:TKPHF)", "forum_title": "All Articles on Seeking Alpha"}, {"id": "yigX6TcvfaiRGSiYBun6f34WEaBctEVV1_V8fGYUXAuPdNBCM7cPLPSKkYQ-kDFU", "result_metadata": {"score": 35.87497}, "author": "Bloomberg News", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.617536, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Here"}, "sentence": "Here's What to Watch in European Stocks This Morning", "object": {"text": "What to Watch"}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}], "concepts": [], "categories": [{"score": 0.99999, "label": "/finance/investing/stocks"}], "relations": [], "keywords": [{"text": "European Stocks", "sentiment": {"score": 0.617536, "label": "positive"}, "relevance": 0.971122}, {"text": "Morning", "sentiment": {"score": 0.617536, "label": "positive"}, "relevance": 0.796729}]}, "crawl_date": "2018-11-01T09:18:43Z", "url": "https://www.bnn.ca/here-s-what-to-watch-in-european-stocks-this-morning-1.1161501", "host": "bnn.ca", "text": "At midday in London, investors in Japan\u2019s Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "main_image_url": "https://www.bnnbloomberg.ca/img/tsn/logos/tsn-logo.png", "country": "CA", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T00:00:00-05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.470771, "label": "negative"}, "text": "Turkey", "relevance": 0.929616, "type": "Location", "disambiguation": {"subtype": ["Brand", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}, {"count": 3, "sentiment": {"score": -0.305291, "label": "negative"}, "text": "London", "relevance": 0.710239, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 3, "sentiment": {"score": -0.402367, "label": "negative"}, "text": "U.K.", "relevance": 0.610451, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 2, "sentiment": {"score": -0.499443, "label": "negative"}, "text": "Swiss Re", "relevance": 0.601738, "type": "Company", "disambiguation": {"subtype": [], "name": "Swiss Re", "dbpedia_resource": "http://dbpedia.org/resource/Swiss_Re"}}, {"count": 2, "sentiment": {"score": -0.285592, "label": "negative"}, "text": "producer", "relevance": 0.567467, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.285592, "label": "negative"}, "text": "Smith & Nephew Plc", "relevance": 0.560191, "type": "Company", "disambiguation": {"subtype": [], "name": "Smith & Nephew", "dbpedia_resource": "http://dbpedia.org/resource/Smith_&_Nephew"}}, {"count": 2, "sentiment": {"score": 0.36346, "label": "positive"}, "text": "U.S.", "relevance": 0.553378, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.75105, "label": "positive"}, "text": "Europe", "relevance": 0.539285, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk A/S", "relevance": 0.519469, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bloomberg", "relevance": 0.51538, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.285592, "label": "negative"}, "text": "Indivior Plc", "relevance": 0.497796, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.499443, "label": "negative"}, "text": "RSA Insurance Group Plc", "relevance": 0.497192, "type": "Company", "disambiguation": {"subtype": [], "name": "RSA Insurance Group", "dbpedia_resource": "http://dbpedia.org/resource/RSA_Insurance_Group"}}, {"count": 1, "sentiment": {"score": -0.370187, "label": "negative"}, "text": "Shire Plc", "relevance": 0.49199, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BBVA", "relevance": 0.488828, "type": "Company", "disambiguation": {"subtype": [], "name": "Banco Bilbao Vizcaya Argentaria", "dbpedia_resource": "http://dbpedia.org/resource/Banco_Bilbao_Vizcaya_Argentaria"}}, {"count": 1, "sentiment": {"score": -0.521685, "label": "negative"}, "text": "Jamal Khashoggi", "relevance": 0.486503, "type": "Person", "disambiguation": {"subtype": [], "name": "Jamal Khashoggi", "dbpedia_resource": "http://dbpedia.org/resource/Jamal_Khashoggi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Coloplast A/S", "relevance": 0.475805, "type": "Company", "disambiguation": {"subtype": [], "name": "Coloplast", "dbpedia_resource": "http://dbpedia.org/resource/Coloplast"}}, {"count": 1, "sentiment": {"score": -0.521685, "label": "negative"}, "text": "Istanbul", "relevance": 0.474235, "type": "Location", "disambiguation": {"subtype": ["OlympicBiddingCity", "City"], "name": "Istanbul", "dbpedia_resource": "http://dbpedia.org/resource/Istanbul"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bank of England", "relevance": 0.469003, "type": "Company", "disambiguation": {"subtype": ["Location", "Invention"], "name": "Bank of England", "dbpedia_resource": "http://dbpedia.org/resource/Bank_of_England"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Renault SA", "relevance": 0.466907, "type": "Company", "disambiguation": {"subtype": ["AutomobileCompany", "AwardWinner"], "name": "Renault", "dbpedia_resource": "http://dbpedia.org/resource/Renault"}}, {"count": 1, "sentiment": {"score": 0.36346, "label": "positive"}, "text": "President Donald Trump", "relevance": 0.465269, "type": "Person", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}, {"count": 1, "sentiment": {"score": 0.321616, "label": "positive"}, "text": "Beth Mellor", "relevance": 0.459888, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SSAB AB", "relevance": 0.45427, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lancashire", "relevance": 0.447207, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.438458, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.437491, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "telecoms", "relevance": 0.435346, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ArcelorMittal", "relevance": 0.434022, "type": "Company", "disambiguation": {"subtype": [], "name": "ArcelorMittal", "dbpedia_resource": "http://dbpedia.org/resource/ArcelorMittal"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American International Group Inc.", "relevance": 0.433876, "type": "Company", "disambiguation": {"subtype": [], "name": "American International Group", "dbpedia_resource": "http://dbpedia.org/resource/American_International_Group"}}, {"count": 1, "sentiment": {"score": -0.370187, "label": "negative"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.432867, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.479615, "label": "positive"}, "text": "Sterling", "relevance": 0.432245, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Telia Co.", "relevance": 0.428762, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tom Lavell", "relevance": 0.422644, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "reporter", "relevance": 0.421529, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Joe Easton", "relevance": 0.419754, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denmark", "relevance": 0.419415, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.499443, "label": "negative"}, "text": "Lancashire Holdings Ltd", "relevance": 0.418527, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.439548, "label": "positive"}, "text": "Brexit", "relevance": 0.416788, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": -0.521685, "label": "negative"}, "text": "Saudi Arabia", "relevance": 0.405638, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.370187, "label": "negative"}, "text": "Japan", "relevance": 0.398091, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.376882, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.305291, "label": "negative"}, "text": "The Times", "relevance": 0.329436, "type": "PrintMedia", "disambiguation": {"subtype": ["AwardPresentingOrganization", "Newspaper"], "name": "The Times", "dbpedia_resource": "http://dbpedia.org/resource/The_Times"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "jeaston7@bloomberg.net", "relevance": 0.329436, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bmellor@bloomberg.net", "relevance": 0.329436, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.329436, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "nine months", "relevance": 0.329436, "type": "Quantity"}], "sentiment": {"document": {"score": -0.153408, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "what we are watching"}, "sentence": " Here\u2019s what we are watching ahead of the market open in Europe:", "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "we"}, "sentence": " Here\u2019s what we are watching ahead of the market open in Europe:", "object": {"text": "watching ahead of the market open in Europe", "keywords": [{"text": "market"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Here\u2019s what we are watching ahead of the market open in Europe:", "action": {"verb": {"text": "watch", "tense": "present"}, "text": "are watching", "normalized": "be watch"}}, {"subject": {"text": "Turkey", "keywords": [{"text": "Turkey"}], "entities": [{"type": "Location", "text": "Turkey", "disambiguation": {"subtype": ["Brand", "Country", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}]}, "sentence": " Turkey\u2019s Priorities", "object": {"text": "Priorities", "keywords": [{"text": "Priorities"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Turkey", "keywords": [{"text": "Turkey"}], "entities": [{"type": "Location", "text": "Turkey", "disambiguation": {"subtype": ["Brand", "Country", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}]}, "sentence": " Turkey didn\u2019t stay out of the spotlight for long.", "object": {"text": "n\u2019t", "keywords": [{"text": "n\u2019t"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "The government", "keywords": [{"text": "government"}]}, "sentence": " The government reignited fears that it\u2019s prioritizing growth over controlling its surging inflation, after announcing a wide range of new tax cuts.", "object": {"text": "fears that it\u2019s prioritizing growth over controlling its surging inflation", "keywords": [{"text": "fears"}, {"text": "inflation"}, {"text": "growth"}]}, "action": {"verb": {"text": "reignite", "tense": "past"}, "text": "reignited", "normalized": "reignite"}}, {"subject": {"text": "it"}, "sentence": " The government reignited fears that it\u2019s prioritizing growth over controlling its surging inflation, after announcing a wide range of new tax cuts.", "object": {"text": "prioritizing growth over controlling its surging inflation", "keywords": [{"text": "inflation"}, {"text": "growth"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "The government", "keywords": [{"text": "government"}]}, "sentence": " The government reignited fears that it\u2019s prioritizing growth over controlling its surging inflation, after announcing a wide range of new tax cuts.", "object": {"text": "a wide range of new tax cuts", "keywords": [{"text": "new tax cuts"}, {"text": "wide range"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announcing", "normalized": "announce"}}, {"subject": {"text": "the nation", "keywords": [{"text": "nation"}]}, "sentence": " The lira slumped and the nation\u2019s bonds dropped.", "object": {"text": "bonds", "keywords": [{"text": "bonds"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The European stocks", "keywords": [{"text": "European stocks"}]}, "sentence": " The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday.", "object": {"text": "to Turkey", "keywords": [{"text": "Turkey"}], "entities": [{"type": "Location", "text": "Turkey", "disambiguation": {"subtype": ["Brand", "Country", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}]}, "action": {"verb": {"text": "expose", "tense": "past"}, "text": "most exposed", "normalized": "most expose"}}, {"subject": {"text": "The European stocks most exposed to Turkey", "keywords": [{"text": "European stocks"}, {"text": "Turkey"}], "entities": [{"type": "Location", "text": "Turkey", "disambiguation": {"subtype": ["Brand", "Country", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}]}, "sentence": " The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday.", "object": {"text": "at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday", "keywords": [{"text": "Spanish lender BBVA"}, {"text": "Tuesday"}, {"text": "crisis"}, {"text": "cost"}], "entities": [{"type": "Company", "text": "BBVA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Banco Bilbao Vizcaya Argentaria", "dbpedia_resource": "http://dbpedia.org/resource/Banco_Bilbao_Vizcaya_Argentaria"}}]}, "action": {"verb": {"text": "fall", "tense": "future"}, "text": "could fall", "normalized": "could fall"}}, {"subject": {"text": "BBVA", "keywords": [{"text": "BBVA"}], "entities": [{"type": "Company", "text": "BBVA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Banco Bilbao Vizcaya Argentaria", "dbpedia_resource": "http://dbpedia.org/resource/Banco_Bilbao_Vizcaya_Argentaria"}}]}, "sentence": " The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday.", "object": {"text": "the cost of the crisis", "keywords": [{"text": "crisis"}, {"text": "cost"}]}, "action": {"verb": {"text": "count", "tense": "past"}, "text": "was counting", "normalized": "be count"}}, {"subject": {"text": "Sterling", "keywords": [{"text": "Sterling"}], "entities": [{"type": "Person", "text": "Sterling"}]}, "sentence": " Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials\u2019 announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "action": {"verb": {"text": "surge", "tense": "past"}, "text": "surged", "normalized": "surge"}}, {"subject": {"text": "Sterling", "keywords": [{"text": "Sterling"}], "entities": [{"type": "Person", "text": "Sterling"}]}, "sentence": " Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials\u2019 announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "action": {"verb": {"text": "rally", "tense": "present"}, "text": "rallying", "normalized": "rally"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}]}, "sentence": " Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials\u2019 announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "object": {"text": "done"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}]}, "sentence": " Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials\u2019 announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "action": {"verb": {"text": "do", "tense": "future"}, "text": "will be done", "normalized": "will be do"}}, {"subject": {"text": "The latest jump in the currency", "keywords": [{"text": "latest jump"}, {"text": "currency"}]}, "sentence": " The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks\u2019 access to EU markets and data post-Brexit.", "object": {"text": "a report from The Times of London", "keywords": [{"text": "report"}, {"text": "Times"}, {"text": "London"}], "entities": [{"type": "PrintMedia", "text": "The Times", "disambiguation": {"subtype": ["AwardPresentingOrganization", "Newspaper"], "name": "The Times", "dbpedia_resource": "http://dbpedia.org/resource/The_Times"}}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "an agreement", "keywords": [{"text": "agreement"}]}, "sentence": " The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks\u2019 access to EU markets and data post-Brexit.", "object": {"text": "to maintain U.K. banks\u2019 access to EU markets and data post-Brexit", "keywords": [{"text": "EU markets"}, {"text": "data post-Brexit"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "strike", "tense": "past"}, "text": "struck", "normalized": "strike"}}, {"subject": {"text": "an agreement", "keywords": [{"text": "agreement"}]}, "sentence": " The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks\u2019 access to EU markets and data post-Brexit.", "object": {"text": "U.K. banks\u2019 access to EU markets and data post-Brexit", "keywords": [{"text": "EU markets"}, {"text": "data post-Brexit"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "maintain", "tense": "past"}, "text": "had been struck to maintain", "normalized": "have be strike to maintain"}}, {"subject": {"text": "A stronger currency", "keywords": [{"text": "stronger currency"}]}, "sentence": " A stronger currency is potentially bad news for a whole raft of dollar earners in the FTSE 100 benchmark this morning, although investors will also contemplate the benefits that a more straightforward divorce could have on British firms\u2019 international trading capabilities.", "object": {"text": "potentially bad news for a whole raft of dollar earners in the FTSE 100 benchmark this morning", "keywords": [{"text": "potentially bad news"}, {"text": "dollar earners"}, {"text": "FTSE"}, {"text": "raft"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " A stronger currency is potentially bad news for a whole raft of dollar earners in the FTSE 100 benchmark this morning, although investors will also contemplate the benefits that a more straightforward divorce could have on British firms\u2019 international trading capabilities.", "object": {"text": "the benefits that a more straightforward divorce could have on British firms\u2019 international trading capabilities", "keywords": [{"text": "straightforward divorce"}, {"text": "international trading capabilities"}, {"text": "British firms"}, {"text": "benefits"}]}, "action": {"verb": {"text": "contemplate", "tense": "future"}, "text": "will also contemplate", "normalized": "will also contemplate"}}, {"subject": {"text": "Note", "keywords": [{"text": "Note"}]}, "sentence": " Note that today is also Bank of England rate-decision day.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "insurers", "keywords": [{"text": "insurers"}]}, "sentence": " When disaster strikes, insurers invariably foot the bill.", "object": {"text": "the bill"}, "action": {"verb": {"text": "foot", "tense": "present"}, "text": "foot", "normalized": "foot"}}, {"subject": {"text": "The non-life sector", "keywords": [{"text": "non-life sector"}]}, "sentence": " The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months.", "object": {"text": "a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc", "keywords": [{"text": "Zurich-based sector heavyweight"}, {"text": "RSA Insurance Group"}, {"text": "Lancashire Holdings"}, {"text": "Plc"}], "entities": [{"type": "Company", "text": "Swiss Re", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Swiss Re", "dbpedia_resource": "http://dbpedia.org/resource/Swiss_Re"}}, {"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Company", "text": "Lancashire Holdings Ltd"}, {"type": "Company", "text": "RSA Insurance Group Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "RSA Insurance Group", "dbpedia_resource": "http://dbpedia.org/resource/RSA_Insurance_Group"}}]}, "action": {"verb": {"text": "endure", "tense": "past"}, "text": "endured", "normalized": "endure"}}, {"subject": {"text": "the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc", "keywords": [{"text": "RSA Insurance Group"}, {"text": "Lancashire Holdings"}, {"text": "Plc"}, {"text": "U.K."}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Company", "text": "Lancashire Holdings Ltd"}, {"type": "Company", "text": "RSA Insurance Group Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "RSA Insurance Group", "dbpedia_resource": "http://dbpedia.org/resource/RSA_Insurance_Group"}}]}, "sentence": " The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months.", "object": {"text": "profit warnings", "keywords": [{"text": "profit warnings"}]}, "action": {"verb": {"text": "release", "tense": "present"}, "text": "releasing", "normalized": "release"}}, {"subject": {"text": "the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings", "keywords": [{"text": "RSA Insurance Group"}, {"text": "Lancashire Holdings"}, {"text": "profit warnings"}, {"text": "Plc"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Company", "text": "Lancashire Holdings Ltd"}, {"type": "Company", "text": "RSA Insurance Group Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "RSA Insurance Group", "dbpedia_resource": "http://dbpedia.org/resource/RSA_Insurance_Group"}}]}, "sentence": " The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months.", "object": {"text": "on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months", "keywords": [{"text": "extreme weather conditions"}, {"text": "natural catastrophes"}, {"text": "globe"}]}, "action": {"verb": {"text": "blame", "tense": "past"}, "text": "blamed", "normalized": "blame"}}, {"subject": {"text": "extreme weather conditions", "keywords": [{"text": "extreme weather conditions"}]}, "sentence": " The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.\u2019s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months.", "action": {"verb": {"text": "see", "tense": "past"}, "text": "seen", "normalized": "see"}}, {"subject": {"text": "U.S. provider American International Group Inc.", "keywords": [{"text": "U.S. provider American"}, {"text": "International Group"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "American International Group Inc.", "disambiguation": {"subtype": ["Company"], "name": "American International Group", "dbpedia_resource": "http://dbpedia.org/resource/American_International_Group"}}]}, "sentence": " Last night, U.S. provider American International Group Inc. slipped in after-hours trading after natural disasters weighed on its third quarter, although another update from Swiss Re noted that sector may have now turned a corner for the year.", "action": {"verb": {"text": "slip", "tense": "past"}, "text": "slipped", "normalized": "slip"}}, {"subject": {"text": "natural disasters", "keywords": [{"text": "natural disasters"}]}, "sentence": " Last night, U.S. provider American International Group Inc. slipped in after-hours trading after natural disasters weighed on its third quarter, although another update from Swiss Re noted that sector may have now turned a corner for the year.", "object": {"text": "on its third quarter", "keywords": [{"text": "quarter"}]}, "action": {"verb": {"text": "weigh", "tense": "past"}, "text": "weighed", "normalized": "weigh"}}, {"subject": {"text": "sector", "keywords": [{"text": "sector"}]}, "sentence": " Last night, U.S. provider American International Group Inc. slipped in after-hours trading after natural disasters weighed on its third quarter, although another update from Swiss Re noted that sector may have now turned a corner for the year.", "action": {"verb": {"text": "have", "tense": "future"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "sector", "keywords": [{"text": "sector"}]}, "sentence": " Last night, U.S. provider American International Group Inc. slipped in after-hours trading after natural disasters weighed on its third quarter, although another update from Swiss Re noted that sector may have now turned a corner for the year.", "object": {"text": "a corner", "keywords": [{"text": "corner"}]}, "action": {"verb": {"text": "turn", "tense": "future"}, "text": "turned", "normalized": "turn"}}, {"subject": {"text": "Lancashire", "keywords": [{"text": "Lancashire"}], "entities": [{"type": "Organization", "text": "Lancashire"}]}, "sentence": " Lancashire also gives another update before the open, and its outlook will be eyed by the entire sector.", "object": {"text": "another update", "keywords": [{"text": "update"}]}, "action": {"verb": {"text": "give", "tense": "present"}, "text": "gives", "normalized": "give"}}, {"subject": {"text": "its outlook", "keywords": [{"text": "outlook"}]}, "sentence": " Lancashire also gives another update before the open, and its outlook will be eyed by the entire sector.", "object": {"text": "eyed by the entire sector", "keywords": [{"text": "entire sector"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by the entire sector", "keywords": [{"text": "entire sector"}]}, "sentence": " Lancashire also gives another update before the open, and its outlook will be eyed by the entire sector.", "object": {"text": "its outlook", "keywords": [{"text": "outlook"}]}, "action": {"verb": {"text": "eye", "tense": "future"}, "text": "will be eyed", "normalized": "will be eye"}}, {"subject": {"text": "The world", "keywords": [{"text": "world"}]}, "sentence": " The world\u2019s largest steel producer, Dutch-listed ArcelorMittal reported \u201csignificantly improved\u201d earnings for the first nine months of the year.", "object": {"text": "largest steel producer", "keywords": [{"text": "largest steel producer"}], "entities": [{"type": "JobTitle", "text": "producer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The world\u2019s largest steel producer, Dutch-listed ArcelorMittal", "keywords": [{"text": "largest steel producer"}, {"text": "Dutch-listed ArcelorMittal"}, {"text": "world"}], "entities": [{"type": "JobTitle", "text": "producer"}, {"type": "Company", "text": "ArcelorMittal", "disambiguation": {"subtype": ["Company"], "name": "ArcelorMittal", "dbpedia_resource": "http://dbpedia.org/resource/ArcelorMittal"}}]}, "sentence": " The world\u2019s largest steel producer, Dutch-listed ArcelorMittal reported \u201csignificantly improved\u201d earnings for the first nine months of the year.", "object": {"text": "significantly improved\u201d earnings for the first nine months of the year", "keywords": [{"text": "earnings"}], "entities": [{"type": "Quantity", "text": "nine months"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm is continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China.", "object": {"text": "continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China", "keywords": [{"text": "President Donald Trump"}, {"text": "cheaper imports"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm is continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China.", "object": {"text": "from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China", "keywords": [{"text": "President Donald Trump"}, {"text": "cheaper imports"}, {"text": "tariffs"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "is continuing to benefit", "normalized": "be continue to benefit"}}, {"subject": {"text": "U.S. President Donald Trump", "keywords": [{"text": "U.S. President"}, {"text": "Trump"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}]}, "sentence": " The firm is continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China.", "object": {"text": "tariffs, which have slashed cheaper imports of the metal from countries like China", "keywords": [{"text": "cheaper imports"}, {"text": "tariffs"}, {"text": "metal"}, {"text": "countries"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "U.S. President Donald Trump\u2019s tariffs", "keywords": [{"text": "President Donald Trump"}, {"text": "tariffs"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}]}, "sentence": " The firm is continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China.", "object": {"text": "slashed cheaper imports of the metal from countries like China", "keywords": [{"text": "cheaper imports"}, {"text": "metal"}, {"text": "countries"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "U.S. President Donald Trump\u2019s tariffs", "keywords": [{"text": "President Donald Trump"}, {"text": "tariffs"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Person", "text": "President Donald Trump", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "Celebrity", "CompanyFounder", "TVPersonality", "TVProducer", "FilmActor", "TVActor"], "name": "Donald Trump", "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}}]}, "sentence": " The firm is continuing to benefit from U.S. President Donald Trump\u2019s tariffs, which have slashed cheaper imports of the metal from countries like China.", "object": {"text": "cheaper imports of the metal", "keywords": [{"text": "cheaper imports"}, {"text": "metal"}]}, "action": {"verb": {"text": "slash", "tense": "past"}, "text": "have slashed", "normalized": "have slash"}}, {"subject": {"text": "it"}, "sentence": " \u201cMarket conditions remain favorable,\u201d it said.", "object": {"text": "Market conditions remain favorable", "keywords": [{"text": "Market conditions"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report could be a marker for the entire metals sector this morning, while investors in close peers like Stockholm-traded SSAB AB will have a particular interest.", "object": {"text": "a marker for the entire metals sector", "keywords": [{"text": "entire metals sector"}, {"text": "marker"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "could be", "normalized": "could be"}}, {"subject": {"text": "investors in close peers like Stockholm-traded SSAB AB", "keywords": [{"text": "Stockholm-traded SSAB AB"}, {"text": "close peers"}], "entities": [{"type": "Company", "text": "SSAB AB"}]}, "sentence": " The report could be a marker for the entire metals sector this morning, while investors in close peers like Stockholm-traded SSAB AB will have a particular interest.", "object": {"text": "a particular interest"}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "will have", "normalized": "will have"}}, {"subject": {"text": "probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote", "keywords": [{"text": "Shire Plc"}, {"text": "chance"}, {"text": "update"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " At midday in London, investors in Japan\u2019s Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "action": {"verb": {"text": "have", "tense": "future"}, "text": "will have", "normalized": "will have"}}, {"subject": {"text": "investors in Japan\u2019s Takeda Pharmaceutical Co.", "keywords": [{"text": "Japan\u2019s Takeda"}, {"text": "investors"}, {"text": "Pharmaceutical"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " At midday in London, investors in Japan\u2019s Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "object": {"text": "a scheduled update from Shire Plc", "keywords": [{"text": "Shire Plc"}, {"text": "update"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "digest", "tense": "future"}, "text": "to digest", "normalized": "to digest"}}, {"subject": {"text": "they"}, "sentence": " At midday in London, investors in Japan\u2019s Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "object": {"text": "asked to vote on a $62 billion bid", "keywords": [{"text": "bid"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "are", "tense": "present"}, "text": "are", "normalized": "are"}}, {"subject": {"text": "they"}, "sentence": " At midday in London, investors in Japan\u2019s Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they\u2019re asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "object": {"text": "on a $62 billion bid to buy the Dublin-headquartered firm", "keywords": [{"text": "Dublin-headquartered firm"}, {"text": "bid"}], "entities": [{"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "re asked to vote", "normalized": "re ask to vote"}}, {"subject": {"text": "the world", "keywords": [{"text": "world"}]}, "sentence": " Elsewhere, the world\u2019s largest maker of insulin, Denmark\u2019s Novo Nordisk A/S and ostomy-care firm Coloplast A/S, also update.", "object": {"text": "largest maker of insulin, Denmark\u2019s Novo Nordisk A/S and ostomy-care firm Coloplast A/S,", "keywords": [{"text": "Novo Nordisk A/S"}, {"text": "firm Coloplast A/S"}], "entities": [{"type": "Location", "text": "Denmark", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Company", "text": "Coloplast A/S", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Coloplast", "dbpedia_resource": "http://dbpedia.org/resource/Coloplast"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the world\u2019s largest maker of insulin, Denmark\u2019s Novo Nordisk A/S and ostomy-care firm Coloplast A/S,", "keywords": [{"text": "Novo Nordisk A/S"}, {"text": "firm Coloplast A/S"}, {"text": "largest maker"}, {"text": "insulin"}], "entities": [{"type": "Location", "text": "Denmark", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Company", "text": "Coloplast A/S", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Coloplast", "dbpedia_resource": "http://dbpedia.org/resource/Coloplast"}}]}, "sentence": " Elsewhere, the world\u2019s largest maker of insulin, Denmark\u2019s Novo Nordisk A/S and ostomy-care firm Coloplast A/S, also update.", "action": {"verb": {"text": "update", "tense": "present"}, "text": "update", "normalized": "update"}}], "concepts": [{"text": "FTSE 100 Index", "relevance": 0.944675, "dbpedia_resource": "http://dbpedia.org/resource/FTSE_100_Index"}, {"text": "International trade", "relevance": 0.933431, "dbpedia_resource": "http://dbpedia.org/resource/International_trade"}, {"text": "European Union", "relevance": 0.834607, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Novo Nordisk", "relevance": 0.797796, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Companies listed on the London Stock Exchange", "relevance": 0.733386, "dbpedia_resource": "http://dbpedia.org/resource/Companies_listed_on_the_London_Stock_Exchange"}, {"text": "Disaster", "relevance": 0.720731, "dbpedia_resource": "http://dbpedia.org/resource/Disaster"}, {"text": "Donald Trump", "relevance": 0.704438, "dbpedia_resource": "http://dbpedia.org/resource/Donald_Trump"}, {"text": "Extreme weather", "relevance": 0.698255, "dbpedia_resource": "http://dbpedia.org/resource/Extreme_weather"}, {"text": "When Disaster Strikes", "relevance": 0.671546, "dbpedia_resource": "http://dbpedia.org/resource/When_Disaster_Strikes"}, {"text": "Natural disaster", "relevance": 0.670743, "dbpedia_resource": "http://dbpedia.org/resource/Natural_disaster"}, {"text": "RSA Insurance Group", "relevance": 0.659402, "dbpedia_resource": "http://dbpedia.org/resource/RSA_Insurance_Group"}, {"text": "Saudi Arabia", "relevance": 0.655522, "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}, {"text": "Europe", "relevance": 0.630851, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "Electronic communication network", "relevance": 0.626903, "dbpedia_resource": "http://dbpedia.org/resource/Electronic_communication_network"}], "categories": [{"score": 0.506772, "label": "/finance/investing"}, {"score": 0.506772, "label": "/finance/investing/beginning investing"}, {"score": 0.486459, "label": "/finance/financial news"}], "relations": [{"type": "agentOf", "sentence": "Separately, note that the latest comments from Istanbul on the manner of columnist Jamal Khashoggi's death are likely to keep tensions between the Turkey and Saudi Arabia elevated.", "score": 0.434359, "arguments": [{"text": "Istanbul", "location": [407, 415], "entities": [{"type": "GeopoliticalEntity", "text": "Istanbul"}]}, {"text": "comments", "location": [393, 401], "entities": [{"type": "EventCommunication", "text": "comments"}]}]}, {"type": "agentOf", "sentence": "Cable's Climbing Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "score": 0.78744, "arguments": [{"text": "officials", "location": [917, 926], "entities": [{"type": "Person", "text": "officials"}]}, {"text": "announcement", "location": [928, 940], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOf", "sentence": "Cable's Climbing Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "score": 0.635097, "arguments": [{"text": "announcement", "location": [928, 940], "entities": [{"type": "EventCommunication", "text": "announcement"}]}, {"text": "talks", "location": [969, 974], "entities": [{"type": "EventMeeting", "text": "talks"}]}]}, {"type": "participantIn", "sentence": "Cable's Climbing Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "score": 0.959036, "arguments": [{"text": "their", "location": [956, 961], "entities": [{"type": "Person", "text": "officials"}]}, {"text": "talks", "location": [969, 974], "entities": [{"type": "EventMeeting", "text": "talks"}]}]}, {"type": "agentOf", "sentence": "The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks' access to EU markets and data post-Brexit.", "score": 0.814356, "arguments": [{"text": "The Times of London", "location": [1084, 1103], "entities": [{"type": "Organization", "text": "The Times of London", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "saying", "location": [1104, 1110], "entities": [{"type": "EventCommunication", "text": "saying"}]}]}, {"type": "basedIn", "sentence": "The latest jump in the currency followed a report from The Times of London saying an agreement had been struck to maintain U.K. banks' access to EU markets and data post-Brexit.", "score": 0.973218, "arguments": [{"text": "banks", "location": [1157, 1162], "entities": [{"type": "Organization", "text": "banks", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.K.", "location": [1152, 1156], "entities": [{"type": "GeopoliticalEntity", "text": "U.K.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "A stronger currency is potentially bad news for a whole raft of dollar earners in the FTSE 100 benchmark this morning, although investors will also contemplate the benefits that a more straightforward divorce could have on British firms' international trading capabilities.", "score": 0.979174, "arguments": [{"text": "firms", "location": [1438, 1443], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "British", "location": [1430, 1437], "entities": [{"type": "GeopoliticalEntity", "text": "British", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "The non-life sector endured a torrid October, with Zurich-based sector heavyweight Swiss Re and the U.K.'s Lancashire Holdings Ltd and RSA Insurance Group Plc all releasing profit warnings blamed largely on the natural catastrophes and extreme weather conditions seen across the globe in the spring and summer months.", "score": 0.910008, "arguments": [{"text": "Lancashire Holdings Ltd", "location": [1719, 1742], "entities": [{"type": "Organization", "text": "Lancashire Holdings Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.K.", "location": [1712, 1716], "entities": [{"type": "GeopoliticalEntity", "text": "U.K.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Tariff Winner The world's largest steel producer, Dutch-listed ArcelorMittal reported \"significantly improved\" earnings for the first nine months of the year.", "score": 0.985776, "arguments": [{"text": "ArcelorMittal", "location": [2342, 2355], "entities": [{"type": "Organization", "text": "ArcelorMittal"}]}, {"text": "reported", "location": [2356, 2364], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "managerOf", "sentence": "The firm is continuing to benefit from U.S. President Donald Trump's tariffs, which have slashed cheaper imports of the metal from countries like China.", "score": 0.575339, "arguments": [{"text": "President", "location": [2482, 2491], "entities": [{"type": "Person", "text": "Donald Trump"}]}, {"text": "U.S.", "location": [2477, 2481], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "The firm is continuing to benefit from U.S. President Donald Trump's tariffs, which have slashed cheaper imports of the metal from countries like China.", "score": 0.372264, "arguments": [{"text": "China", "location": [2584, 2589], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [2569, 2578], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday.", "score": 0.465706, "arguments": [{"text": "lender", "location": [624, 630], "entities": [{"type": "Organization", "text": "lender", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Spanish", "location": [616, 623], "entities": [{"type": "GeopoliticalEntity", "text": "Spanish", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "The report could be a marker for the entire metals sector this morning, while investors in close peers like Stockholm-traded SSAB AB will have a particular interest.", "score": 0.595978, "arguments": [{"text": "peers", "location": [2735, 2740], "entities": [{"type": "Person", "text": "peers"}]}, {"text": "SSAB AB", "location": [2763, 2770], "entities": [{"type": "Organization", "text": "SSAB AB"}]}]}, {"type": "basedIn", "sentence": "The report could be a marker for the entire metals sector this morning, while investors in close peers like Stockholm-traded SSAB AB will have a particular interest.", "score": 0.896095, "arguments": [{"text": "SSAB AB", "location": [2763, 2770], "entities": [{"type": "Organization", "text": "SSAB AB"}]}, {"text": "Stockholm", "location": [2746, 2755], "entities": [{"type": "GeopoliticalEntity", "text": "Stockholm"}]}]}, {"type": "locatedAt", "sentence": "At midday in London, investors in Japan's Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they're asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "score": 0.865233, "arguments": [{"text": "investors", "location": [2885, 2894], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Japan", "location": [2898, 2903], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "At midday in London, investors in Japan's Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they're asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "score": 0.943498, "arguments": [{"text": "Takeda Pharmaceutical Co.", "location": [2906, 2931], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [2898, 2903], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "At midday in London, investors in Japan's Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they're asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "score": 0.900586, "arguments": [{"text": "they", "location": [3020, 3024], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "asked", "location": [3028, 3033], "entities": [{"type": "EventCommunication", "text": "asked"}]}]}, {"type": "basedIn", "sentence": "At midday in London, investors in Japan's Takeda Pharmaceutical Co. will have probably their last chance to digest a scheduled update from Shire Plc before they're asked to vote on a $62 billion bid to buy the Dublin-headquartered firm.", "score": 0.929546, "arguments": [{"text": "firm", "location": [3095, 3099], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Dublin", "location": [3074, 3080], "entities": [{"type": "GeopoliticalEntity", "text": "Dublin"}]}]}, {"type": "employedBy", "sentence": "Prior to that, two other London-listed firms -- medical-device producer Smith & Nephew Plc and opioid addiction treatment-maker Indivior Plc -- also update.", "score": 0.402038, "arguments": [{"text": "Smith", "location": [3173, 3178], "entities": [{"type": "Person", "text": "Smith"}]}, {"text": "& Nephew Plc", "location": [3179, 3191], "entities": [{"type": "Organization", "text": "& Nephew Plc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Elsewhere, the world's largest maker of insulin, Denmark's Novo Nordisk A/S and ostomy-care firm Coloplast A/S, also update.", "score": 0.694959, "arguments": [{"text": "maker of", "location": [3289, 3297], "entities": [{"type": "Organization", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "world", "location": [3273, 3278], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Elsewhere, the world's largest maker of insulin, Denmark's Novo Nordisk A/S and ostomy-care firm Coloplast A/S, also update.", "score": 0.757552, "arguments": [{"text": "Novo Nordisk A/S", "location": [3317, 3333], "entities": [{"type": "Organization", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Denmark", "location": [3307, 3314], "entities": [{"type": "GeopoliticalEntity", "text": "Denmark", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Tom Lavell", "score": 0.419341, "arguments": [{"text": "Joe Easton", "location": [3422, 3432], "entities": [{"type": "Person", "text": "Joe Easton"}]}, {"text": "London", "location": [3436, 3442], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "partOf", "sentence": "The European stocks most exposed to Turkey could fall at the open, such as Spanish lender BBVA, which was counting the cost of the crisis on Tuesday.", "score": 0.669083, "arguments": [{"text": "BBVA", "location": [631, 635], "entities": [{"type": "Organization", "text": "BBVA"}]}, {"text": "lender", "location": [624, 630], "entities": [{"type": "Organization", "text": "lender", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Tom Lavell", "score": 0.804447, "arguments": [{"text": "Beth Mellor", "location": [3520, 3531], "entities": [{"type": "Person", "text": "Beth Mellor"}]}, {"text": "editors", "location": [3484, 3491], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Tom Lavell", "score": 0.624365, "arguments": [{"text": "Tom Lavell", "location": [3558, 3568], "entities": [{"type": "Person", "text": "Tom Lavell"}]}, {"text": "editors", "location": [3484, 3491], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "hasAttribute", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors responsible for this story: Beth Mellor at bmellor@bloomberg.net, Tom Lavell", "score": 0.955885, "arguments": [{"text": "Beth Mellor", "location": [3520, 3531], "entities": [{"type": "Person", "text": "Beth Mellor"}]}, {"text": "bmellor@bloomberg.net", "location": [3535, 3556], "entities": [{"type": "Age", "text": "bmellor@bloomberg.net"}]}]}, {"type": "basedIn", "sentence": "Swedish telecoms operator Telia Co. and carmakers like France's Renault SA are also exposed.", "score": 0.522796, "arguments": [{"text": "telecoms operator", "location": [699, 716], "entities": [{"type": "Organization", "text": "Telia Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Swedish", "location": [691, 698], "entities": [{"type": "GeopoliticalEntity", "text": "Swedish", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Swedish telecoms operator Telia Co. and carmakers like France's Renault SA are also exposed.", "score": 0.291971, "arguments": [{"text": "carmakers", "location": [731, 740], "entities": [{"type": "Organization", "text": "carmakers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "France", "location": [746, 752], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Swedish telecoms operator Telia Co. and carmakers like France's Renault SA are also exposed.", "score": 0.412298, "arguments": [{"text": "carmakers", "location": [731, 740], "entities": [{"type": "Organization", "text": "carmakers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Renault SA", "location": [755, 765], "entities": [{"type": "Organization", "text": "Renault SA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Swedish telecoms operator Telia Co. and carmakers like France's Renault SA are also exposed.", "score": 0.51802, "arguments": [{"text": "Renault SA", "location": [755, 765], "entities": [{"type": "Organization", "text": "Renault SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "France", "location": [746, 752], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Cable's Climbing Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "score": 0.868592, "arguments": [{"text": "officials", "location": [917, 926], "entities": [{"type": "Person", "text": "officials"}]}, {"text": "European", "location": [908, 916], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Cable's Climbing Sterling surged again overnight, after rallying into the European close on Wednesday following British and European officials' announcement of progress in their Brexit talks, with the U.K. saying a deal will be done by Nov. 21.", "score": 0.540488, "arguments": [{"text": "European", "location": [908, 916], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "announcement", "location": [928, 940], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}], "keywords": [{"text": "Zurich-based sector heavyweight", "sentiment": {"score": -0.499443, "label": "negative"}, "relevance": 0.927261}, {"text": "Spanish lender BBVA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910703}, {"text": "Insurance Group Plc", "sentiment": {"score": -0.499443, "label": "negative"}, "relevance": 0.910442}, {"text": "operator Telia Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.904589}, {"text": "firm Coloplast A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.904281}, {"text": "columnist Jamal Khashoggi", "sentiment": {"score": -0.521685, "label": "negative"}, "relevance": 0.904207}, {"text": "new tax cuts", "sentiment": {"score": -0.595047, "label": "negative"}, "relevance": 0.903723}, {"text": "treatment-maker Indivior Plc", "sentiment": {"score": -0.285592, "label": "negative"}, "relevance": 0.901347}, {"text": "international trading capabilities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.897434}, {"text": "Novo Nordisk A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.896217}, {"text": "entire metals sector", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.893938}, {"text": "American International Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.891293}, {"text": "Health care earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.889813}, {"text": "largest steel producer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.887277}, {"text": "Stockholm-traded SSAB AB", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.88495}, {"text": "medical-device producer Smith", "sentiment": {"score": -0.285592, "label": "negative"}, "relevance": 0.884851}, {"text": "extreme weather conditions", "sentiment": {"score": -0.499443, "label": "negative"}, "relevance": 0.883961}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": -0.370187, "label": "negative"}, "relevance": 0.883282}, {"text": "President Donald Trump", "sentiment": {"score": 0.36346, "label": "positive"}, "relevance": 0.872077}, {"text": "non-life sector", "sentiment": {"score": -0.671052, "label": "negative"}, "relevance": 0.834311}, {"text": "Good morning", "sentiment": {"score": 0.640766, "label": "positive"}, "relevance": 0.832168}, {"text": "entire sector", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.822364}, {"text": "Nephew Plc", "sentiment": {"score": -0.285592, "label": "negative"}, "relevance": 0.819818}, {"text": "latest comments", "sentiment": {"score": -0.521685, "label": "negative"}, "relevance": 0.812706}, {"text": "European close", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.811477}, {"text": "wide range", "sentiment": {"score": -0.595047, "label": "negative"}, "relevance": 0.811335}, {"text": "London-listed firms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.811295}, {"text": "dollar earners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.810969}, {"text": "after-hours trading", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.810592}, {"text": "Shire Plc", "sentiment": {"score": -0.370187, "label": "negative"}, "relevance": 0.809992}, {"text": "natural catastrophes", "sentiment": {"score": -0.499443, "label": "negative"}, "relevance": 0.809851}, {"text": "European stocks", "sentiment": {"score": -0.376089, "label": "negative"}, "relevance": 0.809575}, {"text": "British firms", "sentiment": {"score": -0.434045, "label": "negative"}, "relevance": 0.809393}, {"text": "U.K.\u2019s Lancashire", "sentiment": {"score": -0.499443, "label": "negative"}, "relevance": 0.808745}, {"text": "European officials", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.808156}, {"text": "stronger currency", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.806646}, {"text": "France\u2019s Renault", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.806526}, {"text": "Saudi Arabia", "sentiment": {"score": -0.521685, "label": "negative"}, "relevance": 0.806293}, {"text": "straightforward divorce", "sentiment": {"score": -0.434045, "label": "negative"}, "relevance": 0.805979}, {"text": "data post-Brexit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.805712}, {"text": "Market conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.805379}, {"text": "latest jump", "sentiment": {"score": -0.305291, "label": "negative"}, "relevance": 0.804746}, {"text": "Big Health", "sentiment": {"score": 0.625727, "label": "positive"}, "relevance": 0.803778}, {"text": "natural disasters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801355}, {"text": "EU markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.801117}, {"text": "Dublin-headquartered firm", "sentiment": {"score": -0.370187, "label": "negative"}, "relevance": 0.800957}, {"text": "Tariff Winner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.80079}, {"text": "largest maker", "sentiment": {"score": -0.338237, "label": "negative"}, "relevance": 0.800609}, {"text": "Brexit talks", "sentiment": {"score": 0.439548, "label": "positive"}, "relevance": 0.799753}]}, "extracted_metadata": {"sha1": "300c38150ba6af14187074f9616bc542e9568d3c", "filename": "1541063923787.zip-cb7f9569de7f7b81a01cfcfe0e19631a.xml", "file_type": "json"}, "title": "Here's What to Watch in European Stocks This Morning", "forum_title": "News Wire"}, {"id": "KG2vSshKGDvHKMEX4ItfFjGI3mY9BYfC7Sj_YATQ4ZIAN1zvKO84_Jt8JDXbDxHm", "result_metadata": {"score": 33.98524}, "author": "Yogesh Sengar", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.872032, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Major depressive disorder", "relevance": 0.949819, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.880267, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}], "categories": [{"score": 0.736964, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.721018, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.121344, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [], "keywords": [{"text": "Major Depressive Disorder", "sentiment": {"score": -0.872032, "label": "negative"}, "relevance": 0.966209}, {"text": "Present Profitable Opportunities", "sentiment": {"score": -0.872032, "label": "negative"}, "relevance": 0.883148}]}, "crawl_date": "2018-11-01T07:32:10Z", "url": "https://www.findmarketresearch.org/2018/09/major-depressive-disorder-market-present-profitable-opportunities-by-2021/", "host": "findmarketresearch.org", "text": "Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-09-26T07:36:00+05:00", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": -0.719536, "label": "negative"}, "text": "depressive disorder", "relevance": 0.900093, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"count": 2, "sentiment": {"score": -0.568224, "label": "negative"}, "text": "North America", "relevance": 0.138998, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.38955, "label": "negative"}, "text": "depression", "relevance": 0.138373, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": -0.850614, "label": "negative"}, "text": "dysthymia", "relevance": 0.138254, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Asia", "relevance": 0.135783, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck A/S", "relevance": 0.122216, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.116159, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc", "relevance": 0.110458, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Aripiprazole", "relevance": 0.108113, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "R&D", "relevance": 0.106888, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.105827, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.10547, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "India", "relevance": 0.105286, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": -0.317828, "label": "negative"}, "text": "Escitalopram", "relevance": 0.105064, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.503696, "label": "negative"}, "text": "U.S.", "relevance": 0.105054, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.104795, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quetiapine", "relevance": 0.103696, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.101143, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Duloxetine", "relevance": 0.0999781, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Venlafaxine", "relevance": 0.0988713, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.0985993, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vilazodone", "relevance": 0.0971947, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Milnacipran", "relevance": 0.0968757, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.654068, "label": "negative"}, "text": "Spain", "relevance": 0.0920238, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company", "relevance": 0.088447, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.0871368, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.0869563, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Euthymics Bioscience, Inc.", "relevance": 0.0857489, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.0853853, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0.244607, "label": "positive"}, "text": "China", "relevance": 0.0847503, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes", "relevance": 0.0820166, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.542704, "label": "negative"}, "text": "Japan", "relevance": 0.0805724, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.0776505, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "25%", "relevance": 0.0776505, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "10%", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "44 years", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12%", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20%", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5%", "relevance": 0.0776505, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0776505, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.67491, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "as major depression and clinical depression", "keywords": [{"text": "major depression"}, {"text": "clinical depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Major depressive disorder, also known as major depression and clinical depression,", "keywords": [{"text": "Major depressive disorder"}, {"text": "clinical depression"}, {"text": "major depression"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder characterized by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "mental disorder"}, {"text": "pleasure"}, {"text": "loss"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by loss of interest and pleasure in enjoyable environment", "keywords": [{"text": "enjoyable environment"}, {"text": "pleasure"}, {"text": "loss"}]}, "sentence": "Major depressive disorder, also known as major depression and clinical depression, is a mental disorder characterized by loss of interest and pleasure in enjoyable environment.", "object": {"text": "a mental disorder", "keywords": [{"text": "mental disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "by major depression", "keywords": [{"text": "major depression"}]}, "sentence": " People are affected in different ways by major depression.", "object": {"text": "People", "keywords": [{"text": "People"}]}, "action": {"verb": {"text": "affect", "tense": "past"}, "text": "are affected", "normalized": "be affect"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "trouble sleeping", "keywords": [{"text": "trouble sleeping"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people have trouble sleeping, feel agitated and irritable, and have sudden weight loss.", "object": {"text": "sudden weight loss", "keywords": [{"text": "sudden weight loss"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "they"}, "sentence": " Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "object": {"text": "other mental and physical symptoms such as fatigue", "keywords": [{"text": "physical symptoms"}, {"text": "fatigue"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "can have", "normalized": "can have"}}, {"subject": {"text": "Major depressive disorder", "keywords": [{"text": "Major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " Major depressive disorder can affect people in any stage of life.", "object": {"text": "people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "affect", "tense": "future"}, "text": "can affect", "normalized": "can affect"}}, {"subject": {"text": "those"}, "sentence": " In adults, major depressive disorder is most common in those who are 25-44 years of age.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "major depression", "keywords": [{"text": "major depression"}]}, "sentence": " Within an entire lifetime, major depression affects 10% \u2013 25% of women and 5% \u2013 12% of men.", "object": {"text": "10% \u2013 25% of women and 5% \u2013 12% of men", "keywords": [{"text": "women"}, {"text": "men"}], "entities": [{"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "12"}, {"type": "Quantity", "text": "25"}, {"type": "Quantity", "text": "5"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "10% \u2013 25% of people who develop major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "people"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "25"}]}, "sentence": " It is estimated that 10% \u2013 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "object": {"text": "previously diagnosed with dysthymia", "keywords": [{"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some people", "keywords": [{"text": "people"}]}, "sentence": " Some people may suffer from dysthymia and major depressive disorder at the same time.", "object": {"text": "from dysthymia and major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "dysthymia"}], "entities": [{"type": "HealthCondition", "text": "dysthymia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Dysthymia", "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}}, {"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "suffer", "tense": "future"}, "text": "may suffer", "normalized": "may suffer"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "known as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The presence of both conditions at the same time", "keywords": [{"text": "presence"}, {"text": "conditions"}, {"text": "time"}]}, "sentence": " The presence of both conditions at the same time is known as double depression.", "object": {"text": "as double depression", "keywords": [{"text": "double depression"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "is known", "normalized": "be know"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "related to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "may be", "normalized": "may be"}}, {"subject": {"text": "The development of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "sentence": " The development of major depressive disorder may be related to certain medical conditions.", "object": {"text": "to certain medical conditions", "keywords": [{"text": "certain medical conditions"}]}, "action": {"verb": {"text": "relate", "tense": "future"}, "text": "related", "normalized": "relate"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "cancer, diabetes", "keywords": [{"text": "diabetes"}, {"text": "cancer"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions", "keywords": [{"text": "myocardial infarctions"}, {"text": "diabetes"}, {"text": "stroke"}, {"text": "people"}], "entities": [{"type": "Quantity", "text": "20"}, {"type": "Quantity", "text": "25"}]}, "sentence": " Approximately 20% \u2013 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "object": {"text": "major depressive disorder", "keywords": [{"text": "major depressive disorder"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "market"}]}, "sentence": " The global major depressive disorder market is categorized based on various types of therapeutic drugs used to manage this medical condition.", "object": {"text": "on various types of therapeutic drugs used to manage this medical condition", "keywords": [{"text": "therapeutic drugs"}, {"text": "various types"}, {"text": "medical condition"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " Based on type of therapeutic drug, the report covers selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics.", "object": {"text": "selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressants, and antipsychotics", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "serotonin-norepinephrine reuptake inhibitors"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran)", "keywords": [{"text": "Cymbalta"}, {"text": "Savella"}], "entities": [{"type": "Drug", "text": "Escitalopram"}, {"type": "Drug", "text": "Vilazodone"}, {"type": "Drug", "text": "Venlafaxine"}, {"type": "Drug", "text": "Duloxetine"}, {"type": "Drug", "text": "Milnacipran"}]}, "sentence": " Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "object": {"text": "Major brands of selective serotonin-reuptake inhibitors", "keywords": [{"text": "selective serotonin-reuptake inhibitors"}, {"text": "Major brands"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "commonly used in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine),", "keywords": [{"text": "Monoamine Oxidase Inhibitors"}, {"text": "Specific Serotonergic Antidepressants"}, {"text": "Tricyclic Antidepressants"}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors"}]}, "sentence": " Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "object": {"text": "in the management of major depressive disorder", "keywords": [{"text": "major depressive disorder"}, {"text": "management"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are commonly used", "normalized": "be commonly use"}}, {"subject": {"text": "Abilify"}, "sentence": " Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "object": {"text": "antipsychotics", "keywords": [{"text": "antipsychotics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "object": {"text": "the global major depressive disorder market due to increased awareness about various depression conditions in the region", "keywords": [{"text": "major depressive disorder"}, {"text": "various depression conditions"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for major depressive disorder in North America, followed by Canada.", "object": {"text": "the largest market for major depressive disorder in North America, followed by Canada", "keywords": [{"text": "major depressive disorder"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "HealthCondition", "text": "depressive disorder", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Major depressive disorder", "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "This market in Asia", "keywords": [{"text": "market"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " This market in Asia is expected to expand at a significant rate over the next five years.", "action": {"verb": {"text": "expand", "tense": "future"}, "text": "is expected to expand", "normalized": "be expect to expand"}}, {"subject": {"text": "various companies", "keywords": [{"text": "various companies"}]}, "sentence": " This is due to various companies setting up manufacturing facilities in the region.", "object": {"text": "manufacturing facilities in the region", "keywords": [{"text": "facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "set", "tense": "present"}, "text": "setting", "normalized": "set"}}, {"subject": {"text": "awareness", "keywords": [{"text": "awareness"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "increasing awareness about various depression episodes and rise in geriatric population", "keywords": [{"text": "various depression episodes"}, {"text": "geriatric population"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "sentence": " Moreover, increasing awareness about various depression episodes and rise in geriatric population are also driving the growth of the market in the region.", "object": {"text": "the growth of the market in the region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are also driving", "normalized": "be also drive"}}, {"subject": {"text": "India, China, and Japan", "keywords": [{"text": "India"}, {"text": "China"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " India, China, and Japan are expected to be the fastest growing major depressive disorder markets in Asia.", "object": {"text": "the fastest growing major depressive disorder markets in Asia", "keywords": [{"text": "major depressive disorder"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "investments", "keywords": [{"text": "investments"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "action": {"verb": {"text": "Increased", "tense": "past"}, "text": "Increased", "normalized": "Increased"}}, {"subject": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "sentence": " Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs have also fueled the growth of this market.", "object": {"text": "Increased investments in R&D in the pharmaceutical sector and introduction of innovative drugs", "keywords": [{"text": "pharmaceutical sector"}, {"text": "innovative drugs"}, {"text": "investments"}, {"text": "R&D"}], "entities": [{"type": "Location", "text": "R&D", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "fuel", "tense": "past"}, "text": "have also fueled", "normalized": "have also fuel"}}, {"subject": {"text": "The ongoing development of drugs with properties, such as improved safety and high patient compliance,", "keywords": [{"text": "high patient compliance"}, {"text": "ongoing development"}, {"text": "improved safety"}, {"text": "drugs"}]}, "sentence": " The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the global major depressive disorder market.", "object": {"text": "the growth of the global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "are also supporting", "normalized": "be also support"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "immense potential to spur the growth of this market", "keywords": [{"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Therapies, such as biological therapy, meditation, and physiotherapy,", "keywords": [{"text": "biological therapy"}, {"text": "physiotherapy"}, {"text": "Therapies"}, {"text": "meditation"}]}, "sentence": " Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market.", "object": {"text": "the growth of this market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "spur", "tense": "future"}, "text": "to spur", "normalized": "to spur"}}, {"subject": {"text": "by various governments", "keywords": [{"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "stringent regulations", "keywords": [{"text": "stringent regulations"}]}, "action": {"verb": {"text": "impose", "tense": "past"}, "text": "imposed", "normalized": "impose"}}, {"subject": {"text": "stringent regulations imposed by various governments", "keywords": [{"text": "stringent regulations"}, {"text": "various governments"}]}, "sentence": " However, stringent regulations imposed by various governments hamper the growth of global major depressive disorder market.", "object": {"text": "the growth of global major depressive disorder market", "keywords": [{"text": "major depressive disorder"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "drugs", "keywords": [{"text": "drugs"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "an annual sale of USD 1.0 million and above", "keywords": [{"text": "annual sale"}, {"text": "USD"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "side-effects", "keywords": [{"text": "side-effects"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "with antidepressants", "keywords": [{"text": "antidepressants"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "side-effects associated with antidepressants", "keywords": [{"text": "side-effects"}, {"text": "antidepressants"}]}, "sentence": " Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hinder", "tense": "past"}, "text": "have hindered", "normalized": "have hinder"}}, {"subject": {"text": "The major companies", "keywords": [{"text": "major companies"}], "entities": [{"type": "Company", "text": "H. Lundbeck A/S", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "sentence": " The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.969701, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Sertraline", "relevance": 0.752809, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Major depressive disorder", "relevance": 0.698929, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Dysthymia", "relevance": 0.665843, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Venlafaxine", "relevance": 0.641244, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Bipolar disorder", "relevance": 0.594635, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Serotonin", "relevance": 0.581192, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Paroxetine", "relevance": 0.561318, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Citalopram", "relevance": 0.512812, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Mood disorder", "relevance": 0.511403, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Escitalopram", "relevance": 0.497569, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Tricyclic antidepressant", "relevance": 0.494454, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Fluoxetine", "relevance": 0.482256, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Antidepressant", "relevance": 0.428578, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Atypical depression", "relevance": 0.418066, "dbpedia_resource": "http://dbpedia.org/resource/Atypical_depression"}, {"text": "Suicide", "relevance": 0.398234, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.390351, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Bupropion", "relevance": 0.387691, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Imipramine", "relevance": 0.372183, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Schizophrenia", "relevance": 0.354049, "dbpedia_resource": "http://dbpedia.org/resource/Schizophrenia"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.350634, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}], "categories": [{"score": 0.773858, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.396319, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}, {"score": 0.308019, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [{"type": "hasAttribute", "sentence": "People are affected in different ways by major depression.", "score": 0.895334, "arguments": [{"text": "People", "location": [177, 183], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depression", "location": [224, 234], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "Approximately 20% - 25% of people who have cancer, diabetes, stroke, and myocardial infarctions are likely to develop major depressive disorder.", "score": 0.813019, "arguments": [{"text": "who", "location": [1192, 1195], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [1201, 1207], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.672047, "arguments": [{"text": "inhibitors", "location": [1667, 1677], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "locatedAt", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.681218, "arguments": [{"text": "Lexapro", "location": [1686, 1693], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}, {"text": "Escitalopram", "location": [1695, 1707], "entities": [{"type": "GeopoliticalEntity", "text": "Escitalopram"}]}]}, {"type": "playsRoleOf", "sentence": "Major brands of selective serotonin-reuptake inhibitors include Lexapro (Escitalopram), Viibryd (Vilazodone), Effexor (Venlafaxine), Cymbalta (Duloxetine), Pristiq (Desvenlafaxine), Fetzima (Levomilnacipran), and Savella (Milnacipran).", "score": 0.419738, "arguments": [{"text": "Milnacipran", "location": [1844, 1855], "entities": [{"type": "Person", "text": "Levomilnacipran"}]}, {"text": "Savella", "location": [1835, 1842], "entities": [{"type": "Person", "text": "Savella"}]}]}, {"type": "hasAttribute", "sentence": "Antidepressants, such as Noradrenaline, Specific Serotonergic Antidepressants, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, and Brintellix (Vortioxetine), are commonly used in the management of major depressive disorder.", "score": 0.490678, "arguments": [{"text": "Vortioxetine", "location": [2055, 2067], "entities": [{"type": "Person", "text": "Vortioxetine"}]}, {"text": "depressive disorder", "location": [2115, 2134], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "productOf", "sentence": "Major brands of antipsychotics include Abilify (Aripiprazole) and Seroquel XR (Quetiapine).", "score": 0.527122, "arguments": [{"text": "Seroquel XR", "location": [2202, 2213], "entities": [{"type": "Product", "text": "Seroquel XR"}]}, {"text": "Abilify", "location": [2175, 2182], "entities": [{"type": "Organization", "text": "Abilify", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "In terms of geography, North America dominates the global major depressive disorder market due to increased awareness about various depression conditions in the region.", "score": 0.469682, "arguments": [{"text": "depression", "location": [2360, 2370], "entities": [{"type": "HealthCondition", "text": "depression"}]}, {"text": "depressive disorder", "location": [2292, 2311], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.943846, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2515, 2522], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.568243, "arguments": [{"text": "Europe", "location": [2507, 2513], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "France", "location": [2524, 2530], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, France, the U.K., Italy, and Spain account for a major share of the major depressive disorder market.", "score": 0.773073, "arguments": [{"text": "U.K.", "location": [2536, 2540], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Italy", "location": [2542, 2547], "entities": [{"type": "GeopoliticalEntity", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.791566, "arguments": [{"text": "they", "location": [339, 343], "entities": [{"type": "Person", "text": "People"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "ownerOf", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.230617, "arguments": [{"text": "companies", "location": [2739, 2748], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to various companies setting up manufacturing facilities in the region.", "score": 0.897746, "arguments": [{"text": "facilities", "location": [2774, 2784], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2792, 2798], "entities": [{"type": "GeopoliticalEntity", "text": "Lexapro"}]}]}, {"type": "hasAttribute", "sentence": "In recent times, increased demand for therapeutic products for the treatment of this medical condition is a key driver for the global major depressive disorder market.", "score": 0.690833, "arguments": [{"text": "driver", "location": [3173, 3179], "entities": [{"type": "Person", "text": "driver"}]}, {"text": "depressive disorder", "location": [3201, 3220], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "locatedAt", "sentence": "Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) and risk of complications and side-effects associated with antidepressants have hindered the growth of the market.", "score": 0.323359, "arguments": [{"text": "drugs", "location": [3852, 3857], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3840, 3851], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "agentOf", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request a Sample Brochure of the Report @ https://www.persistencemarketresearch.com/samples/4190", "score": 0.950385, "arguments": [{"text": "Pfizer Inc.", "location": [4455, 4466], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Request", "location": [4467, 4474], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "affectedBy", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request a Sample Brochure of the Report @ https://www.persistencemarketresearch.com/samples/4190", "score": 0.489506, "arguments": [{"text": "Sample Brochure", "location": [4477, 4492], "entities": [{"type": "Person", "text": "Sample Brochure"}]}, {"text": "Request", "location": [4467, 4474], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "hasAttribute", "sentence": "The major companies operating in this market are H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., AstraZeneca Plc, Alkermes, Takeda Pharmaceutical Company Limited, Naurex, Euthymics Bioscience, Inc., e-Therapeutics plc, Eli Lilly and Company, and Pfizer Inc. Request a Sample Brochure of the Report @ https://www.persistencemarketresearch.com/samples/4190", "score": 0.457249, "arguments": [{"text": "Report @", "location": [4500, 4508], "entities": [{"type": "Organization", "text": "Report @"}]}, {"text": "https://www.persistencemarketresearch.com/samples/", "location": [4509, 4559], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/samples/"}]}]}, {"type": "partOfMany", "sentence": "Moreover, they can have other mental and physical symptoms such as fatigue, memory loss, feeling of hopelessness, body aches, headaches, and thoughts of suicide.", "score": 0.428244, "arguments": [{"text": "fatigue", "location": [396, 403], "entities": [{"type": "HealthCondition", "text": "fatigue"}]}, {"text": "mental", "location": [359, 365], "entities": [{"type": "HealthCondition", "text": "mental disorder"}]}]}, {"type": "hasAttribute", "sentence": "Major depressive disorder can affect people in any stage of life.", "score": 0.668099, "arguments": [{"text": "people", "location": [528, 534], "entities": [{"type": "Person", "text": "People"}]}, {"text": "depressive disorder", "location": [497, 516], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "In adults, major depressive disorder is most common in those who are 25-44 years of age.", "score": 0.629755, "arguments": [{"text": "adults", "location": [560, 566], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "depressive disorder", "location": [574, 593], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Within an entire lifetime, major depression affects 10% - 25% of women and 5% - 12% of men.", "score": 0.490187, "arguments": [{"text": "women", "location": [711, 716], "entities": [{"type": "Person", "text": "women"}]}, {"text": "depression", "location": [679, 689], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "It is estimated that 10% - 25% of people who develop major depressive disorder are previously diagnosed with dysthymia (dysthymic disorder), a form of depression.", "score": 0.80017, "arguments": [{"text": "who", "location": [779, 782], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [797, 816], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.90085, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "dysthymia", "location": [929, 938], "entities": [{"type": "HealthCondition", "text": "dysthymic disorder"}]}]}, {"type": "hasAttribute", "sentence": "Some people may suffer from dysthymia and major depressive disorder at the same time.", "score": 0.769645, "arguments": [{"text": "people", "location": [906, 912], "entities": [{"type": "Person", "text": "people"}]}, {"text": "depressive disorder", "location": [949, 968], "entities": [{"type": "HealthCondition", "text": "depressive disorder"}]}]}], "keywords": [{"text": "major depressive disorder", "sentiment": {"score": -0.697479, "label": "negative"}, "relevance": 0.926807}, {"text": "depressive disorder market", "sentiment": {"score": -0.698439, "label": "negative"}, "relevance": 0.709473}, {"text": "depressive disorder markets", "sentiment": {"score": -0.542704, "label": "negative"}, "relevance": 0.505033}, {"text": "major depression", "sentiment": {"score": -0.546771, "label": "negative"}, "relevance": 0.47783}, {"text": "reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475328}, {"text": "serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459096}, {"text": "serotonin-norepinephrine reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458474}, {"text": "Norepinephrine-Dopamine Reuptake Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45756}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453775}, {"text": "Specific Serotonergic Antidepressants", "sentiment": {"score": -0.353355, "label": "negative"}, "relevance": 0.452993}, {"text": "various depression conditions", "sentiment": {"score": -0.632753, "label": "negative"}, "relevance": 0.452763}, {"text": "Major brands", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45211}, {"text": "selective serotonin-reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451931}, {"text": "various depression episodes", "sentiment": {"score": -0.38955, "label": "negative"}, "relevance": 0.449677}, {"text": "sudden weight loss", "sentiment": {"score": -0.697599, "label": "negative"}, "relevance": 0.448021}, {"text": "North America", "sentiment": {"score": -0.568224, "label": "negative"}, "relevance": 0.444127}, {"text": "medical condition", "sentiment": {"score": -0.76802, "label": "negative"}, "relevance": 0.443421}, {"text": "certain medical conditions", "sentiment": {"score": -0.72957, "label": "negative"}, "relevance": 0.443228}, {"text": "Otsuka Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44136}, {"text": "H. Lundbeck A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.44044}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440314}, {"text": "drug manufacturing companies", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.439952}, {"text": "mental disorder", "sentiment": {"score": -0.769998, "label": "negative"}, "relevance": 0.439584}, {"text": "high patient compliance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438789}, {"text": "rapid product launches", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.4379}, {"text": "clinical depression", "sentiment": {"score": -0.636587, "label": "negative"}, "relevance": 0.437341}, {"text": "major share", "sentiment": {"score": -0.654068, "label": "negative"}, "relevance": 0.436341}, {"text": "dysthymic disorder", "sentiment": {"score": -0.7953, "label": "negative"}, "relevance": 0.436073}, {"text": "major companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435634}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.332703, "label": "negative"}, "relevance": 0.435137}, {"text": "major trends", "sentiment": {"score": -0.884817, "label": "negative"}, "relevance": 0.434202}, {"text": "double depression", "sentiment": {"score": -0.479211, "label": "negative"}, "relevance": 0.433562}, {"text": "largest market", "sentiment": {"score": -0.503696, "label": "negative"}, "relevance": 0.430535}, {"text": "body aches", "sentiment": {"score": -0.584501, "label": "negative"}, "relevance": 0.427512}, {"text": "therapeutic drugs", "sentiment": {"score": -0.824404, "label": "negative"}, "relevance": 0.426989}, {"text": "memory loss", "sentiment": {"score": -0.473238, "label": "negative"}, "relevance": 0.426406}, {"text": "different ways", "sentiment": {"score": -0.674716, "label": "negative"}, "relevance": 0.426195}, {"text": "enjoyable environment", "sentiment": {"score": -0.769998, "label": "negative"}, "relevance": 0.426192}, {"text": "physical symptoms", "sentiment": {"score": -0.625794, "label": "negative"}, "relevance": 0.425918}, {"text": "blockbuster drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425363}, {"text": "various types", "sentiment": {"score": -0.824404, "label": "negative"}, "relevance": 0.425197}, {"text": "people", "sentiment": {"score": -0.759444, "label": "negative"}, "relevance": 0.425043}, {"text": "Seroquel XR", "sentiment": {"score": -0.440344, "label": "negative"}, "relevance": 0.42452}, {"text": "innovative drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424451}, {"text": "various companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424342}, {"text": "myocardial infarctions", "sentiment": {"score": -0.713444, "label": "negative"}, "relevance": 0.424129}, {"text": "therapeutic drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423312}, {"text": "Spain account", "sentiment": {"score": -0.654068, "label": "negative"}, "relevance": 0.422116}, {"text": "entire lifetime", "sentiment": {"score": 0.499582, "label": "positive"}, "relevance": 0.42207}, {"text": "patent expiries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421782}]}, "extracted_metadata": {"sha1": "a036151e124f263fb373b539c4229e78aabe5c87", "filename": "1541057530252.zip-7166a36c2f04a9a0aba7ca54b0c2e782.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/major-depressive-disorder-market.asp", "https://www.persistencemarketresearch.com/samples/4190"], "title": "Major Depressive Disorder Present Profitable Opportunities by 2021", "forum_title": "Research Insights \u2013 Page 176 \u2013 Find Market Research"}, {"id": "v7jB7bfWjyNQt7ZYVFHUibaPNUoGSWlROAsbBZA3sO2T5hLpUkLUeRpCMRhuFYRN", "result_metadata": {"score": 32.44015}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-01T13:49:11Z", "url": "https://www.businesswire.com/news/home/20181101005588/en/BARCLAYS-PLC-UK-Regulatory-Announcement-FORM-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T12:29:00-05:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.745279, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.712004, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.577645, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.574151, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.552355, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542931, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.527935, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512924, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.470273, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453311, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,300 1.29%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,073,064 1.39%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,894,286 1.50%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,304,179 1.55%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,488,950 4.21%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,501,079 4.22%", "relevance": 0.453311, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453311, "type": "Quantity"}], "sentiment": {"document": {"score": 0.106395, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,488,950 4.21% 33,501,079 4.22% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,488,950 4.21"}, {"type": "Quantity", "text": "33,501,079 4.22"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,073,064 1.39% 12,304,179 1.55% (2) Cash-settled derivatives: 11,894,286 1.50% 10,255,300 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,488,950 4.21% 33,501,079 4.22% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 1 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658625 Time of Receipt (offset from UTC): 20181101T120148+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.981759, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.741275, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.703128, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.628463, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.50962, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.412645, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.411816, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.380147, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.351192, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Contract", "relevance": 0.331497, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.327877, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.305102, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "United States dollar", "relevance": 0.30188, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Barclays", "relevance": 0.297664, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.574244, "label": "/real estate/buying and selling homes"}, {"score": 0.472744, "label": "/finance/financial news"}, {"score": 0.452629, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9239, 9240], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9230, 9238], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 658625 Time of Receipt (offset from UTC): 20181101T120148+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10050, 10053], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10029, 10036], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "employedBy", "sentence": "4,570.0000 JPY Ordinary NPV Sale 40,000 4,528.0000 JPY Ordinary NPV Sale 50,000 4,533.0180 JPY Ordinary NPV Sale 94,600 4,529.0919 JPY Ordinary NPV Sale 107,000 4,534.3364 JPY Ordinary NPV Sale 291,100 4,547.9134 JPY Ordinary NPV Sale 344,300 4,536.8739 JPY Ordinary NPV Sale 348,400 4,537.0849 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,503.0000 JPY Ordinary NPV SWAP Long 2,400 4,541.5620 JPY Ordinary NPV CFD Long 80,000 4,548.9321 JPY Ordinary NPV CFD Short 28,300 4,543.4542 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [4868, 4872], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [4914, 4928], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "4,570.0000 JPY Ordinary NPV Sale 40,000 4,528.0000 JPY Ordinary NPV Sale 50,000 4,533.0180 JPY Ordinary NPV Sale 94,600 4,529.0919 JPY Ordinary NPV Sale 107,000 4,534.3364 JPY Ordinary NPV Sale 291,100 4,547.9134 JPY Ordinary NPV Sale 344,300 4,536.8739 JPY Ordinary NPV Sale 348,400 4,537.0849 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 100 4,503.0000 JPY Ordinary NPV SWAP Long 2,400 4,541.5620 JPY Ordinary NPV CFD Long 80,000 4,548.9321 JPY Ordinary NPV CFD Short 28,300 4,543.4542 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.657678, "arguments": [{"text": "i", "location": [5254, 5255], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Sale"}]}, {"text": "Writing", "location": [5257, 5264], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [5854, 5859], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [5864, 5868], "entities": [{"type": "Organization", "text": "Type e.g. American"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6228, 6234], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6245, 6252], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 1 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7153, 7159], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7167, 7171], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7599, 7605], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7613, 7626], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7234, 7258], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7226, 7231], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9745, 9769], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9737, 9742], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7393, 7398], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7412, 7439], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9904, 9909], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [9923, 9950], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7675, 7681], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7707, 7719], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.986624}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.794417}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.784091}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509299}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505174}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505034}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503356}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502451}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.493696}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459047}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453093}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446129}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43843}, {"text": "NPV CFD Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438275}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416938}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411379}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.36204}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357519}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357172}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.355515}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354786}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354207}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.3538}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353296}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352325}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351511}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351107}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339769}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338829}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.335089}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.334833}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334823}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33464}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334294}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33407}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334048}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333777}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333591}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.333495}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332965}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332672}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.332623}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33239}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332002}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331948}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331368}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.331325}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331185}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331183}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330453}]}, "extracted_metadata": {"sha1": "b635fc6bfd2e71499768cc9296f66c8dba69d80e", "filename": "1541080151678.zip-b486c2916dadc1e70831ea480c9ce5c2.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: FORM 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "GVvfmSMx4iJguCwShTjfdMAd-fcDgbVPgrhrQIS03aNsryY-2Lz-_aikjeVCkQKN", "result_metadata": {"score": 32.290115}, "author": "Allied Market Research", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.579606, "label": "positive"}, "text": "Evoke Pharma", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.393579, "label": "negative"}, "text": "Gastroparesis", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Arzneimittel GmbH", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.347806, "label": "negative"}, "text": "Cadila Pharmaceuticals Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ETX Pharma", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Top Companies Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc., Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma", "keywords": [{"text": "Abbott Arzneimittel GmbH"}, {"text": "Evoke Pharma"}, {"text": "Abbott Laboratories"}, {"text": "Cadila Pharmaceuticals Ltd."}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Company", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"type": "Company", "text": "Abbott Arzneimittel GmbH"}, {"type": "Company", "text": "AstraZeneca Plc."}, {"type": "Company", "text": "Cadila Pharmaceuticals Ltd."}, {"type": "Company", "text": "ETX Pharma"}, {"type": "Company", "text": "Evoke Pharma"}]}, "sentence": "Gastroparesis Market: Including Top Companies Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc., Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma", "object": {"text": "Gastroparesis Market", "keywords": [{"text": "Gastroparesis Market"}], "entities": [{"type": "HealthCondition", "text": "Gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}]}, "action": {"verb": {"text": "Including", "tense": "present"}, "text": "Including", "normalized": "Including"}}], "concepts": [{"text": "Cambridge Antibody Technology", "relevance": 0.941403, "dbpedia_resource": "http://dbpedia.org/resource/Cambridge_Antibody_Technology"}, {"text": "Pharmaceutical industry", "relevance": 0.858918, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Multinational companies", "relevance": 0.84735, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}], "categories": [{"score": 0.771211, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.443086, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Abbott Arzneimittel GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.908636}, {"text": "Evoke Pharma", "sentiment": {"score": 0.579606, "label": "positive"}, "relevance": 0.763839}, {"text": "Cadila Pharmaceuticals Ltd.", "sentiment": {"score": -0.347806, "label": "negative"}, "relevance": 0.708174}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.701903}, {"text": "Gastroparesis Market", "sentiment": {"score": -0.393579, "label": "negative"}, "relevance": 0.543654}, {"text": "AstraZeneca Plc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470269}]}, "crawl_date": "2018-11-01T09:25:04Z", "url": "https://www.openpr.com/news/1344730/Gastroparesis-Market-Including-Top-Companies-Allergan-Plc-Abbott-Laboratories-Abbott-Arzneimittel-GmbH-AstraZeneca-Plc-Cadila-Pharmaceuticals-Ltd-ETX-Pharma-Inc-Evoke-Pharma.html", "host": "openpr.com", "text": "\u2022 Valeant Pharmaceuticals International Inc. \u2022 Theravance Biopharma.Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company LtdThe prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T08:57:00Z", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": -0.520366, "label": "negative"}, "text": "gastroparesis", "relevance": 0.927714, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}, {"count": 2, "sentiment": {"score": 0.407671, "label": "positive"}, "text": "Allied Market Research", "relevance": 0.258617, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.181306, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Altos Therapeutics LLC", "relevance": 0.170121, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant Pharmaceuticals International Inc.", "relevance": 0.167625, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Portland", "relevance": 0.157698, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Portland, Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Portland,_Oregon"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEVA Group PLC", "relevance": 0.156488, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allied Analytics LLP", "relevance": 0.152461, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Us", "relevance": 0.145833, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hexal AG", "relevance": 0.145276, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prokinetic", "relevance": 0.14512, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Theravance", "relevance": 0.142221, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.140572, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan N.V.", "relevance": 0.136523, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.130371, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.6%", "relevance": 0.130371, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.130371, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "four-fifths", "relevance": 0.130371, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "two-fifths", "relevance": 0.130371, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34.9%", "relevance": 0.130371, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.0%", "relevance": 0.130371, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.2%", "relevance": 0.130371, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.5%", "relevance": 0.130371, "type": "Quantity"}], "sentiment": {"document": {"score": -0.0357093, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company LtdThe prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis", "keywords": [{"text": "CEVA Group PLC"}, {"text": "Altos Therapeutics LLC"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "prokinetic agents segment"}], "entities": [{"type": "Company", "text": "Altos Therapeutics LLC"}, {"type": "Company", "text": "Mylan N.V."}, {"type": "Company", "text": "Hexal AG"}, {"type": "Company", "text": "CEVA Group PLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}]}, "sentence": "\u2022 Valeant Pharmaceuticals International Inc. \u2022 Theravance Biopharma.Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company LtdThe prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis.", "object": {"text": "\u2022 Valeant Pharmaceuticals International Inc. \u2022 Theravance Biopharma.Key players in the value chain", "keywords": [{"text": "Valeant Pharmaceuticals International"}, {"text": "Theravance Biopharma.Key players"}, {"text": "value chain"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Valeant Pharmaceuticals International Inc."}, {"type": "Company", "text": "Theravance"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "CEVA Group PLC, and Takeda Pharmaceutical Company LtdThe prokinetic agents segment", "keywords": [{"text": "CEVA Group PLC"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "prokinetic agents segment"}, {"text": "LtdThe"}], "entities": [{"type": "Company", "text": "CEVA Group PLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "\u2022 Valeant Pharmaceuticals International Inc. \u2022 Theravance Biopharma.Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company LtdThe prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis.", "object": {"text": "the largest share", "keywords": [{"text": "largest share"}]}, "action": {"verb": {"text": "occupy", "tense": "past"}, "text": "occupied", "normalized": "occupy"}}, {"subject": {"text": "the botulinum toxin injection segment", "keywords": [{"text": "botulinum toxin injection"}, {"text": "segment"}]}, "sentence": " Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period.", "object": {"text": "at the highest CAGR of 5.6%", "keywords": [{"text": "highest CAGR"}], "entities": [{"type": "Quantity", "text": "5.6"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "the botulinum toxin injection segment", "keywords": [{"text": "botulinum toxin injection"}, {"text": "segment"}]}, "sentence": " Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period.", "object": {"text": "anticipated to continue its dominance", "keywords": [{"text": "dominance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the botulinum toxin injection segment", "keywords": [{"text": "botulinum toxin injection"}, {"text": "segment"}]}, "sentence": " Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period.", "object": {"text": "its dominance", "keywords": [{"text": "dominance"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "is anticipated to continue", "normalized": "be anticipate to continue"}}, {"subject": {"text": "The utilization rate of gastroparesis drugs for idiopathic gastroparesis", "keywords": [{"text": "idiopathic gastroparesis"}, {"text": "gastroparesis drugs"}, {"text": "utilization rate"}], "entities": [{"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}, {"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}]}, "sentence": " The utilization rate of gastroparesis drugs for idiopathic gastroparesis is high, however post-surgical gastroparesis segment is expected to grow at a CAGR of 5.2% during the forecast period.", "object": {"text": "high"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "post-surgical gastroparesis segment", "keywords": [{"text": "post-surgical gastroparesis segment"}], "entities": [{"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}]}, "sentence": " The utilization rate of gastroparesis drugs for idiopathic gastroparesis is high, however post-surgical gastroparesis segment is expected to grow at a CAGR of 5.2% during the forecast period.", "object": {"text": "at a CAGR of 5.2%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "5.2"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "This"}, "sentence": " This is attributed to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis.For More Information @ www.alliedmarketresearch.com/purchase-enquiry/4153?utm_so...", "object": {"text": "to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis.For More Information @ www.alliedmarketresearch.com/purchase-enquiry/4153?utm_so", "keywords": [{"text": "various types"}, {"text": "incidence"}, {"text": "surgeries"}, {"text": "transplantation"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "is attributed", "normalized": "be attribute"}}, {"subject": {"text": "various types of surgeries, such as transplantation", "keywords": [{"text": "surgeries"}, {"text": "transplantation"}, {"text": "various types"}]}, "sentence": " This is attributed to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis.For More Information @ www.alliedmarketresearch.com/purchase-enquiry/4153?utm_so...", "object": {"text": "in postsurgical gastroparesis.For More Information @ www.alliedmarketresearch.com/purchase-enquiry/4153", "keywords": [{"text": "Information  www.alliedmarketresearch.com/purchase-enquiry/4153"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "result", "normalized": "result"}}, {"subject": {"text": "This"}, "sentence": " This is attributed to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis.", "object": {"text": "to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis", "keywords": [{"text": "gastroparesis drugs"}, {"text": "early approval"}, {"text": "incidence"}], "entities": [{"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}, {"type": "HealthCondition", "text": "gastroparesis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Gastroparesis", "dbpedia_resource": "http://dbpedia.org/resource/Gastroparesis"}}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "is attributed", "normalized": "be attribute"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " However, Asia-Pacific is expected to grow at the highest CAGR of 5.5% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward gastroparesis drugs.Access Full Summery @ www.alliedmarketresearch.com/press-release/gastroparesis-...", "object": {"text": "at the highest CAGR of 5.5%", "keywords": [{"text": "highest CAGR"}], "entities": [{"type": "Quantity", "text": "5.5"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "Allied Market Research, a market research and advisory company of Allied Analytics LLP,", "keywords": [{"text": "Allied Analytics LLP"}, {"text": "Allied Market Research"}, {"text": "advisory company"}], "entities": [{"type": "Company", "text": "Allied Market Research"}, {"type": "Company", "text": "Allied Analytics LLP"}]}, "sentence": " About Us:Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises.", "object": {"text": "business insights and market research reports", "keywords": [{"text": "business insights"}, {"text": "market research reports"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.Contact: 5933 NE Win Sivers Drive #205, Portland, OR 97220", "object": {"text": "its clients", "keywords": [{"text": "clients"}]}, "action": {"verb": {"text": "assist", "tense": "present"}, "text": "assists", "normalized": "assist"}}, {"subject": {"text": "its clients", "keywords": [{"text": "clients"}]}, "sentence": " The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.Contact: 5933 NE Win Sivers Drive #205, Portland, OR 97220", "object": {"text": "business policies", "keywords": [{"text": "business policies"}]}, "action": {"verb": {"text": "strategize", "tense": "future"}, "text": "to strategize", "normalized": "to strategize"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.Contact: 5933 NE Win Sivers Drive #205, Portland, OR 97220", "object": {"text": "sustainable growth", "keywords": [{"text": "sustainable growth"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieve", "normalized": "achieve"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.917421, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Botulinum toxin", "relevance": 0.903877, "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}, {"text": "Ribavirin", "relevance": 0.832616, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Pharmaceutical drug", "relevance": 0.820532, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacology", "relevance": 0.78346, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.744182, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Years in the future", "relevance": 0.73476, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Microbial toxins", "relevance": 0.688363, "dbpedia_resource": "http://dbpedia.org/resource/Microbial_toxins"}], "categories": [{"score": 0.592395, "label": "/health and fitness"}, {"score": 0.545466, "label": "/health and fitness/drugs"}, {"score": 0.364417, "label": "/finance/financial news"}], "relations": [{"type": "partOf", "sentence": "Access Full Summery @ www.alliedmarketresearch.com/press-release/gastroparesis-... About Us:Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises.", "score": 0.826038, "arguments": [{"text": "company", "location": [2182, 2189], "entities": [{"type": "Organization", "text": "Allied Market Research"}]}, {"text": "Allied Analytics LLP", "location": [2193, 2213], "entities": [{"type": "Organization", "text": "Allied Analytics LLP"}]}]}, {"type": "employedBy", "sentence": "The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.Contact: 5933 NE Win Sivers Drive #205, Portland, OR 97220", "score": 0.601787, "arguments": [{"text": "clients", "location": [2342, 2349], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "its", "location": [2338, 2341], "entities": [{"type": "Organization", "text": "Allied Market Research"}]}]}, {"type": "residesIn", "sentence": "The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.Contact: 5933 NE Win Sivers Drive #205, Portland, OR 97220", "score": 0.898888, "arguments": [{"text": "NE Win Sivers Drive #205", "location": [2461, 2485], "entities": [{"type": "Person", "text": "NE Win Sivers Drive #205"}]}, {"text": "Portland", "location": [2487, 2495], "entities": [{"type": "GeopoliticalEntity", "text": "Portland"}]}]}], "keywords": [{"text": "gastroparesis drugs market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994266}, {"text": "global gastroparesis drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.934089}, {"text": "post-surgical gastroparesis segment", "sentiment": {"score": -0.611456, "label": "negative"}, "relevance": 0.781735}, {"text": "Idiopathic gastroparesis segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763641}, {"text": "toxin injection segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689124}, {"text": "prokinetic agents segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682589}, {"text": "botulinum toxin injection", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637565}, {"text": "gastroparesis drugs.Access", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589979}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.482784}, {"text": "CEVA Group PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481008}, {"text": "Altos Therapeutics LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47824}, {"text": "LtdThe prokinetic agents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477429}, {"text": "Theravance Biopharma.Key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475666}, {"text": "Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475261}, {"text": "forecast period", "sentiment": {"score": -0.562166, "label": "negative"}, "relevance": 0.470504}, {"text": "market research", "sentiment": {"score": 0.407671, "label": "positive"}, "relevance": 0.468507}, {"text": "respective market domain.Contact", "sentiment": {"score": 0.549614, "label": "positive"}, "relevance": 0.463009}, {"text": "highest CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460089}, {"text": "Allied Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458225}, {"text": "Pharmacies segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45582}, {"text": "nearly two-fifths share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455282}, {"text": "NE Win Sivers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453429}, {"text": "leading revenue contributor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.449991}, {"text": "Allied Analytics LLP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439003}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404541}, {"text": "largest share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398877}, {"text": "four-fifths share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.396857}, {"text": "value chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395434}, {"text": "Mylan N.V.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395258}, {"text": "high usage", "sentiment": {"score": 0.361805, "label": "positive"}, "relevance": 0.39235}, {"text": "Hexal AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391823}, {"text": "nearly one-third", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.388346}, {"text": "various types", "sentiment": {"score": -0.323313, "label": "negative"}, "relevance": 0.384788}, {"text": "utilization rate", "sentiment": {"score": -0.677443, "label": "negative"}, "relevance": 0.383165}, {"text": "healthcare expenditure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.382023}, {"text": "Key findings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381445}, {"text": "2023North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.381177}, {"text": "early approval", "sentiment": {"score": -0.567068, "label": "negative"}, "relevance": 0.379907}, {"text": "study period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379097}, {"text": "sustainable growth", "sentiment": {"score": 0.549614, "label": "positive"}, "relevance": 0.378369}, {"text": "business policies", "sentiment": {"score": 0.549614, "label": "positive"}, "relevance": 0.378078}, {"text": "advisory company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377324}, {"text": "medium enterprises", "sentiment": {"score": 0.407671, "label": "positive"}, "relevance": 0.375668}, {"text": "business insights", "sentiment": {"score": 0.407671, "label": "positive"}, "relevance": 0.373382}, {"text": "incidence", "sentiment": {"score": -0.445191, "label": "negative"}, "relevance": 0.333458}, {"text": "Summery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.322105}, {"text": "affordability", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318818}, {"text": "applicability", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318521}, {"text": "dominance", "sentiment": {"score": -0.512875, "label": "negative"}, "relevance": 0.317438}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315463}]}, "extracted_metadata": {"sha1": "373b526efa8c328d6938528c750e0ba0d5d06fee", "filename": "1541064304800.zip-16d72ed8d5483d2719e83d7a72a8836f.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/purchase-enquiry/4153?utm_source=sy-Openpr", "https://www.alliedmarketresearch.com/press-release/gastroparesis-drugs-market.html?utm_source=sy-Openpr"], "title": "Gastroparesis Market: Including Top Companies Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc., Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma", "forum_title": "openPR.com - New Public Relations: Health & Medicine"}, {"id": "bT_IKiXlvrc1cbnFA-9qASeyZ4eKqcg8rGzWtsO-93iJqNo7Gj9PnBM5ioWnFnae", "result_metadata": {"score": 31.908054}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.765789, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Stock market", "relevance": 0.847016, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.627213, "label": "/pets/zoo"}, {"score": 0.435329, "label": "/finance/investing"}, {"score": 0.435329, "label": "/finance/investing/beginning investing"}], "relations": [], "keywords": [{"text": "Exhibit Impressive Growth", "sentiment": {"score": 0.765789, "label": "positive"}, "relevance": 0.982384}, {"text": "Facial Aesthetic", "sentiment": {"score": 0.765789, "label": "positive"}, "relevance": 0.794613}, {"text": "Remodeling Market", "sentiment": {"score": 0.765789, "label": "positive"}, "relevance": 0.626816}]}, "crawl_date": "2018-11-01T04:36:08Z", "url": "https://www.findmarketresearch.org/2018/11/facial-aesthetic-remodeling-market-to-exhibit-impressive-growth-during-2017-2025/", "host": "findmarketresearch.org", "text": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T04:19:00Z", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": 0.22809, "label": "positive"}, "text": "Facial Aesthetic Remodeling", "relevance": 0.911333, "type": "PrintMedia"}, {"count": 6, "sentiment": {"score": 0.502725, "label": "positive"}, "text": "Facial Aesthetic Remodeling Market", "relevance": 0.515987, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0.670452, "label": "positive"}, "text": "Facial Aesthetic Industry", "relevance": 0.221333, "type": "PrintMedia"}, {"count": 4, "sentiment": {"score": -0.135489, "label": "negative"}, "text": "Botox", "relevance": 0.0804524, "type": "HealthCondition", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"count": 1, "sentiment": {"score": -0.250729, "label": "negative"}, "text": "skin discoloration", "relevance": 0.0710931, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.290672, "label": "positive"}, "text": "Dermal Fillers", "relevance": 0.0608961, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Society of Plastic Surgeons", "relevance": 0.0566316, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Society of Plastic Surgeons", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Plastic_Surgeons"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.0515274, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.344037, "label": "negative"}, "text": "USA", "relevance": 0.0491595, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.594191, "label": "negative"}, "text": "North America", "relevance": 0.0471543, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.045415, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0451008, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck KGaA", "relevance": 0.0449663, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck KGaA", "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}}, {"count": 1, "sentiment": {"score": -0.374807, "label": "negative"}, "text": "Galderma SA", "relevance": 0.0445248, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.590552, "label": "positive"}, "text": "Merz Aesthetics", "relevance": 0.0412755, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.0412169, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.219436, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.0411343, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.219436, "label": "negative"}, "text": "Japan", "relevance": 0.0403932, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0402243, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0402143, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Suneva Medical", "relevance": 0.0401889, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.422693, "label": "positive"}, "text": "Cynosure Inc", "relevance": 0.0387461, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0357278, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "four months", "relevance": 0.0357278, "type": "Quantity"}], "sentiment": {"document": {"score": 0.461867, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty", "keywords": [{"text": "cosmetic procedure"}, {"text": "comprehensive evaluation"}, {"text": "nature"}, {"text": "art"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cosmetic procedure", "keywords": [{"text": "cosmetic procedure"}]}, "sentence": " Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face", "keywords": [{"text": "youthful appearance"}, {"text": "skin discoloration"}, {"text": "comprehensive evaluation"}, {"text": "human face"}], "entities": [{"type": "HealthCondition", "text": "skin discoloration"}]}, "action": {"verb": {"text": "entail", "tense": "present"}, "text": "entails", "normalized": "entail"}}, {"subject": {"text": "skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face", "keywords": [{"text": "youthful appearance"}, {"text": "skin discoloration"}, {"text": "human face"}, {"text": "skin laxity"}], "entities": [{"type": "HealthCondition", "text": "skin discoloration"}]}, "sentence": " Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "conditions", "keywords": [{"text": "conditions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "ageism in industrialized societies", "keywords": [{"text": "industrialized societies"}, {"text": "ageism"}]}, "sentence": " As ageism in industrialized societies is rapidly increasing, as one ages, facial aesthetic units gradually become distinct and lose due to a contour of the facial skeleton, the location of facial ligaments, differences in skin thickness and composition of subcutaneous tissue, so the demand for Facial Aesthetic Remodeling services is also emerging significantly.", "object": {"text": "rapidly increasing"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "facial aesthetic units", "keywords": [{"text": "facial aesthetic units"}]}, "sentence": " As ageism in industrialized societies is rapidly increasing, as one ages, facial aesthetic units gradually become distinct and lose due to a contour of the facial skeleton, the location of facial ligaments, differences in skin thickness and composition of subcutaneous tissue, so the demand for Facial Aesthetic Remodeling services is also emerging significantly.", "object": {"text": "distinct"}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "become", "normalized": "become"}}, {"subject": {"text": "surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence", "keywords": [{"text": "advanced aesthetic enhancements"}, {"text": "nonsurgical procedures"}, {"text": "confidence"}, {"text": "appearance"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "surgical and nonsurgical procedures", "keywords": [{"text": "nonsurgical procedures"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "a solution", "keywords": [{"text": "solution"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "surgical and nonsurgical procedures", "keywords": [{"text": "nonsurgical procedures"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "the structure of the body", "keywords": [{"text": "structure"}, {"text": "body"}]}, "action": {"verb": {"text": "reshape", "tense": "present"}, "text": "reshape", "normalized": "reshape"}}, {"subject": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "dramatic benefits", "keywords": [{"text": "dramatic benefits"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling ability"}, {"text": "dramatic benefits"}, {"text": "surgery"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "made these procedures more accessible", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling ability"}, {"text": "dramatic benefits"}, {"text": "surgery"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "these procedures", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "has made", "normalized": "have make"}}, {"subject": {"text": "caused something of a revolution", "keywords": [{"text": "revolution"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "their increasing popularity", "keywords": [{"text": "popularity"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "something of a revolution", "keywords": [{"text": "revolution"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "has caused", "normalized": "have cause"}}, {"subject": {"text": "The most popular procedure of Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "popular procedure"}, {"text": "Remodeling"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "Botox which injected into the Facial muscles without affecting it", "keywords": [{"text": "Facial muscles"}, {"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "into the Facial muscles", "keywords": [{"text": "Facial muscles"}]}, "action": {"verb": {"text": "inject", "tense": "past"}, "text": "injected", "normalized": "inject"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "it"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "the skin", "keywords": [{"text": "skin"}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "smooth, the effect of Botox last for approximately for three to four months", "keywords": [{"text": "Botox"}, {"text": "effect"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "Quantity", "text": "four months"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "14.2 million non-minimally invasive facial aesthetics treatments", "keywords": [{"text": "invasive facial aesthetics"}, {"text": "treatments"}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "object": {"text": "carried out in the USA", "keywords": [{"text": "USA"}], "entities": [{"type": "Location", "text": "USA", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "14.2 million non-minimally invasive facial aesthetics treatments", "keywords": [{"text": "invasive facial aesthetics"}, {"text": "treatments"}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "action": {"verb": {"text": "carry", "tense": "past"}, "text": "were carried", "normalized": "be carry"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "object": {"text": "a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total", "keywords": [{"text": "Dermal Fillers"}, {"text": "clear favorite"}, {"text": "procedures"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "Company", "text": "Dermal Fillers"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The market of Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling"}, {"text": "market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}, {"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The market of Facial Aesthetic Remodeling have tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort.", "object": {"text": "tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort", "keywords": [{"text": "high-technology skin care"}, {"text": "significant discomfort"}, {"text": "tremendous opportunity"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "significant discomfort", "keywords": [{"text": "significant discomfort"}]}, "sentence": " The market of Facial Aesthetic Remodeling have tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort.", "object": {"text": "high-technology skin", "keywords": [{"text": "high-technology skin"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involving", "normalized": "involve"}}, {"subject": {"text": "The Desire to enhance the beauty and physical appearance", "keywords": [{"text": "physical appearance"}, {"text": "Desire"}, {"text": "beauty"}]}, "sentence": " The Desire to enhance the beauty and physical appearance among women with Increase in Awareness of the facial aesthetic procedures among the general public is the major factor that drives the Facial Aesthetic Remodeling Market.", "object": {"text": "the major factor that drives the Facial Aesthetic Remodeling Market", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "major factor"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Facial Aesthetic Industry", "keywords": [{"text": "Industry"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Industry"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries", "keywords": [{"text": "non-invasive dermal fillers"}, {"text": "disposable income"}, {"text": "job opportunities"}, {"text": "rise"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "non-invasive dermal fillers", "keywords": [{"text": "non-invasive dermal fillers"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period", "keywords": [{"text": "disposable income"}, {"text": "Facial Aesthetic"}, {"text": "market revenue"}, {"text": "forecast period"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "non-invasive dermal fillers", "keywords": [{"text": "non-invasive dermal fillers"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "aging"}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "address", "normalized": "address"}}, {"subject": {"text": "the market revenue for Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "market revenue"}, {"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries", "keywords": [{"text": "non-invasive dermal fillers"}, {"text": "Facial Aesthetic"}, {"text": "disposable income"}, {"text": "job opportunities"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Industry"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is also expected to fuel", "normalized": "be also expect to fuel"}}, {"subject": {"text": "certain side effects", "keywords": [{"text": "certain side effects"}]}, "sentence": " However, high expenses of treatments, and certain side effects associated with the procedures can hamper the growth of the Facial Aesthetic Remodeling market to some extent.", "object": {"text": "with the procedures", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high expenses of treatments, and certain side effects associated with the procedures", "keywords": [{"text": "high expenses"}, {"text": "certain side effects"}, {"text": "treatments"}, {"text": "procedures"}]}, "sentence": " However, high expenses of treatments, and certain side effects associated with the procedures can hamper the growth of the Facial Aesthetic Remodeling market to some extent.", "object": {"text": "the growth of the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "hamper", "tense": "future"}, "text": "can hamper", "normalized": "can hamper"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling market is segmented into the following:Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling market is segmented into the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers", "object": {"text": "segmented into the following"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling market is segmented into the following:Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling market is segmented into the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers", "object": {"text": "into the following"}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling market is segmented into the following:Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling market is segmented into the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers", "object": {"text": "segmented into the following"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling market is segmented into the following:Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling market is segmented into the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers", "object": {"text": "into the following"}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling market is expected to extend at a noteworthy development rate crosswise over regions due to the rise in per capita expenditure on healthcare in the developed nations and increasing incidence of accidents.", "object": {"text": "at a noteworthy development rate crosswise over regions due to the rise in per capita expenditure on healthcare in the developed nations and increasing incidence of accidents", "keywords": [{"text": "noteworthy development rate"}, {"text": "capita expenditure"}, {"text": "incidence"}, {"text": "rise"}], "entities": []}, "action": {"verb": {"text": "extend", "tense": "future"}, "text": "is expected to extend", "normalized": "be expect to extend"}}, {"subject": {"text": "Continuous research by Pharmaceutical Companies", "keywords": [{"text": "Continuous research"}, {"text": "Pharmaceutical Companies"}], "entities": []}, "sentence": " Continuous research by Pharmaceutical Companies to develop certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market.", "object": {"text": "certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "youthful look"}, {"text": "potential revenues"}, {"text": "loose skin"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "their potential revenues", "keywords": [{"text": "potential revenues"}]}, "sentence": " Continuous research by Pharmaceutical Companies to develop certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market.", "object": {"text": "in the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "to increase", "normalized": "to increase"}}, {"subject": {"text": "more areas", "keywords": [{"text": "areas"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "with the wider range of products", "keywords": [{"text": "wider range"}, {"text": "products"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "demand to treat", "normalized": "demand to treat"}}, {"subject": {"text": "The rise in patients demand to treat more areas with the wider range of products and techniques", "keywords": [{"text": "wider range"}, {"text": "rise"}, {"text": "patients"}, {"text": "areas"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "can also drive", "normalized": "can also drive"}}, {"subject": {"text": "the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "a meteoric growth", "keywords": [{"text": "meteoric growth"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "is expected to have", "normalized": "be expect to have"}}, {"subject": {"text": "it"}, "sentence": " A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "object": {"text": "been segmented into five broad regions", "keywords": [{"text": "broad regions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "object": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "action": {"verb": {"text": "exclude", "tense": "present"}, "text": "excluding", "normalized": "exclude"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America represents the largest Facial Aesthetic Remodeling market due to rising demand for the use of minimally invasive techniques and increasing population of elder people.", "object": {"text": "the largest Facial Aesthetic Remodeling market due to rising demand for the use of minimally invasive techniques and increasing population of elder people", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "minimally invasive techniques"}, {"text": "elder people"}, {"text": "demand"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "Asia-Pacific regions", "keywords": [{"text": "Asia-Pacific regions"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "upon to show high development rate in Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "high development rate"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "rely", "tense": "past"}, "text": "are also relied", "normalized": "be also rely"}}, {"subject": {"text": "Asia-Pacific regions", "keywords": [{"text": "Asia-Pacific regions"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "high development rate in Facial Aesthetic Remodeling market", "keywords": [{"text": "high development rate"}, {"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "to show", "normalized": "to show"}}, {"subject": {"text": "high spending on latest technologies along with peer group encouragement", "keywords": [{"text": "peer group encouragement"}, {"text": "high spending"}, {"text": "latest technologies"}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "the Facial Aesthetic Remodeling market growth", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market growth"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "would propel", "normalized": "would propel"}}], "concepts": [{"text": "Skin", "relevance": 0.976196, "dbpedia_resource": "http://dbpedia.org/resource/Skin"}, {"text": "Dermis", "relevance": 0.850404, "dbpedia_resource": "http://dbpedia.org/resource/Dermis"}, {"text": "Beauty", "relevance": 0.756139, "dbpedia_resource": "http://dbpedia.org/resource/Beauty"}, {"text": "Plastic surgery", "relevance": 0.737194, "dbpedia_resource": "http://dbpedia.org/resource/Plastic_surgery"}, {"text": "Subcutaneous tissue", "relevance": 0.641333, "dbpedia_resource": "http://dbpedia.org/resource/Subcutaneous_tissue"}, {"text": "Aesthetics", "relevance": 0.58643, "dbpedia_resource": "http://dbpedia.org/resource/Aesthetics"}, {"text": "Invasive", "relevance": 0.504156, "dbpedia_resource": "http://dbpedia.org/resource/Invasive_(medical)"}, {"text": "Skin cancer", "relevance": 0.491027, "dbpedia_resource": "http://dbpedia.org/resource/Skin_cancer"}, {"text": "Facial muscles", "relevance": 0.483375, "dbpedia_resource": "http://dbpedia.org/resource/Facial_muscles"}, {"text": "Human skin color", "relevance": 0.482248, "dbpedia_resource": "http://dbpedia.org/resource/Human_skin_color"}], "categories": [{"score": 0.692263, "label": "/health and fitness"}, {"score": 0.421944, "label": "/health and fitness/therapy"}, {"score": 0.3785, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "tanuj 0 Comments Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "score": 0.740111, "arguments": [{"text": "Facial Aesthetic Remodeling", "location": [17, 44], "entities": [{"type": "Person", "text": "Facial Aesthetic Remodeling Market"}]}, {"text": "Comments", "location": [8, 16], "entities": [{"type": "EventCommunication", "text": "Comments"}]}]}, {"type": "employedBy", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.509042, "arguments": [{"text": "Participants", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Participants"}]}, {"text": "Key Market", "location": [5111, 5121], "entities": [{"type": "Organization", "text": "Key Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.601235, "arguments": [{"text": "Allergan", "location": [5209, 5217], "entities": [{"type": "Person", "text": "Allergan"}]}, {"text": "Participants", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Participants"}]}]}, {"type": "partOfMany", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.820612, "arguments": [{"text": "Galderma SA", "location": [5219, 5230], "entities": [{"type": "Person", "text": "Galderma SA"}]}, {"text": "Participants", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Participants"}]}]}, {"type": "partOfMany", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.692845, "arguments": [{"text": "Merz Aesthetics", "location": [5288, 5303], "entities": [{"type": "Person", "text": "Merz Aesthetics"}]}, {"text": "Participants", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Participants"}]}]}, {"type": "partOfMany", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.520221, "arguments": [{"text": "Suneva Medical", "location": [5305, 5319], "entities": [{"type": "Person", "text": "Suneva Medical"}]}, {"text": "Participants", "location": [5122, 5134], "entities": [{"type": "Person", "text": "Participants"}]}]}, {"type": "agentOf", "sentence": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "score": 0.562709, "arguments": [{"text": "their", "location": [1102, 1107], "entities": [{"type": "Person", "text": "their"}]}, {"text": "revolution", "location": [1162, 1172], "entities": [{"type": "EventDemonstration", "text": "revolution"}]}]}, {"type": "partOfMany", "sentence": "The treatment employed dermal facial fillers, injections of Botox, chemical peels, laser hair removal, etc. The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "score": 0.365385, "arguments": [{"text": "Facial Aesthetic Remodeling", "location": [1340, 1367], "entities": [{"type": "Person", "text": "Facial Aesthetic Remodeling Market"}]}, {"text": "Facial", "location": [1401, 1407], "entities": [{"type": "Person", "text": "Facial"}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.535698, "arguments": [{"text": "regions", "location": [4493, 4500], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [4517, 4530], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.525495, "arguments": [{"text": "regions", "location": [4493, 4500], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [4532, 4538], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.498109, "arguments": [{"text": "regions", "location": [4493, 4500], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [4592, 4598], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.465392, "arguments": [{"text": "Asia-Pacific", "location": [4540, 4552], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "Japan", "location": [4563, 4568], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "score": 0.462822, "arguments": [{"text": "Asia-Pacific", "location": [4781, 4793], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "regions", "location": [4794, 4801], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "partOf", "sentence": "Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "score": 0.411011, "arguments": [{"text": "peer group", "location": [4985, 4995], "entities": [{"type": "Organization", "text": "peer group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Facial Aesthetic Remodeling", "location": [4856, 4883], "entities": [{"type": "Organization", "text": "Facial Aesthetic Remodeling Market"}]}]}], "keywords": [{"text": "Facial Aesthetic", "sentiment": {"score": 0.152614, "label": "positive"}, "relevance": 0.997857}, {"text": "Facial Aesthetic Remodeling", "sentiment": {"score": 0.102311, "label": "positive"}, "relevance": 0.885929}, {"text": "aesthetic remodeling market", "sentiment": {"score": 0.159407, "label": "positive"}, "relevance": 0.770292}, {"text": "facial aesthetic units", "sentiment": {"score": -0.217384, "label": "negative"}, "relevance": 0.64907}, {"text": "Aesthetic Remodeling services", "sentiment": {"score": 0.525214, "label": "positive"}, "relevance": 0.617076}, {"text": "facial aesthetic procedures", "sentiment": {"score": 0.868239, "label": "positive"}, "relevance": 0.614913}, {"text": "largest Facial Aesthetic", "sentiment": {"score": -0.594191, "label": "negative"}, "relevance": 0.581473}, {"text": "dermal facial fillers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512018}, {"text": "facial aesthetics treatments", "sentiment": {"score": -0.344037, "label": "negative"}, "relevance": 0.495432}, {"text": "advanced aesthetic enhancements", "sentiment": {"score": 0.956825, "label": "positive"}, "relevance": 0.487354}, {"text": "facial ligaments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484922}, {"text": "facial skeleton", "sentiment": {"score": -0.217384, "label": "negative"}, "relevance": 0.483431}, {"text": "Remodeling market constitute", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472815}, {"text": "Facial muscles", "sentiment": {"score": -0.205767, "label": "negative"}, "relevance": 0.468944}, {"text": "Remodeling market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466603}, {"text": "Remodeling ability", "sentiment": {"score": 0.750532, "label": "positive"}, "relevance": 0.441442}, {"text": "dermal fillers", "sentiment": {"score": 0.480562, "label": "positive"}, "relevance": 0.374177}, {"text": "Key Market Participants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.373606}, {"text": "non-invasive dermal fillers", "sentiment": {"score": 0.670452, "label": "positive"}, "relevance": 0.370739}, {"text": "high-technology skin care", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36568}, {"text": "Rejuvenation,Dermal fillers,Laser skin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362409}, {"text": "forecast period", "sentiment": {"score": 0.590284, "label": "positive"}, "relevance": 0.359932}, {"text": "laser hair removal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.359335}, {"text": "Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358862}, {"text": "Clinics,Ambulatory Surgical Centers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358799}, {"text": "Head Procedure,Ear Surgery,Eyelid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356708}, {"text": "Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.356636}, {"text": "development rate", "sentiment": {"score": -0.89126, "label": "negative"}, "relevance": 0.35624}, {"text": "development rate crosswise", "sentiment": {"score": -0.89126, "label": "negative"}, "relevance": 0.354079}, {"text": "End User", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353496}, {"text": "minimally invasive techniques", "sentiment": {"score": -0.594191, "label": "negative"}, "relevance": 0.352566}, {"text": "high development rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352463}, {"text": "North America", "sentiment": {"score": -0.594191, "label": "negative"}, "relevance": 0.351464}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351373}, {"text": "market revenue", "sentiment": {"score": 0.670452, "label": "positive"}, "relevance": 0.351051}, {"text": "peer group encouragement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.350172}, {"text": "skin discoloration", "sentiment": {"score": -0.250729, "label": "negative"}, "relevance": 0.344896}, {"text": "skin laxity", "sentiment": {"score": -0.438744, "label": "negative"}, "relevance": 0.343303}, {"text": "skin thickness", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341924}, {"text": "nonsurgical procedures", "sentiment": {"score": 0.956825, "label": "positive"}, "relevance": 0.340934}, {"text": "youthful appearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339078}, {"text": "cosmetic procedure", "sentiment": {"score": 0.612916, "label": "positive"}, "relevance": 0.337113}, {"text": "comprehensive evaluation", "sentiment": {"score": 0.612916, "label": "positive"}, "relevance": 0.336549}, {"text": "subcutaneous tissue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335924}, {"text": "popular procedure", "sentiment": {"score": -0.205767, "label": "negative"}, "relevance": 0.335797}, {"text": "anti-ageing industry", "sentiment": {"score": 0.750532, "label": "positive"}, "relevance": 0.335759}, {"text": "industrialized societies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335054}, {"text": "loose skin", "sentiment": {"score": 0.882438, "label": "positive"}, "relevance": 0.334692}, {"text": "human face", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333909}, {"text": "chemical peels", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333727}]}, "extracted_metadata": {"sha1": "1d46279d6b33f03b34d741befb34f5d2fd74d383", "filename": "1541046968638.zip-3ac6c97e010efec1e6ff1b3136f19db5.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/facial-aesthetic-remodeling-market.asp", "https://www.persistencemarketresearch.com/samples/15190"], "title": "Facial Aesthetic Remodeling Market to Exhibit Impressive Growth During 2017-2025", "forum_title": "Find Market Research"}, {"id": "kAemnsFChH4daX_07Il6ZxJ3XlZdfSqj526yoJjpp7hPLqRpNqiqWBj_FdvXAqRy", "result_metadata": {"score": 31.867437}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Marketing", "relevance": 0.901128, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}], "categories": [{"score": 0.52651, "label": "/automotive and vehicles/vehicle brands/ferrari"}, {"score": 0.495994, "label": "/business and industrial/advertising and marketing"}, {"score": 0.477487, "label": "/business and industrial/metals"}], "relations": [], "keywords": [{"text": "Delivers Product Sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.968355}, {"text": "Key Priorities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725405}, {"text": "Q3", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544376}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471144}, {"text": "Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333272}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330712}]}, "crawl_date": "2018-11-01T12:47:03Z", "url": "https://www.marketscreener.com/SHIRE-9590198/news/Shire-Delivers-Product-Sales-Growth-of-6-and-Continues-to-Execute-Against-Key-Priorities-in-Q3-20-27526259/", "host": "marketscreener.com", "text": "Risks associated with this outlook include the potential uncertainty resulting from the announcement by Takeda Pharmaceutical Company Limited (Takeda) on May 8, 2018 of a recommended offer for Shire under the U.K.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T00:00:00Z", "enriched_text": {"entities": [{"count": 43, "sentiment": {"score": -0.302182, "label": "negative"}, "text": "Shire", "relevance": 0.810715, "type": "Organization"}, {"count": 14, "sentiment": {"score": -0.304631, "label": "negative"}, "text": "Shire", "relevance": 0.422948, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.376925, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Chief Executive Officer", "relevance": 0.308728, "type": "JobTitle"}, {"count": 8, "sentiment": {"score": 0.0383804, "label": "positive"}, "text": "U.S.", "relevance": 0.297797, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": 0.389476, "label": "positive"}, "text": "TAKHZYRO", "relevance": 0.272321, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.204997, "label": "positive"}, "text": "Shire", "relevance": 0.247119, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.376961, "label": "positive"}, "text": "U.S. Food and Drug Administration", "relevance": 0.224517, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 4, "sentiment": {"score": 0.281043, "label": "positive"}, "text": "United Kingdom", "relevance": 0.218104, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.204124, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.203043, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.183449, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Flemming Ornskov", "relevance": 0.181637, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LSE", "relevance": 0.181111, "type": "Company", "disambiguation": {"subtype": ["Location", "Facility", "TouristAttraction"], "name": "London Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/London_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": -0.25242, "label": "negative"}, "text": "hereditary angioedema", "relevance": 0.17976, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Hereditary angioedema", "dbpedia_resource": "http://dbpedia.org/resource/Hereditary_angioedema"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.179558, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0.357496, "label": "positive"}, "text": "Canada", "relevance": 0.176683, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0.357496, "label": "positive"}, "text": "Committee for Medicinal Products", "relevance": 0.175751, "type": "Organization"}, {"count": 5, "sentiment": {"score": -0.67216, "label": "negative"}, "text": "Japan", "relevance": 0.172916, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.169922, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.376961, "label": "positive"}, "text": "Health Canada", "relevance": 0.165873, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CIC", "relevance": 0.164409, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADHD", "relevance": 0.164271, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Attention deficit hyperactivity disorder", "dbpedia_resource": "http://dbpedia.org/resource/Attention_deficit_hyperactivity_disorder"}}, {"count": 1, "sentiment": {"score": -0.319633, "label": "negative"}, "text": "ADDERALL", "relevance": 0.161911, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Internal Medicine", "relevance": 0.159372, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities and Exchange Commission", "relevance": 0.158633, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "sanaplasma AG", "relevance": 0.157058, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dyax Corp.", "relevance": 0.156721, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.42995, "label": "negative"}, "text": "von Willebrand disease", "relevance": 0.156254, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Von Willebrand disease", "dbpedia_resource": "http://dbpedia.org/resource/Von_Willebrand_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "iTunes Store", "relevance": 0.155115, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ONIVYDE", "relevance": 0.154043, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.153718, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ophthalmics", "relevance": 0.153424, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Medicines Agency", "relevance": 0.152237, "type": "Organization", "disambiguation": {"subtype": [], "name": "European Medicines Agency", "dbpedia_resource": "http://dbpedia.org/resource/European_Medicines_Agency"}}, {"count": 1, "sentiment": {"score": 0.296068, "label": "positive"}, "text": "Shionogi & Co.", "relevance": 0.147674, "type": "Company", "disambiguation": {"subtype": [], "name": "Shionogi", "dbpedia_resource": "http://dbpedia.org/resource/Shionogi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Covington", "relevance": 0.147294, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Covington, Georgia", "dbpedia_resource": "http://dbpedia.org/resource/Covington,_Georgia"}}, {"count": 2, "sentiment": {"score": -0.67216, "label": "negative"}, "text": "FIRAZYR", "relevance": 0.146127, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "VEYVONDI", "relevance": 0.14497, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA Gastrointestinal Drugs Advisory Committee", "relevance": 0.144283, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.446696, "label": "positive"}, "text": "Stephen Williams", "relevance": 0.144277, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Czech Republic", "relevance": 0.143906, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Czech Republic", "dbpedia_resource": "http://dbpedia.org/resource/Czech_Republic"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Baxalta", "relevance": 0.138866, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Deputy Company Secretary", "relevance": 0.138447, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.0921132, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "by Immunology, recently-launched products, and international expansion", "keywords": [{"text": "international expansion"}, {"text": "recently-launched products"}, {"text": "Immunology"}]}, "sentence": "Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion", "object": {"text": "growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "driven", "normalized": "drive"}}, {"subject": {"text": "the leading global biotech company", "keywords": [{"text": "global biotech company"}]}, "sentence": " November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "object": {"text": "unaudited results", "keywords": [{"text": "unaudited results"}]}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "the three months", "entities": [{"type": "Quantity", "text": "three months"}]}, "sentence": " November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "'We", "entities": [{"type": "JobTitle", "text": "Shire Chief Executive Officer"}]}, "sentence": " 'We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline.", "object": {"text": "to deliver solid growth", "keywords": [{"text": "solid growth"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "'We", "entities": [{"type": "JobTitle", "text": "Shire Chief Executive Officer"}]}, "sentence": " 'We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline.", "object": {"text": "solid growth", "keywords": [{"text": "solid growth"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "continue to deliver", "normalized": "continue to deliver"}}, {"subject": {"text": "'We", "entities": [{"type": "JobTitle", "text": "Shire Chief Executive Officer"}]}, "sentence": " 'We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline.", "object": {"text": "our debt", "keywords": [{"text": "debt"}]}, "action": {"verb": {"text": "pay", "tense": "present"}, "text": "pay", "normalized": "pay"}}, {"subject": {"text": "Our growth", "keywords": [{"text": "growth"}]}, "sentence": " Our growth was once again driven by our Immunology franchise, recently-launched products, and expansion in international markets.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by our Immunology franchise, recently-launched products, and expansion in international markets", "keywords": [{"text": "Immunology franchise"}, {"text": "recently-launched products"}, {"text": "international markets"}, {"text": "expansion"}]}, "sentence": " Our growth was once again driven by our Immunology franchise, recently-launched products, and expansion in international markets.", "object": {"text": "Our growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "driven", "normalized": "drive"}}, {"subject": {"text": "Proceeds from the sale of our Oncology franchise", "keywords": [{"text": "Oncology franchise"}, {"text": "Proceeds"}, {"text": "sale"}]}, "sentence": " Proceeds from the sale of our Oncology franchise coupled with strong free cash flow allowed us to reduce net debt by $3.9 billion year to date.", "object": {"text": "with strong free cash flow allowed us to reduce net debt by $3.9 billion year to date", "keywords": [{"text": "strong free cash"}, {"text": "net debt"}, {"text": "flow"}, {"text": "date"}], "entities": [{"type": "Quantity", "text": "3.9 billion year"}, {"type": "Quantity", "text": "$3.9 billion"}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "Proceeds from the sale of our Oncology franchise coupled with strong free cash flow", "keywords": [{"text": "strong free cash"}, {"text": "Proceeds"}, {"text": "sale"}, {"text": "franchise"}], "entities": []}, "sentence": " Proceeds from the sale of our Oncology franchise coupled with strong free cash flow allowed us to reduce net debt by $3.9 billion year to date.", "object": {"text": "us to reduce net debt by $3.9 billion year to date", "keywords": [{"text": "net debt"}, {"text": "date"}], "entities": [{"type": "Quantity", "text": "3.9 billion year"}, {"type": "Quantity", "text": "$3.9 billion"}]}, "action": {"verb": {"text": "allow", "tense": "past"}, "text": "allowed", "normalized": "allow"}}, {"subject": {"text": "'We"}, "sentence": " 'We recently launched TAKHZYRO, the first monoclonal antibody to prevent hereditary angioedema (HAE) attacks, in the U.S. We also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization in Europe.", "object": {"text": "TAKHZYRO", "keywords": [{"text": "TAKHZYRO"}], "entities": [{"type": "Company", "text": "TAKHZYRO"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "the first monoclonal antibody to prevent hereditary angioedema (HAE)", "keywords": [{"text": "hereditary angioedema"}, {"text": "monoclonal antibody"}, {"text": "HAE"}], "entities": [{"type": "HealthCondition", "text": "hereditary angioedema", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Hereditary angioedema", "dbpedia_resource": "http://dbpedia.org/resource/Hereditary_angioedema"}}]}, "sentence": " 'We recently launched TAKHZYRO, the first monoclonal antibody to prevent hereditary angioedema (HAE) attacks, in the U.S. We also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization in Europe.", "object": {"text": "a positive opinion", "keywords": [{"text": "positive opinion"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "marketing authorization", "keywords": [{"text": "authorization"}, {"text": "marketing"}]}, "sentence": " 'We recently launched TAKHZYRO, the first monoclonal antibody to prevent hereditary angioedema (HAE) attacks, in the U.S. We also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization in Europe.", "action": {"verb": {"text": "recommend", "tense": "present"}, "text": "recommending", "normalized": "recommend"}}, {"subject": {"text": "integration planning", "keywords": [{"text": "integration planning"}]}, "sentence": " While integration planning is ongoing, our solid performance through the third quarter of 2018 demonstrates our continued focus on delivering for patients and executing against our key priorities.'", "object": {"text": "ongoing, our solid performance", "keywords": [{"text": "solid performance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "this release", "keywords": [{"text": "release"}]}, "sentence": " (2) The Non GAAP financial measures included within this release are explained on pages 27 - 28, and are reconciled to the most directly comparable financial measures prepared in accordance with U.S. GAAP on pages 19 - 22.", "object": {"text": "explained on pages", "keywords": [{"text": "pages"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "All franchises", "keywords": [{"text": "franchises"}]}, "sentence": " All franchises demonstrated product sales growth on a Non GAAP constant exchange rate basis, excluding Oncology which was sold during the quarter.", "object": {"text": "product sales growth", "keywords": [{"text": "product sales growth"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "2018"}, "sentence": " Encouraging early trajectory of TAKHZYRO since U.S. launch on August 23, 2018 with $51 million in initial launch stocking.", "object": {"text": "early trajectory of TAKHZYRO", "keywords": [{"text": "early trajectory"}, {"text": "TAKHZYRO"}], "entities": [{"type": "Company", "text": "TAKHZYRO"}]}, "action": {"verb": {"text": "Encouraging", "tense": "present"}, "text": "Encouraging", "normalized": "Encouraging"}}, {"subject": {"text": "Non GAAP", "keywords": [{"text": "Non GAAP"}]}, "sentence": " Generated Non GAAP diluted earnings per ADS of $3.64, a decrease of 4%, as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "earnings per ADS", "keywords": [{"text": "earnings"}, {"text": "ADS"}]}, "action": {"verb": {"text": "dilute", "tense": "past"}, "text": "diluted", "normalized": "dilute"}}, {"subject": {"text": "Non GAAP", "keywords": [{"text": "Non GAAP"}]}, "sentence": " Generated Non GAAP diluted earnings per ADS of $3.64, a decrease of 4%, as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "expense discipline", "keywords": [{"text": "expense discipline"}]}, "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "product sales growth and operating expense discipline", "keywords": [{"text": "product sales growth"}, {"text": "expense"}, {"text": "discipline"}]}, "sentence": " Generated Non GAAP diluted earnings per ADS of $3.64, a decrease of 4%, as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments", "keywords": [{"text": "lower gross margins"}, {"text": "unfavorable foreign exchange"}, {"text": "unrealized losses"}, {"text": "equity investments"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "product sales growth and operating expense discipline", "keywords": [{"text": "product sales growth"}, {"text": "expense"}, {"text": "discipline"}]}, "sentence": " Generated Non GAAP diluted earnings per ADS of $3.64, a decrease of 4%, as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments", "keywords": [{"text": "lower gross margins"}, {"text": "unfavorable foreign exchange"}, {"text": "unrealized losses"}, {"text": "equity investments"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "were offset", "normalized": "be offset"}}, {"subject": {"text": "Non GAAP EBITDA margin of 42%, a slight decline from Q3 2017, primarily due to lower gross margins,", "keywords": [{"text": "GAAP EBITDA margin"}, {"text": "lower gross margins"}, {"text": "slight decline"}, {"text": "Q3"}], "entities": [{"type": "Quantity", "text": "42"}]}, "sentence": " Reported Non GAAP EBITDA margin of 42%, a slight decline from Q3 2017, primarily due to lower gross margins, as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products, partially offset by ongoing cost discipline and operating expense synergies.", "action": {"verb": {"text": "Reported", "tense": "past"}, "text": "Reported", "normalized": "Reported"}}, {"subject": {"text": "favorability from the timing of changes in the costs to manufacture certain products, partially offset by ongoing cost discipline and operating expense synergies", "keywords": [{"text": "ongoing cost discipline"}, {"text": "operating expense"}, {"text": "certain products"}, {"text": "synergies"}]}, "sentence": " Reported Non GAAP EBITDA margin of 42%, a slight decline from Q3 2017, primarily due to lower gross margins, as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products, partially offset by ongoing cost discipline and operating expense synergies.", "object": {"text": "a slight decline from Q3 2017, primarily due to lower gross margins, as Q3 2017", "keywords": [{"text": "lower gross margins"}, {"text": "slight decline"}, {"text": "Q3"}]}, "action": {"verb": {"text": "reflect", "tense": "past"}, "text": "reflected", "normalized": "reflect"}}, {"subject": {"text": "Proceeds from the sale of our Oncology franchise and strong free cash flow during the year", "keywords": [{"text": "Oncology franchise"}, {"text": "cash flow"}, {"text": "Proceeds"}, {"text": "sale"}], "entities": []}, "sentence": " Proceeds from the sale of our Oncology franchise and strong free cash flow during the year enabled a $3,915 million reduction in Non GAAP net debt since December 31, 2017.", "object": {"text": "a $3,915 million reduction in Non GAAP net debt", "keywords": [{"text": "GAAP net debt"}, {"text": "reduction"}, {"text": "Non"}], "entities": [{"type": "Quantity", "text": "$3,915 million"}]}, "action": {"verb": {"text": "enable", "tense": "past"}, "text": "enabled", "normalized": "enable"}}, {"subject": {"text": "THIRD QUARTER 2018", "keywords": [{"text": "QUAER"}]}, "sentence": " FINANCIAL SUMMARY - THIRD QUARTER 2018 COMPARED TO THIRD QUARTER 2017", "object": {"text": "TO THIRD QUARTER 2017", "keywords": [{"text": "QUAER"}]}, "action": {"verb": {"text": "COMPARED", "tense": "past"}, "text": "COMPARED", "normalized": "COMPARED"}}, {"subject": {"text": "Product sales", "keywords": [{"text": "Product sales"}]}, "sentence": " Product sales increased 6% to $3,753 million (Q3 2017: $3,534 million), driven by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%.", "object": {"text": "6%", "entities": [{"type": "Quantity", "text": "6"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%", "keywords": [{"text": "Genetic Diseases"}, {"text": "Internal Medicine"}, {"text": "Immunology"}, {"text": "Neuroscience"}], "entities": [{"type": "Company", "text": "Internal Medicine"}, {"type": "Person", "text": "Ophthalmics"}, {"type": "Quantity", "text": "6"}, {"type": "Quantity", "text": "10"}, {"type": "Quantity", "text": "12"}, {"type": "Quantity", "text": "21"}]}, "sentence": " Product sales increased 6% to $3,753 million (Q3 2017: $3,534 million), driven by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%.", "object": {"text": "$3,534 million)", "entities": [{"type": "Quantity", "text": "$3,534 million"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "driven", "normalized": "drive"}}, {"subject": {"text": "Royalties and other revenues", "keywords": [{"text": "Royalties"}, {"text": "revenues"}]}, "sentence": " Royalties and other revenues decreased 27% to $119 million (Q3 2017: $164 million), primarily due to certain royalty expirations, the reclassification of ADDERALL XR from royalty revenue to product sales, and other changes as required under the new revenue accounting standard.", "object": {"text": "27%", "entities": [{"type": "Quantity", "text": "27"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "other changes", "keywords": [{"text": "changes"}]}, "sentence": " Royalties and other revenues decreased 27% to $119 million (Q3 2017: $164 million), primarily due to certain royalty expirations, the reclassification of ADDERALL XR from royalty revenue to product sales, and other changes as required under the new revenue accounting standard.", "action": {"verb": {"text": "require", "tense": "past"}, "text": "required", "normalized": "require"}}, {"subject": {"text": "Operating income", "keywords": [{"text": "income"}]}, "sentence": " Operating income increased 35% to $956 million (Q3 2017: $709 million), due to the gain on the sale of Shire's Oncology franchise and lower integration and acquisition costs, partially offset by increased reorganization costs.", "object": {"text": "35%", "entities": [{"type": "Quantity", "text": "35"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "Non GAAP operating income", "keywords": [{"text": "GAAP operating income"}, {"text": "Non"}]}, "sentence": " Non GAAP operating income decreased 2% to $1,475 million (Q3 2017: $1,498 million), primarily due to lower gross margins as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products.", "object": {"text": "2%", "entities": [{"type": "Quantity", "text": "2"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "favorability from the timing of changes in the costs to manufacture certain products", "keywords": [{"text": "certain products"}, {"text": "timing"}, {"text": "costs"}, {"text": "favorability"}]}, "sentence": " Non GAAP operating income decreased 2% to $1,475 million (Q3 2017: $1,498 million), primarily due to lower gross margins as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products.", "object": {"text": "primarily due to lower gross margins as Q3 2017", "keywords": [{"text": "lower gross margins"}, {"text": "Q3"}]}, "action": {"verb": {"text": "reflect", "tense": "past"}, "text": "reflected", "normalized": "reflect"}}, {"subject": {"text": "Non GAAP EBITDA margin", "keywords": [{"text": "GAAP EBITDA margin"}, {"text": "Non"}]}, "sentence": " Non GAAP EBITDA margin was slightly down to 42% (Q3 2017: 44%), primarily due to lower gross margins partially offset by ongoing cost discipline and operating expense synergies.", "object": {"text": "slightly down to 42% (Q3 2017", "entities": [{"type": "Quantity", "text": "42"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "lower gross margins", "keywords": [{"text": "lower gross margins"}]}, "sentence": " Non GAAP EBITDA margin was slightly down to 42% (Q3 2017: 44%), primarily due to lower gross margins partially offset by ongoing cost discipline and operating expense synergies.", "object": {"text": "by ongoing cost discipline and operating expense synergies", "keywords": [{"text": "ongoing cost discipline"}, {"text": "operating expense"}, {"text": "synergies"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}, {"subject": {"text": "Non GAAP", "keywords": [{"text": "Non GAAP"}]}, "sentence": " Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "earnings per ADS", "keywords": [{"text": "earnings"}, {"text": "ADS"}]}, "action": {"verb": {"text": "dilute", "tense": "past"}, "text": "diluted", "normalized": "dilute"}}, {"subject": {"text": "ADS", "keywords": [{"text": "ADS"}]}, "sentence": " Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "4%", "entities": [{"type": "Quantity", "text": "4"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "product sales growth and operating expense discipline", "keywords": [{"text": "product sales growth"}, {"text": "expense"}, {"text": "discipline"}]}, "sentence": " Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "object": {"text": "offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments", "keywords": [{"text": "lower gross margins"}, {"text": "unfavorable foreign exchange"}, {"text": "unrealized losses"}, {"text": "equity investments"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "by operating activities", "keywords": [{"text": "activities"}]}, "sentence": " Net cash provided by operating activities decreased 19% to $858 million (Q3 2017: $1,055 million), driven by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO.", "object": {"text": "Net cash", "keywords": [{"text": "Net cash"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "Net cash provided by operating activities", "keywords": [{"text": "Net cash"}, {"text": "activities"}]}, "sentence": " Net cash provided by operating activities decreased 19% to $858 million (Q3 2017: $1,055 million), driven by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO.", "object": {"text": "19%", "entities": [{"type": "Quantity", "text": "19"}]}, "action": {"verb": {"text": "decrease", "tense": "past"}, "text": "decreased", "normalized": "decrease"}}, {"subject": {"text": "by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO", "keywords": [{"text": "contingent consideration payment"}, {"text": "Dyax Corp."}, {"text": "shareholders"}, {"text": "approval"}], "entities": [{"type": "Company", "text": "Dyax Corp."}, {"type": "Company", "text": "TAKHZYRO"}, {"type": "Quantity", "text": "$251 million"}]}, "sentence": " Net cash provided by operating activities decreased 19% to $858 million (Q3 2017: $1,055 million), driven by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO.", "object": {"text": "$1,055 million)", "entities": [{"type": "Quantity", "text": "$1,055 million"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "driven", "normalized": "drive"}}, {"subject": {"text": "Non GAAP free cash flow", "keywords": [{"text": "GAAP free cash"}, {"text": "Non"}], "entities": []}, "sentence": " Non GAAP free cash flow increased 8% to $971 million (Q3 2017: $901 million).", "object": {"text": "8%", "entities": [{"type": "Quantity", "text": "8"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "capital expenditures of $203 million (Q3 2017", "keywords": [{"text": "capital expenditures"}, {"text": "Q3"}], "entities": [{"type": "Quantity", "text": "$203 million"}]}, "sentence": " Non GAAP free cash flow includes capital expenditures of $203 million (Q3 2017: $174 million) and excludes payments relating to milestone and license arrangements of $316 million (Q3 2017: $20 million).", "object": {"text": "Non GAAP free cash flow", "keywords": [{"text": "GAAP free cash"}, {"text": "Non"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "payments", "keywords": [{"text": "payments"}]}, "sentence": " Non GAAP free cash flow includes capital expenditures of $203 million (Q3 2017: $174 million) and excludes payments relating to milestone and license arrangements of $316 million (Q3 2017: $20 million).", "object": {"text": "to milestone and license arrangements of $316 million (Q3 2017: $20 million)", "keywords": [{"text": "arrangements"}], "entities": [{"type": "Quantity", "text": "$316 million"}, {"type": "Quantity", "text": "$20 million"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "existing cash balances", "keywords": [{"text": "cash balances"}]}, "sentence": " A combination of proceeds from the sale of Shire's Oncology franchise, Non GAAP free cash flow, and existing cash balances were utilized to repay debt during the year.", "object": {"text": "utilized to repay debt", "keywords": [{"text": "debt"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "debt", "keywords": [{"text": "debt"}]}, "sentence": " A combination of proceeds from the sale of Shire's Oncology franchise, Non GAAP free cash flow, and existing cash balances were utilized to repay debt during the year.", "action": {"verb": {"text": "repay", "tense": "past"}, "text": "to repay", "normalized": "to repay"}}, {"subject": {"text": "Non GAAP net debt", "keywords": [{"text": "GAAP net debt"}, {"text": "Non"}]}, "sentence": " Non GAAP net debt represents aggregate long and short term borrowings of $14,980 million, and capital leases of $367 million, partially offset by cash and cash equivalents of $193 million.", "object": {"text": "aggregate long and short term borrowings of $14,980 million, and capital leases of $367 million", "keywords": [{"text": "short term borrowings"}, {"text": "capital leases"}, {"text": "aggregate"}], "entities": [{"type": "Quantity", "text": "$14,980 million"}, {"type": "Quantity", "text": "$367 million"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "borrowings of $14,980 million, and capital leases of $367 million", "keywords": [{"text": "capital leases"}, {"text": "borrowings"}], "entities": [{"type": "Quantity", "text": "$14,980 million"}, {"type": "Quantity", "text": "$367 million"}]}, "sentence": " Non GAAP net debt represents aggregate long and short term borrowings of $14,980 million, and capital leases of $367 million, partially offset by cash and cash equivalents of $193 million.", "object": {"text": "by cash and cash equivalents of $193 million", "keywords": [{"text": "cash equivalents"}], "entities": [{"type": "Quantity", "text": "$193 million"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}, {"subject": {"text": "Our 2018 guidance", "keywords": [{"text": "guidance"}]}, "sentence": " Our 2018 guidance, presented in the table below, has been updated to adjust for the sale of our Oncology franchise, which closed on August 31, 2018.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "Our 2018 guidance", "keywords": [{"text": "guidance"}]}, "sentence": " Our 2018 guidance, presented in the table below, has been updated to adjust for the sale of our Oncology franchise, which closed on August 31, 2018.", "object": {"text": "updated to adjust for the sale of our Oncology franchise, which closed on August 31, 2018", "keywords": [{"text": "Oncology franchise"}, {"text": "sale"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "our Oncology franchise", "keywords": [{"text": "Oncology franchise"}]}, "sentence": " Our 2018 guidance, presented in the table below, has been updated to adjust for the sale of our Oncology franchise, which closed on August 31, 2018.", "action": {"verb": {"text": "close", "tense": "past"}, "text": "closed", "normalized": "close"}}], "concepts": [{"text": "Revenue", "relevance": 0.983076, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Free cash flow", "relevance": 0.941314, "dbpedia_resource": "http://dbpedia.org/resource/Free_cash_flow"}, {"text": "Income statement", "relevance": 0.927189, "dbpedia_resource": "http://dbpedia.org/resource/Income_statement"}, {"text": "Cash flow", "relevance": 0.827611, "dbpedia_resource": "http://dbpedia.org/resource/Cash_flow"}, {"text": "Operating cash flow", "relevance": 0.771972, "dbpedia_resource": "http://dbpedia.org/resource/Operating_cash_flow"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.629828, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Income", "relevance": 0.625659, "dbpedia_resource": "http://dbpedia.org/resource/Income"}, {"text": "Net income", "relevance": 0.573398, "dbpedia_resource": "http://dbpedia.org/resource/Net_income"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.549065, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Cash flow statement", "relevance": 0.536489, "dbpedia_resource": "http://dbpedia.org/resource/Cash_flow_statement"}, {"text": "Food and Drug Administration", "relevance": 0.459714, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Economic growth", "relevance": 0.450853, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Cash", "relevance": 0.434162, "dbpedia_resource": "http://dbpedia.org/resource/Cash"}, {"text": "Discounted cash flow", "relevance": 0.416377, "dbpedia_resource": "http://dbpedia.org/resource/Discounted_cash_flow"}, {"text": "Earnings per share", "relevance": 0.408193, "dbpedia_resource": "http://dbpedia.org/resource/Earnings_per_share"}, {"text": "Earnings before interest and taxes", "relevance": 0.389073, "dbpedia_resource": "http://dbpedia.org/resource/Earnings_before_interest_and_taxes"}, {"text": "Depreciation", "relevance": 0.386896, "dbpedia_resource": "http://dbpedia.org/resource/Depreciation"}, {"text": "Operating expense", "relevance": 0.379127, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Total revenue", "relevance": 0.373362, "dbpedia_resource": "http://dbpedia.org/resource/Total_revenue"}], "categories": [{"score": 0.645581, "label": "/finance/financial news"}, {"score": 0.457396, "label": "/business and industrial/company/earnings"}, {"score": 0.394403, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion Received U.S. Food and Drug Administration and Health Canada approval for TAKHZYRO (lanadelumab-flyo) and launched in the U.S. Accelerated debt pay-down through proceeds from the $2.4 billion sale of the Oncology franchise and strong net operating cash flow November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "score": 0.725938, "arguments": [{"text": "Immunology", "location": [58, 68], "entities": [{"type": "Organization", "text": "Immunology", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$3.8 billion", "location": [27, 39], "entities": [{"type": "Money", "text": "$3.8 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "While integration planning is ongoing, our solid performance through the third quarter of 2018 demonstrates our continued focus on delivering for patients and executing against our key priorities.", "score": 0.659774, "arguments": [{"text": "our", "location": [1708, 1711], "entities": [{"type": "Person", "text": "our"}]}, {"text": "demonstrates", "location": [1764, 1776], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "While integration planning is ongoing, our solid performance through the third quarter of 2018 demonstrates our continued focus on delivering for patients and executing against our key priorities.", "score": 0.733748, "arguments": [{"text": "2018", "location": [1759, 1763], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "demonstrates", "location": [1764, 1776], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "affectedBy", "sentence": "While integration planning is ongoing, our solid performance through the third quarter of 2018 demonstrates our continued focus on delivering for patients and executing against our key priorities.", "score": 0.519387, "arguments": [{"text": "our", "location": [1777, 1780], "entities": [{"type": "Person", "text": "our"}]}, {"text": "demonstrates", "location": [1764, 1776], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOfMany", "sentence": "While integration planning is ongoing, our solid performance through the third quarter of 2018 demonstrates our continued focus on delivering for patients and executing against our key priorities.", "score": 0.723939, "arguments": [{"text": "our", "location": [1777, 1780], "entities": [{"type": "Person", "text": "our"}]}, {"text": "patients", "location": [1815, 1823], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "employedBy", "sentence": "' Product sales $3,753 million +6% +7% Total revenues $3,872 million +5% +6% Operating income from continuing operations $956 million +35% Non GAAP operating income (2) $1,475 million -2% -1% Net income margin (3)(4) 14% -1ppc Non GAAP EBITDA margin (2)(3)(4) 42% -2ppc Net income $537 million -2% Non GAAP net income (2) $1,119 million -3% Diluted earnings per ADS (5) $1.75 -3% Non GAAP diluted earnings per ADS (2)(5) $3.64 -4% -4% Net cash provided by operating activities $858 million -19% Non GAAP free cash flow (2) $971 million +8% (1)", "score": 0.735614, "arguments": [{"text": "7%", "location": [1901, 1903], "entities": [{"type": "Person", "text": "7%"}]}, {"text": "Total", "location": [1904, 1909], "entities": [{"type": "Organization", "text": "Total", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "' Product sales $3,753 million +6% +7% Total revenues $3,872 million +5% +6% Operating income from continuing operations $956 million +35% Non GAAP operating income (2) $1,475 million -2% -1% Net income margin (3)(4) 14% -1ppc Non GAAP EBITDA margin (2)(3)(4) 42% -2ppc Net income $537 million -2% Non GAAP net income (2) $1,119 million -3% Diluted earnings per ADS (5) $1.75 -3% Non GAAP diluted earnings per ADS (2)(5) $3.64 -4% -4% Net cash provided by operating activities $858 million -19% Non GAAP free cash flow (2) $971 million +8% (1)", "score": 0.881927, "arguments": [{"text": "Total", "location": [1904, 1909], "entities": [{"type": "Organization", "text": "Total", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$3,872 million +5", "location": [1919, 1936], "entities": [{"type": "Money", "text": "$3,872 million +5", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "(2) The Non GAAP financial measures included within this release are explained on pages 27 - 28, and are reconciled to the most directly comparable financial measures prepared in accordance with U.S. GAAP on pages 19 - 22.", "score": 0.91136, "arguments": [{"text": "Non GAAP", "location": [2503, 2511], "entities": [{"type": "Person", "text": "Non GAAP Outlook"}]}, {"text": "explained", "location": [2564, 2573], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Reported Non GAAP EBITDA margin of 42%, a slight decline from Q3 2017, primarily due to lower gross margins, as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products, partially offset by ongoing cost discipline and operating expense synergies.", "score": 0.647923, "arguments": [{"text": "Non GAAP EBITDA", "location": [3542, 3557], "entities": [{"type": "Person", "text": "Non GAAP Outlook"}]}, {"text": "Reported", "location": [3533, 3541], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "score": 0.625473, "arguments": [{"text": "Non GAAP", "location": [5532, 5540], "entities": [{"type": "Person", "text": "Non GAAP Outlook"}]}, {"text": "decreased", "location": [5566, 5575], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOf", "sentence": "(2) The Non GAAP financial measures included within this release are explained on pages 27 - 28, and are reconciled to the most directly comparable financial measures prepared in accordance with U.S. GAAP on pages 19 - 22.", "score": 0.98623, "arguments": [{"text": "GAAP", "location": [2695, 2699], "entities": [{"type": "Organization", "text": "GAAP", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [2690, 2694], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Our U.S. GAAP diluted earnings per ADS outlook reflects anticipated amortization, integration, acquisition, and reorganization costs, as well as the gain on sale of our Oncology franchise and the impact from debt repurchase.", "score": 0.986919, "arguments": [{"text": "GAAP", "location": [7459, 7463], "entities": [{"type": "Organization", "text": "GAAP", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [7454, 7458], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "(3) See page 22 for a reconciliation between U.S. GAAP diluted earnings per ADS and Non GAAP diluted earnings per ADS.", "score": 0.986919, "arguments": [{"text": "GAAP", "location": [8462, 8466], "entities": [{"type": "Organization", "text": "GAAP", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [8457, 8461], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Encouraging early trajectory of TAKHZYRO since U.S. launch on August 23, 2018 with $51 million in initial launch stocking.", "score": 0.671657, "arguments": [{"text": "TAKHZYRO", "location": [3076, 3084], "entities": [{"type": "GeopoliticalEntity", "text": "TAKHZYRO"}]}, {"text": "U.S.", "location": [3091, 3095], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Growth of recently-launched products of 45%, primarily due to TAKHZYRO, ADYNOVATE, CUVITRU, and XIIDRA.", "score": 0.973046, "arguments": [{"text": "TAKHZYRO", "location": [3229, 3237], "entities": [{"type": "GeopoliticalEntity", "text": "TAKHZYRO"}]}, {"text": "ADYNOVATE", "location": [3239, 3248], "entities": [{"type": "GeopoliticalEntity", "text": "ADYNOVATE"}]}]}, {"type": "partOf", "sentence": "Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion Received U.S. Food and Drug Administration and Health Canada approval for TAKHZYRO (lanadelumab-flyo) and launched in the U.S. Accelerated debt pay-down through proceeds from the $2.4 billion sale of the Oncology franchise and strong net operating cash flow November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "score": 0.986069, "arguments": [{"text": "Food and Drug Administration", "location": [140, 168], "entities": [{"type": "Organization", "text": "FDA Gastrointestinal Drugs Advisory Committee", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [135, 139], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Products TAKHZYRO, a first-of-its-kind monoclonal antibody (mAb) preventive treatment for HAE On August 23, 2018, Shire announced that the U.S. Food and Drug Administration (FDA) had approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older.", "score": 0.965164, "arguments": [{"text": "Food and Drug Administration", "location": [9927, 9955], "entities": [{"type": "Organization", "text": "FDA Gastrointestinal Drugs Advisory Committee", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [9922, 9926], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Growth of recently-launched products of 45%, primarily due to TAKHZYRO, ADYNOVATE, CUVITRU, and XIIDRA.", "score": 0.954008, "arguments": [{"text": "ADYNOVATE", "location": [3239, 3248], "entities": [{"type": "GeopoliticalEntity", "text": "ADYNOVATE"}]}, {"text": "CUVITRU", "location": [3250, 3257], "entities": [{"type": "GeopoliticalEntity", "text": "CUVITRU"}]}]}, {"type": "hasAttribute", "sentence": "Product sales increased 6% to $3,753 million (Q3 2017: $3,534 million), driven by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%.", "score": 0.367929, "arguments": [{"text": "Q3", "location": [4203, 4205], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$3,753 million", "location": [4187, 4201], "entities": [{"type": "Money", "text": "$3,753 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Product sales increased 6% to $3,753 million (Q3 2017: $3,534 million), driven by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%.", "score": 0.622824, "arguments": [{"text": "Internal Medicine", "location": [4305, 4322], "entities": [{"type": "Organization", "text": "Internal Medicine", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$3,753 million", "location": [4187, 4201], "entities": [{"type": "Money", "text": "$3,753 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Product sales increased 6% to $3,753 million (Q3 2017: $3,534 million), driven by Immunology, up 12%, Neuroscience, up 6%, Genetic Diseases, up 6%, Internal Medicine, up 10%, and Ophthalmics, up 21%.", "score": 0.552633, "arguments": [{"text": "Q3", "location": [4203, 4205], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$3,534 million", "location": [4212, 4226], "entities": [{"type": "Money", "text": "$3,534 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Royalties and other revenues decreased 27% to $119 million (Q3 2017: $164 million), primarily due to certain royalty expirations, the reclassification of ADDERALL XR from royalty revenue to product sales, and other changes as required under the new revenue accounting standard.", "score": 0.367929, "arguments": [{"text": "Q3", "location": [4417, 4419], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$119 million", "location": [4403, 4415], "entities": [{"type": "Money", "text": "$119 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Royalties and other revenues decreased 27% to $119 million (Q3 2017: $164 million), primarily due to certain royalty expirations, the reclassification of ADDERALL XR from royalty revenue to product sales, and other changes as required under the new revenue accounting standard.", "score": 0.589651, "arguments": [{"text": "Q3", "location": [4417, 4419], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$164 million", "location": [4426, 4438], "entities": [{"type": "Money", "text": "$164 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Operating results Operating income increased 35% to $956 million (Q3 2017: $709 million), due to the gain on the sale of Shire's Oncology franchise and lower integration and acquisition costs, partially offset by increased reorganization costs.", "score": 0.540798, "arguments": [{"text": "Q3", "location": [4701, 4703], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$709 million", "location": [4710, 4722], "entities": [{"type": "Money", "text": "$709 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "Operating results Operating income increased 35% to $956 million (Q3 2017: $709 million), due to the gain on the sale of Shire's Oncology franchise and lower integration and acquisition costs, partially offset by increased reorganization costs.", "score": 0.390519, "arguments": [{"text": "Shire", "location": [4756, 4761], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Oncology", "location": [4764, 4772], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}]}, {"type": "employedBy", "sentence": "A combination of proceeds from the sale of Shire's Oncology franchise, Non GAAP free cash flow, and existing cash balances were utilized to repay debt during the year.", "score": 0.384122, "arguments": [{"text": "Shire", "location": [6490, 6495], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Oncology", "location": [6498, 6506], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}]}, {"type": "agentOf", "sentence": "Operating results Operating income increased 35% to $956 million (Q3 2017: $709 million), due to the gain on the sale of Shire's Oncology franchise and lower integration and acquisition costs, partially offset by increased reorganization costs.", "score": 0.446246, "arguments": [{"text": "franchise", "location": [4773, 4782], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}, {"text": "acquisition", "location": [4809, 4820], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP operating income decreased 2% to $1,475 million (Q3 2017: $1,498 million), primarily due to lower gross margins as Q3 2017 reflected favorability from the timing of changes in the costs to manufacture certain products.", "score": 0.631172, "arguments": [{"text": "Q3", "location": [4938, 4940], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$1,498 million", "location": [4947, 4961], "entities": [{"type": "Money", "text": "$1,498 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "basedIn", "sentence": "Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion Received U.S. Food and Drug Administration and Health Canada approval for TAKHZYRO (lanadelumab-flyo) and launched in the U.S. Accelerated debt pay-down through proceeds from the $2.4 billion sale of the Oncology franchise and strong net operating cash flow November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "score": 0.900167, "arguments": [{"text": "Accelerated", "location": [253, 264], "entities": [{"type": "Organization", "text": "Accelerated"}]}, {"text": "U.S.", "location": [248, 252], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "score": 0.820378, "arguments": [{"text": "ADS", "location": [5562, 5565], "entities": [{"type": "Organization", "text": "American Depository Share"}]}, {"text": "decreased", "location": [5566, 5575], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP diluted earnings per ADS decreased 4% to $3.64 (Q3 2017: $3.81) as product sales growth and operating expense discipline were offset by unfavorable foreign exchange, lower gross margins, and unrealized losses on equity investments.", "score": 0.466272, "arguments": [{"text": "Q3", "location": [5589, 5591], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$3.81", "location": [5598, 5603], "entities": [{"type": "Money", "text": "$3.81"}]}]}, {"type": "hasAttribute", "sentence": "Cash flows Net cash provided by operating activities decreased 19% to $858 million (Q3 2017: $1,055 million), driven by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO.", "score": 0.585499, "arguments": [{"text": "Q3", "location": [5857, 5859], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$1,055 million", "location": [5866, 5880], "entities": [{"type": "Money", "text": "$1,055 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "Cash flows Net cash provided by operating activities decreased 19% to $858 million (Q3 2017: $1,055 million), driven by a $251 million contingent consideration payment to former shareholders of Dyax Corp. due to the approval of TAKHZYRO.", "score": 0.409792, "arguments": [{"text": "shareholders", "location": [5951, 5963], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Dyax Corp.", "location": [5967, 5977], "entities": [{"type": "Organization", "text": "Dyax Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP free cash flow increased 8% to $971 million (Q3 2017: $901 million).", "score": 0.346111, "arguments": [{"text": "Q3", "location": [6065, 6067], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$971 million", "location": [6051, 6063], "entities": [{"type": "Money", "text": "$971 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP free cash flow increased 8% to $971 million (Q3 2017: $901 million).", "score": 0.562675, "arguments": [{"text": "Q3", "location": [6065, 6067], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$901 million", "location": [6074, 6086], "entities": [{"type": "Money", "text": "$901 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP free cash flow includes capital expenditures of $203 million (Q3 2017: $174 million) and excludes payments relating to milestone and license arrangements of $316 million (Q3 2017: $20 million).", "score": 0.690951, "arguments": [{"text": "Q3", "location": [6160, 6162], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$174 million", "location": [6169, 6181], "entities": [{"type": "Money", "text": "$174 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP free cash flow includes capital expenditures of $203 million (Q3 2017: $174 million) and excludes payments relating to milestone and license arrangements of $316 million (Q3 2017: $20 million).", "score": 0.739014, "arguments": [{"text": "Q3", "location": [6269, 6271], "entities": [{"type": "Person", "text": "Q3"}]}, {"text": "$20 million", "location": [6278, 6289], "entities": [{"type": "Money", "text": "$20 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "Debt Non GAAP net debt as of September 30, 2018 decreased $3,915 million since December 31, 2017, to $15,154 million (December 31, 2017: $19,069 million).", "score": 0.895888, "arguments": [{"text": "September 30, 2018", "location": [6321, 6339], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "decreased", "location": [6340, 6349], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "Debt Non GAAP net debt as of September 30, 2018 decreased $3,915 million since December 31, 2017, to $15,154 million (December 31, 2017: $19,069 million).", "score": 0.532741, "arguments": [{"text": "December 31, 2017", "location": [6371, 6388], "entities": [{"type": "Date", "text": "December 31, 2017"}]}, {"text": "decreased", "location": [6340, 6349], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Delivered product sales of $3.8 billion; growth driven by Immunology, recently-launched products, and international expansion Received U.S. Food and Drug Administration and Health Canada approval for TAKHZYRO (lanadelumab-flyo) and launched in the U.S. Accelerated debt pay-down through proceeds from the $2.4 billion sale of the Oncology franchise and strong net operating cash flow November 1, 2018 - Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG), the leading global biotech company focused on rare diseases, announces unaudited results for the three months ended September 30, 2018.", "score": 0.53359, "arguments": [{"text": "biotech company", "location": [466, 481], "entities": [{"type": "Organization", "text": "Health Canada"}]}, {"text": "announces", "location": [508, 517], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "hasAttribute", "sentence": "Non GAAP net debt represents aggregate long and short term borrowings of $14,980 million, and capital leases of $367 million, partially offset by cash and cash equivalents of $193 million.", "score": 0.703037, "arguments": [{"text": "Non GAAP", "location": [6615, 6623], "entities": [{"type": "Person", "text": "Non GAAP Outlook"}]}, {"text": "$14,980 million", "location": [6688, 6703], "entities": [{"type": "Money", "text": "$14,980 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Similarly, our projected 2020 revenue target has been updated to $16.5 - $17.5 billion, reflecting the removal of $0.5 billion of Oncology sales in our original projection.", "score": 0.855821, "arguments": [{"text": "Oncology", "location": [7091, 7099], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}, {"text": "$0.5 billion", "location": [7075, 7087], "entities": [{"type": "Money", "text": "$0.5 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Risks associated with this outlook include the potential uncertainty resulting from the announcement by Takeda Pharmaceutical Company Limited (Takeda) on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code.", "score": 0.682046, "arguments": [{"text": "Takeda", "location": [7779, 7785], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announcement", "location": [7763, 7775], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.748733, "arguments": [{"text": "Takeda", "location": [18890, 18896], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "announcement", "location": [18874, 18886], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Risks associated with this outlook include the potential uncertainty resulting from the announcement by Takeda Pharmaceutical Company Limited (Takeda) on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code.", "score": 0.527436, "arguments": [{"text": "Pharmaceutical Company Limited", "location": [7786, 7816], "entities": [{"type": "Organization", "text": "Pharmaceutical Company Limited"}]}, {"text": "announcement", "location": [7763, 7775], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.816293, "arguments": [{"text": "Pharmaceutical Company Limited", "location": [18897, 18927], "entities": [{"type": "Organization", "text": "Pharmaceutical Company Limited"}]}, {"text": "announcement", "location": [18874, 18886], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "managerOf", "sentence": "Risks associated with this outlook include the potential uncertainty resulting from the announcement by Takeda Pharmaceutical Company Limited (Takeda) on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code.", "score": 0.408765, "arguments": [{"text": "Takeda", "location": [7779, 7785], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceutical Company Limited", "location": [7786, 7816], "entities": [{"type": "Organization", "text": "Pharmaceutical Company Limited"}]}]}, {"type": "managerOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.613597, "arguments": [{"text": "Takeda", "location": [18890, 18896], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceutical Company Limited", "location": [18897, 18927], "entities": [{"type": "Organization", "text": "Pharmaceutical Company Limited"}]}]}, {"type": "basedIn", "sentence": "Pursuant to a change in U.S. GAAP related to accounting for revenue, certain revenue formerly classified as royalties are now recorded as product sales.", "score": 0.70827, "arguments": [{"text": "GAAP", "location": [8288, 8292], "entities": [{"type": "Organization", "text": "GAAP", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [8283, 8287], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "participantIn", "sentence": "Takeda has already received clearances from regulatory agencies in the U.S., Japan, China, and other countries and is in discussions with the European Commission as part of its Phase 1 review of the proposed acquisition.", "score": 0.551842, "arguments": [{"text": "Takeda", "location": [8736, 8742], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "discussions", "location": [8857, 8868], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "participantIn", "sentence": "Takeda has already received clearances from regulatory agencies in the U.S., Japan, China, and other countries and is in discussions with the European Commission as part of its Phase 1 review of the proposed acquisition.", "score": 0.886591, "arguments": [{"text": "European Commission", "location": [8878, 8897], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "discussions", "location": [8857, 8868], "entities": [{"type": "EventMeeting", "text": "discussions"}]}]}, {"type": "agentOf", "sentence": "Takeda has already received clearances from regulatory agencies in the U.S., Japan, China, and other countries and is in discussions with the European Commission as part of its Phase 1 review of the proposed acquisition.", "score": 0.546003, "arguments": [{"text": "its", "location": [8909, 8912], "entities": [{"type": "Organization", "text": "regulatory agencies"}]}, {"text": "acquisition", "location": [8944, 8955], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Business Development Sale of Oncology franchise On August 31, 2018, Shire announced it had completed the sale of its Oncology franchise to Servier S.A.S. (Servier) for $2.4 billion.", "score": 0.992101, "arguments": [{"text": "Shire", "location": [9025, 9030], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [9031, 9040], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Acquisition of sanaplasma AG On September 6, 2018, Shire announced the acquisition of sanaplasma AG, a source plasma collection company headquartered in Switzerland.", "score": 0.996279, "arguments": [{"text": "Shire", "location": [9325, 9330], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [9331, 9340], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Products TAKHZYRO, a first-of-its-kind monoclonal antibody (mAb) preventive treatment for HAE On August 23, 2018, Shire announced that the U.S. Food and Drug Administration (FDA) had approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older.", "score": 0.86727, "arguments": [{"text": "Shire", "location": [9897, 9902], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [9903, 9912], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "On September 20, 2018, Shire announced that Health Canada had authorized TAKHZYRO for routine prevention of attacks of HAE in patients 12 years of age and older.", "score": 0.996893, "arguments": [{"text": "Shire", "location": [10099, 10104], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [10105, 10114], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "On October 19, 2018, Shire announced that the CHMP of the European Medicines Agency (EMA) had issued a positive opinion recommending the granting of marketing authorization in the European Union (EU) for lanadelumab for the prevention of HAE attacks.", "score": 0.995718, "arguments": [{"text": "Shire", "location": [10259, 10264], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [10265, 10274], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "FIRAZYR for the treatment of HAE attacks in Japan On September 21, 2018, Shire announced that the Ministry of Health, Labour and Welfare in Japan had granted manufacturing and marketing authorization for FIRAZYR, for the acute treatment of HAE attacks in adult patients with HAE.", "score": 0.993475, "arguments": [{"text": "Shire", "location": [10562, 10567], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [10568, 10577], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "VEYVONDI, for adults with von Willebrand disease (VWD) On September 12, 2018, Shire announced that the European Commission had granted Marketing Authorization for VEYVONDI, for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with VWD when desmopressin treatment alone is ineffective or not indicated.", "score": 0.995718, "arguments": [{"text": "Shire", "location": [10847, 10852], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [10853, 10862], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.996475, "arguments": [{"text": "Shire", "location": [11238, 11243], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [11244, 11253], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Pipeline Prucalopride (SHP555) for the treatment of chronic idiopathic constipation (CIC) On October 18, 2018, Shire announced that the FDA Gastrointestinal Drugs Advisory Committee voted unanimously that the risk-benefit profile of prucalopride supports the approval of this NDA, which has a Prescription Drug User Fee Act (PDUFA) date of December 21, 2018.", "score": 0.98275, "arguments": [{"text": "Shire", "location": [11510, 11515], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [11516, 11525], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Facilities On October 25, 2018, Shire announced it had filed a second submission to the FDA for approval to manufacture albumin therapy at its new plasma manufacturing facility near Covington, Georgia.", "score": 0.994385, "arguments": [{"text": "Shire", "location": [11790, 11795], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "announced", "location": [11796, 11805], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.928492, "arguments": [{"text": "Shire", "location": [19099, 19104], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Report", "location": [19126, 19132], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "residesIn", "sentence": "Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: 'We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline.", "score": 0.752276, "arguments": [{"text": "Flemming Ornskov", "location": [583, 599], "entities": [{"type": "Person", "text": "Flemming Ornskov"}]}, {"text": "M.D.", "location": [601, 605], "entities": [{"type": "GeopoliticalEntity", "text": "M.D."}]}]}, {"type": "agentOf", "sentence": "Business Development Sale of Oncology franchise On August 31, 2018, Shire announced it had completed the sale of its Oncology franchise to Servier S.A.S. (Servier) for $2.4 billion.", "score": 0.511588, "arguments": [{"text": "it", "location": [9041, 9043], "entities": [{"type": "Organization", "text": "GAAP", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "sale", "location": [9062, 9066], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Acquisition of sanaplasma AG On September 6, 2018, Shire announced the acquisition of sanaplasma AG, a source plasma collection company headquartered in Switzerland.", "score": 0.868237, "arguments": [{"text": "September 6, 2018", "location": [9306, 9323], "entities": [{"type": "Date", "text": "September 6, 2018"}]}, {"text": "announced", "location": [9331, 9340], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOf", "sentence": "The tender offer was funded from the proceeds of the sale of its Oncology franchise.", "score": 0.485936, "arguments": [{"text": "Oncology", "location": [9763, 9771], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}, {"text": "its", "location": [9759, 9762], "entities": [{"type": "Organization", "text": "Health Canada"}]}]}, {"type": "timeOf", "sentence": "Products TAKHZYRO, a first-of-its-kind monoclonal antibody (mAb) preventive treatment for HAE On August 23, 2018, Shire announced that the U.S. Food and Drug Administration (FDA) had approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older.", "score": 0.49793, "arguments": [{"text": "August 23, 2018", "location": [9880, 9895], "entities": [{"type": "Date", "text": "August 23, 2018"}]}, {"text": "announced", "location": [9903, 9912], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "affectedBy", "sentence": "Products TAKHZYRO, a first-of-its-kind monoclonal antibody (mAb) preventive treatment for HAE On August 23, 2018, Shire announced that the U.S. Food and Drug Administration (FDA) had approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older.", "score": 0.487332, "arguments": [{"text": "patients", "location": [10040, 10048], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "attacks", "location": [10022, 10029], "entities": [{"type": "EventViolence", "text": "attacks"}]}]}, {"type": "timeOf", "sentence": "Products TAKHZYRO, a first-of-its-kind monoclonal antibody (mAb) preventive treatment for HAE On August 23, 2018, Shire announced that the U.S. Food and Drug Administration (FDA) had approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older.", "score": 0.59813, "arguments": [{"text": "12 years", "location": [10049, 10057], "entities": [{"type": "Duration", "text": "12 years"}]}, {"text": "attacks", "location": [10022, 10029], "entities": [{"type": "EventViolence", "text": "attacks"}]}]}, {"type": "timeOf", "sentence": "On September 20, 2018, Shire announced that Health Canada had authorized TAKHZYRO for routine prevention of attacks of HAE in patients 12 years of age and older.", "score": 0.933578, "arguments": [{"text": "September 20, 2018", "location": [10079, 10097], "entities": [{"type": "Date", "text": "September 20, 2018"}]}, {"text": "announced", "location": [10105, 10114], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "affectedBy", "sentence": "On September 20, 2018, Shire announced that Health Canada had authorized TAKHZYRO for routine prevention of attacks of HAE in patients 12 years of age and older.", "score": 0.5676, "arguments": [{"text": "Health Canada", "location": [10120, 10133], "entities": [{"type": "Organization", "text": "Health Canada"}]}, {"text": "announced", "location": [10105, 10114], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "On September 20, 2018, Shire announced that Health Canada had authorized TAKHZYRO for routine prevention of attacks of HAE in patients 12 years of age and older.", "score": 0.639315, "arguments": [{"text": "12 years", "location": [10211, 10219], "entities": [{"type": "Duration", "text": "12 years"}]}, {"text": "attacks", "location": [10184, 10191], "entities": [{"type": "EventViolence", "text": "attacks"}]}]}, {"type": "timeOf", "sentence": "On October 19, 2018, Shire announced that the CHMP of the European Medicines Agency (EMA) had issued a positive opinion recommending the granting of marketing authorization in the European Union (EU) for lanadelumab for the prevention of HAE attacks.", "score": 0.938509, "arguments": [{"text": "October 19, 2018", "location": [10241, 10257], "entities": [{"type": "Date", "text": "October 19, 2018"}]}, {"text": "announced", "location": [10265, 10274], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "locatedAt", "sentence": "Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer, commented: 'We continue to deliver solid growth and pay down our debt while advancing our late-stage pipeline.", "score": 0.932656, "arguments": [{"text": "M.D.", "location": [601, 605], "entities": [{"type": "GeopoliticalEntity", "text": "M.D."}]}, {"text": "M.P.H.", "location": [607, 613], "entities": [{"type": "GeopoliticalEntity", "text": "M.P.H."}]}]}, {"type": "locatedAt", "sentence": "FIRAZYR for the treatment of HAE attacks in Japan On September 21, 2018, Shire announced that the Ministry of Health, Labour and Welfare in Japan had granted manufacturing and marketing authorization for FIRAZYR, for the acute treatment of HAE attacks in adult patients with HAE.", "score": 0.834365, "arguments": [{"text": "attacks", "location": [10522, 10529], "entities": [{"type": "EventViolence", "text": "attacks"}]}, {"text": "Japan", "location": [10533, 10538], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "FIRAZYR for the treatment of HAE attacks in Japan On September 21, 2018, Shire announced that the Ministry of Health, Labour and Welfare in Japan had granted manufacturing and marketing authorization for FIRAZYR, for the acute treatment of HAE attacks in adult patients with HAE.", "score": 0.712879, "arguments": [{"text": "September 21, 2018", "location": [10542, 10560], "entities": [{"type": "Date", "text": "September 21, 2018"}]}, {"text": "attacks", "location": [10522, 10529], "entities": [{"type": "EventViolence", "text": "attacks"}]}]}, {"type": "basedIn", "sentence": "FIRAZYR for the treatment of HAE attacks in Japan On September 21, 2018, Shire announced that the Ministry of Health, Labour and Welfare in Japan had granted manufacturing and marketing authorization for FIRAZYR, for the acute treatment of HAE attacks in adult patients with HAE.", "score": 0.526136, "arguments": [{"text": "Ministry of Health, Labour and Welfare", "location": [10587, 10625], "entities": [{"type": "Organization", "text": "Ministry of Health, Labour and Welfare", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Japan", "location": [10629, 10634], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "FIRAZYR for the treatment of HAE attacks in Japan On September 21, 2018, Shire announced that the Ministry of Health, Labour and Welfare in Japan had granted manufacturing and marketing authorization for FIRAZYR, for the acute treatment of HAE attacks in adult patients with HAE.", "score": 0.609537, "arguments": [{"text": "patients", "location": [10750, 10758], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "attacks", "location": [10733, 10740], "entities": [{"type": "EventViolence", "text": "attacks"}]}]}, {"type": "timeOf", "sentence": "VEYVONDI, for adults with von Willebrand disease (VWD) On September 12, 2018, Shire announced that the European Commission had granted Marketing Authorization for VEYVONDI, for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with VWD when desmopressin treatment alone is ineffective or not indicated.", "score": 0.913169, "arguments": [{"text": "September 12, 2018", "location": [10827, 10845], "entities": [{"type": "Date", "text": "September 12, 2018"}]}, {"text": "announced", "location": [10853, 10862], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "hasAttribute", "sentence": "VEYVONDI, for adults with von Willebrand disease (VWD) On September 12, 2018, Shire announced that the European Commission had granted Marketing Authorization for VEYVONDI, for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with VWD when desmopressin treatment alone is ineffective or not indicated.", "score": 0.450037, "arguments": [{"text": "adults", "location": [11028, 11034], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "18 and older", "location": [11040, 11052], "entities": [{"type": "Age", "text": "18 and older"}]}]}, {"type": "hasAttribute", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.855964, "arguments": [{"text": "adults", "location": [11211, 11217], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "ADHD", "location": [11202, 11206], "entities": [{"type": "HealthCondition", "text": "ADHD"}]}]}, {"type": "timeOf", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.915591, "arguments": [{"text": "August 13, 2018", "location": [11221, 11236], "entities": [{"type": "Date", "text": "August 13, 2018"}]}, {"text": "announced", "location": [11244, 11253], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOf", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.788847, "arguments": [{"text": "partner", "location": [11263, 11270], "entities": [{"type": "Organization", "text": "Committee for Medicinal Products for Human Use"}]}, {"text": "its", "location": [11259, 11262], "entities": [{"type": "Organization", "text": "Health Canada"}]}]}, {"type": "locatedAt", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.37302, "arguments": [{"text": "partner", "location": [11263, 11270], "entities": [{"type": "Organization", "text": "Committee for Medicinal Products for Human Use"}]}, {"text": "Japan", "location": [11274, 11279], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Our growth was once again driven by our Immunology franchise, recently-launched products, and expansion in international markets.", "score": 0.741569, "arguments": [{"text": "franchise", "location": [952, 961], "entities": [{"type": "Organization", "text": "Oncology pipeline"}]}, {"text": "Immunology", "location": [941, 951], "entities": [{"type": "Organization", "text": "Immunology", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "productOf", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.963927, "arguments": [{"text": "Drug Application", "location": [11321, 11337], "entities": [{"type": "Product", "text": "Drug Application"}]}, {"text": "Ltd", "location": [11297, 11300], "entities": [{"type": "Organization", "text": "Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "INTUNIV, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults On August 13, 2018, Shire announced that its partner in Japan, Shionogi & Co., Ltd had submitted a New Drug Application (NDA) for the manufacture and marketing in Japan of INTUNIV.", "score": 0.681924, "arguments": [{"text": "INTUNIV", "location": [11390, 11397], "entities": [{"type": "GeopoliticalEntity", "text": "INTUNIV"}]}, {"text": "Japan", "location": [11381, 11386], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Pipeline Prucalopride (SHP555) for the treatment of chronic idiopathic constipation (CIC) On October 18, 2018, Shire announced that the FDA Gastrointestinal Drugs Advisory Committee voted unanimously that the risk-benefit profile of prucalopride supports the approval of this NDA, which has a Prescription Drug User Fee Act (PDUFA) date of December 21, 2018.", "score": 0.802626, "arguments": [{"text": "FDA Gastrointestinal Drugs Advisory Committee", "location": [11535, 11580], "entities": [{"type": "Organization", "text": "FDA Gastrointestinal Drugs Advisory Committee", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "voted", "location": [11581, 11586], "entities": [{"type": "EventElection", "text": "voted"}]}]}, {"type": "timeOf", "sentence": "Facilities On October 25, 2018, Shire announced it had filed a second submission to the FDA for approval to manufacture albumin therapy at its new plasma manufacturing facility near Covington, Georgia.", "score": 0.84844, "arguments": [{"text": "October 25, 2018", "location": [11772, 11788], "entities": [{"type": "Date", "text": "October 25, 2018"}]}, {"text": "announced", "location": [11796, 11805], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "ownerOf", "sentence": "Facilities On October 25, 2018, Shire announced it had filed a second submission to the FDA for approval to manufacture albumin therapy at its new plasma manufacturing facility near Covington, Georgia.", "score": 0.652425, "arguments": [{"text": "its", "location": [11897, 11900], "entities": [{"type": "Organization", "text": "Health Canada"}]}, {"text": "manufacturing facility", "location": [11912, 11934], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}]}, {"type": "near", "sentence": "Facilities On October 25, 2018, Shire announced it had filed a second submission to the FDA for approval to manufacture albumin therapy at its new plasma manufacturing facility near Covington, Georgia.", "score": 0.490894, "arguments": [{"text": "manufacturing facility", "location": [11912, 11934], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "Covington", "location": [11940, 11949], "entities": [{"type": "GeopoliticalEntity", "text": "Covington"}]}]}, {"type": "locatedAt", "sentence": "Facilities On October 25, 2018, Shire announced it had filed a second submission to the FDA for approval to manufacture albumin therapy at its new plasma manufacturing facility near Covington, Georgia.", "score": 0.965712, "arguments": [{"text": "Covington", "location": [11940, 11949], "entities": [{"type": "GeopoliticalEntity", "text": "Covington"}]}, {"text": "Georgia", "location": [11951, 11958], "entities": [{"type": "GeopoliticalEntity", "text": "Georgia"}]}]}, {"type": "participantIn", "sentence": "Download the PDF for the full announcement For further information please contact: Dial in details for the live conference call for investors at 14:00 GMT / 10:00 EDT on November 1, 2018: U.K. dial in: 0800 358 9473 or +44 333 300 0804 U.S. dial in: 1 855 857 0686 or 1 631 913 1422 International Access Numbers: Click here Password/Conf ID: 28705371 # Live Webcast: Click here The quarterly earnings presentation will be available today at 13:00 GMT / 9:00 EDT on: - Shire.com Investors section - Shire's IR Briefcase in the iTunes Store NOTES TO EDITORS Stephen Williams, Deputy Company Secretary, is responsible for arranging the release of this announcement.", "score": 0.785272, "arguments": [{"text": "investors", "location": [12092, 12101], "entities": [{"type": "Person", "text": "Investors"}]}, {"text": "conference", "location": [12072, 12082], "entities": [{"type": "EventMeeting", "text": "conference"}]}]}, {"type": "timeOf", "sentence": "Download the PDF for the full announcement For further information please contact: Dial in details for the live conference call for investors at 14:00 GMT / 10:00 EDT on November 1, 2018: U.K. dial in: 0800 358 9473 or +44 333 300 0804 U.S. dial in: 1 855 857 0686 or 1 631 913 1422 International Access Numbers: Click here Password/Conf ID: 28705371 # Live Webcast: Click here The quarterly earnings presentation will be available today at 13:00 GMT / 9:00 EDT on: - Shire.com Investors section - Shire's IR Briefcase in the iTunes Store NOTES TO EDITORS Stephen Williams, Deputy Company Secretary, is responsible for arranging the release of this announcement.", "score": 0.582692, "arguments": [{"text": "November 1, 2018", "location": [12130, 12146], "entities": [{"type": "Date", "text": "November 1, 2018"}]}, {"text": "conference", "location": [12072, 12082], "entities": [{"type": "EventMeeting", "text": "conference"}]}]}, {"type": "partOfMany", "sentence": "Download the PDF for the full announcement For further information please contact: Dial in details for the live conference call for investors at 14:00 GMT / 10:00 EDT on November 1, 2018: U.K. dial in: 0800 358 9473 or +44 333 300 0804 U.S. dial in: 1 855 857 0686 or 1 631 913 1422 International Access Numbers: Click here Password/Conf ID: 28705371 # Live Webcast: Click here The quarterly earnings presentation will be available today at 13:00 GMT / 9:00 EDT on: - Shire.com Investors section - Shire's IR Briefcase in the iTunes Store NOTES TO EDITORS Stephen Williams, Deputy Company Secretary, is responsible for arranging the release of this announcement.", "score": 0.952697, "arguments": [{"text": "Stephen Williams", "location": [12516, 12532], "entities": [{"type": "Person", "text": "Stephen Williams"}]}, {"text": "EDITORS", "location": [12508, 12515], "entities": [{"type": "Person", "text": "EDITORS"}]}]}, {"type": "residesIn", "sentence": "'We recently launched TAKHZYRO, the first monoclonal antibody to prevent hereditary angioedema (HAE) attacks, in the U.S. We also gained approval for this innovative treatment in Canada and received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization in Europe.", "score": 0.534174, "arguments": [{"text": "We", "location": [1297, 1299], "entities": [{"type": "Person", "text": "our"}]}, {"text": "U.S.", "location": [1292, 1296], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.513919, "arguments": [{"text": "Shire\nShire", "location": [12695, 12706], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "diseases", "location": [12769, 12777], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "employedBy", "sentence": "About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.407986, "arguments": [{"text": "patients", "location": [12750, 12758], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "biotechnology leader", "location": [12721, 12741], "entities": [{"type": "Organization", "text": "International Access Numbers"}]}]}, {"type": "hasAttribute", "sentence": "About Shire Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.", "score": 0.905064, "arguments": [{"text": "patients", "location": [12750, 12758], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diseases", "location": [12769, 12777], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "residesIn", "sentence": "Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "score": 0.538306, "arguments": [{"text": "patients", "location": [13088, 13096], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "communities", "location": [13128, 13139], "entities": [{"type": "Location", "text": "communities"}]}]}, {"type": "locatedAt", "sentence": "Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients.", "score": 0.715022, "arguments": [{"text": "communities", "location": [13128, 13139], "entities": [{"type": "Location", "text": "communities"}]}, {"text": "countries", "location": [13152, 13161], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.", "score": 0.396177, "arguments": [{"text": "Our", "location": [13322, 13325], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "areas", "location": [13359, 13364], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "partOfMany", "sentence": "Championing patients is our call to action - it brings the opportunity - and responsibility - to change people's lives.", "score": 0.317973, "arguments": [{"text": "patients", "location": [13478, 13486], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "our", "location": [13490, 13493], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "agentOf", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.428883, "arguments": [{"text": "Shire", "location": [17084, 17089], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "acquisitions", "location": [17092, 17104], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "affectedBy", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.45478, "arguments": [{"text": "its", "location": [17246, 17249], "entities": [{"type": "Organization", "text": "its"}]}, {"text": "sale", "location": [17388, 17392], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "enforce or defend the intellectual property rights required to conduct its business; Shire faces intense competition for highly qualified personnel from other companies and organizations; failure to successfully execute or attain strategic objectives from Shire's acquisitions and growth strategy may adversely affect Shire's financial condition and results of operations; Shire's growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products; a slowdown of global economic growth, or economic instability of countries in which Shire does business, could have negative consequences for Shire's business and increase the risk of non-payment by Shire's customers; changes in foreign currency exchange rates and interest rates could have a material adverse effect on Shire's operating results and liquidity;", "score": 0.599442, "arguments": [{"text": "Shire", "location": [17494, 17499], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "countries", "location": [17475, 17484], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "'Takeda's proposed acquisition of Shire remains on track to close in H1 2019, subject to shareholder approval of both companies and additional regulatory approvals.", "score": 0.494655, "arguments": [{"text": "Takeda", "location": [1505, 1511], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "acquisition", "location": [1523, 1534], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Shire is subject to evolving and complex tax laws, which may result in additional liabilities that may adversely affect Shire's financial condition or results of operations; if a marketed product fails to work effectively or causes adverse side effects, this could result in damage to Shire's reputation, the withdrawal of the product and legal action against Shire; Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire's revenues, financial condition or results of operations; Shire faces risks relating to the expected exit of the United Kingdom from the European Union; Shire incurred substantial additional indebtedness to finance the Baxalta acquisition,", "score": 0.667534, "arguments": [{"text": "Baxalta", "location": [18654, 18661], "entities": [{"type": "Organization", "text": "Baxalta"}]}, {"text": "acquisition", "location": [18662, 18673], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.631513, "arguments": [{"text": "partners", "location": [18846, 18854], "entities": [{"type": "Organization", "text": "partners"}]}, {"text": "announcement", "location": [18874, 18886], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.882854, "arguments": [{"text": "10-K", "location": [19141, 19145], "entities": [{"type": "Date", "text": "10-K"}]}, {"text": "Report", "location": [19126, 19132], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "which has increased its borrowing costs and may decrease its business flexibility; the potential uncertainty among our employees, customers, suppliers, and other business partners resulting from the announcement by Takeda Pharmaceutical Company Limited on May 8, 2018 of a recommended offer for Shire under the U.K. Takeover Code; and a further list and description of risks, uncertainties and other matters can be found in Shire's most recent Annual Report on Form 10-K and in Shire's subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in 'ITEM 1A: Risk Factors', and in subsequent reports on Form 8-K and other Securities and Exchange Commission filings, all of which are available on Shire's website.", "score": 0.979376, "arguments": [{"text": "Shire", "location": [19153, 19158], "entities": [{"type": "Person", "text": "Shire\nShire"}]}, {"text": "Reports", "location": [19182, 19189], "entities": [{"type": "EventCommunication", "text": "Reports"}]}]}, {"type": "agentOf", "sentence": "Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.", "score": 0.834273, "arguments": [{"text": "Readers", "location": [19572, 19579], "entities": [{"type": "Person", "text": "Readers"}]}, {"text": "cautioned", "location": [19584, 19593], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Attachments Original document Permalink Disclaimer Shire plc published this content on 01 November 2018 and is solely responsible for the information contained herein.", "score": 0.966635, "arguments": [{"text": "Shire plc", "location": [19958, 19967], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "published", "location": [19968, 19977], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "Attachments Original document Permalink Disclaimer Shire plc published this content on 01 November 2018 and is solely responsible for the information contained herein.", "score": 0.639173, "arguments": [{"text": "November 2018", "location": [19997, 20010], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [19968, 19977], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "Non GAAP", "sentiment": {"score": -0.544386, "label": "negative"}, "relevance": 0.966039}, {"text": "Shire", "sentiment": {"score": -0.0268554, "label": "negative"}, "relevance": 0.796512}, {"text": "product sales", "sentiment": {"score": -0.480086, "label": "negative"}, "relevance": 0.641023}, {"text": "Oncology franchise", "sentiment": {"score": 0.238518, "label": "positive"}, "relevance": 0.637291}, {"text": "Non GAAP EBITDA", "sentiment": {"score": -0.465803, "label": "negative"}, "relevance": 0.522295}, {"text": "GAAP EBITDA margin", "sentiment": {"score": -0.465803, "label": "negative"}, "relevance": 0.514614}, {"text": "free cash flow", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476883}, {"text": "lower gross margins", "sentiment": {"score": -0.460326, "label": "negative"}, "relevance": 0.474581}, {"text": "GAAP free cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465913}, {"text": "GAAP net debt", "sentiment": {"score": -0.400587, "label": "negative"}, "relevance": 0.404049}, {"text": "product sales growth", "sentiment": {"score": -0.394915, "label": "negative"}, "relevance": 0.388809}, {"text": "Shire Chief Executive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378617}, {"text": "GAAP operating income", "sentiment": {"score": -0.494183, "label": "negative"}, "relevance": 0.375882}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.361834}, {"text": "U.S. GAAP", "sentiment": {"score": -0.684652, "label": "negative"}, "relevance": 0.331551}, {"text": "-1ppc Non GAAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326142}, {"text": "Generated Non GAAP", "sentiment": {"score": -0.621513, "label": "negative"}, "relevance": 0.308795}, {"text": "GAAP net income", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.307544}, {"text": "mid-forties Non GAAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302074}, {"text": "Non GAAP Outlook", "sentiment": {"score": -0.434542, "label": "negative"}, "relevance": 0.296607}, {"text": "GAAP financial measures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28917}, {"text": "GAAP constant exchange", "sentiment": {"score": -0.377285, "label": "negative"}, "relevance": 0.285365}, {"text": "forward-looking statements", "sentiment": {"score": -0.595081, "label": "negative"}, "relevance": 0.275355}, {"text": "material adverse effect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272111}, {"text": "operating expense synergies", "sentiment": {"score": -0.247157, "label": "negative"}, "relevance": 0.266459}, {"text": "unfavorable foreign exchange", "sentiment": {"score": -0.403731, "label": "negative"}, "relevance": 0.259046}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255596}, {"text": "products", "sentiment": {"score": -0.167106, "label": "negative"}, "relevance": 0.253578}, {"text": "financial condition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24891}, {"text": "ongoing cost discipline", "sentiment": {"score": -0.247157, "label": "negative"}, "relevance": 0.248462}, {"text": "Pharmaceutical Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248087}, {"text": "U.K. Takeover Code", "sentiment": {"score": 0.357088, "label": "positive"}, "relevance": 0.247864}, {"text": "Diluted earnings", "sentiment": {"score": -0.496856, "label": "negative"}, "relevance": 0.247325}, {"text": "total revenues", "sentiment": {"score": -0.535555, "label": "negative"}, "relevance": 0.241153}, {"text": "recently-launched products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240819}, {"text": "net operating cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232769}, {"text": "intellectual property rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.22765}, {"text": "reorganization costs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.222911}, {"text": "total product sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.218288}, {"text": "marketing authorization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.217406}, {"text": "HAE attacks", "sentiment": {"score": -0.602626, "label": "negative"}, "relevance": 0.206925}, {"text": "Net income margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.202834}, {"text": "total revenue", "sentiment": {"score": 0.359156, "label": "positive"}, "relevance": 0.2015}, {"text": "strong free cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.201166}, {"text": "sanaplasma ag", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.200873}, {"text": "certain products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.200475}, {"text": "Net cash", "sentiment": {"score": -0.270655, "label": "negative"}, "relevance": 0.200224}]}, "extracted_metadata": {"sha1": "e2e0d21baffecf35aa928977b8ab165639279817", "filename": "1541076423535.zip-49f32a47e3fea28e9ac999e60c865733.xml", "file_type": "json"}, "external_links": ["https://www.shire.com/en/newsroom/2018/november/ow7tan", "https://www.shire.com/-/media/shire/shireglobal/shirecom/pdffiles/newsroom/2018/pr-01-11-2018.pdf?la=en&hash=82626AA57B9538AC0D264E97AE843436404F538C", "http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations", "http://events.arkadin.com/ev/docs/NE_W2_TF_Events_International_Access_List.pdf", "https://itunes.apple.com/us/app/shire-ir-briefcase/id529486874?mt=8", "http://www.publicnow.com/view/69E4D353C8088F82C954DD09C27BE697E12E8117", "http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations.aspx"], "title": "Shire : Delivers Product Sales Growth of 6% and Continues to Execute Against Key Priorities in Q3 2018 | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "NVcvk88HEfPHqSMmGgdDWUtWCN_S_kaho71TbCB-s5t8S0K4vBpguLW2uMPJxGm9", "result_metadata": {"score": 30.94664}, "author": "Tracy Colman", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.701998, "label": "negative"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.701998, "label": "negative"}, "text": "Blue Cross", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}], "sentiment": {"document": {"score": -0.701998, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Settlement", "keywords": [{"text": "Settlement"}]}, "sentence": "Settlement Resolves Actos Cancer Lawsuit Between Takeda and Blue Cross", "object": {"text": "Actos Cancer Lawsuit Between Takeda and Blue Cross", "keywords": [{"text": "Actos Cancer Lawsuit"}, {"text": "Takeda"}, {"text": "Blue Cross"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Company", "text": "Blue Cross", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}]}, "action": {"verb": {"text": "Resolves", "tense": "present"}, "text": "Resolves", "normalized": "Resolves"}}], "concepts": [{"text": "Civil procedure", "relevance": 0.847551, "dbpedia_resource": "http://dbpedia.org/resource/Civil_procedure"}, {"text": "Cross symbols", "relevance": 0.719048, "dbpedia_resource": "http://dbpedia.org/resource/Cross_symbols"}], "categories": [{"score": 0.912736, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "employedBy", "sentence": "Settlement Resolves Actos Cancer Lawsuit Between Takeda and Blue Cross", "score": 0.665605, "arguments": [{"text": "Between Takeda", "location": [41, 55], "entities": [{"type": "Person", "text": "Between Takeda"}]}, {"text": "Actos Cancer Lawsuit", "location": [20, 40], "entities": [{"type": "Organization", "text": "Actos Cancer Lawsuit"}]}]}], "keywords": [{"text": "Actos Cancer Lawsuit", "sentiment": {"score": -0.701998, "label": "negative"}, "relevance": 0.952115}, {"text": "Takeda", "sentiment": {"score": -0.701998, "label": "negative"}, "relevance": 0.580845}, {"text": "Blue Cross", "sentiment": {"score": -0.701998, "label": "negative"}, "relevance": 0.524113}, {"text": "Settlement", "sentiment": {"score": -0.701998, "label": "negative"}, "relevance": 0.480543}]}, "crawl_date": "2018-11-01T00:51:28Z", "url": "https://topclassactions.com/lawsuit-settlements/lawsuit-news/853591-settlement-resolves-actos-cancer-lawsuit-between-takeda-and-blue-cross/", "host": "topclassactions.com", "text": "Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "main_image_url": "https://s11284.pcdn.co/wp-content/uploads/2018/08/actos-bladder-cancer-lawsuit.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-08-24T00:00:00-05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.563794, "label": "negative"}, "text": "bladder cancer", "relevance": 0.922332, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Bladder cancer", "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}}, {"count": 4, "sentiment": {"score": -0.452306, "label": "negative"}, "text": "Takeda", "relevance": 0.731709, "type": "Person"}, {"count": 3, "sentiment": {"score": -0.534753, "label": "negative"}, "text": "Blue Cross & Blue Shield", "relevance": 0.725398, "type": "Organization", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"count": 5, "sentiment": {"score": -0.392221, "label": "negative"}, "text": "U.S. Food and Drug Administration", "relevance": 0.634469, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 2, "sentiment": {"score": -0.493082, "label": "negative"}, "text": "Blue Shield", "relevance": 0.421151, "type": "Company", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"count": 2, "sentiment": {"score": -0.43388, "label": "negative"}, "text": "Massachusetts", "relevance": 0.358231, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.305501, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MDL", "relevance": 0.289933, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.618097, "label": "negative"}, "text": "Asia", "relevance": 0.286638, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": -0.249663, "label": "negative"}, "text": "U.S.", "relevance": 0.2774, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly Co.", "relevance": 0.250415, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "10-year", "relevance": 0.226214, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2.4 billion", "relevance": 0.226214, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$38 million", "relevance": 0.226214, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$9 billion", "relevance": 0.226214, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30 percent", "relevance": 0.226214, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5-year", "relevance": 0.226214, "type": "Quantity"}], "sentiment": {"document": {"score": -0.662854, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "by the U.S. Food and Drug Administration", "keywords": [{"text": "U.S. Food"}, {"text": "Drug Administration"}], "entities": [{"type": "Organization", "text": "U.S. Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": "Actos\u2014a medication for type-2 diabetes manufactured and distributed by the Takeda Corp.\u2014was approved by the U.S. Food and Drug Administration in 1999.", "object": {"text": "the Takeda Corp.\u2014was", "keywords": [{"text": "Takeda Corp.\u2014was"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "by Blue Cross & Blue Shield of Massachusetts", "keywords": [{"text": "Blue Shield"}, {"text": "Blue Cross"}, {"text": "Massachusetts"}], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "sentence": " Numerous Actos cancer lawsuit actions were later filed against Asia\u2019s largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "object": {"text": "Numerous Actos cancer lawsuit actions", "keywords": [{"text": "Actos cancer lawsuit"}, {"text": "actions"}]}, "action": {"verb": {"text": "file", "tense": "past"}, "text": "filed", "normalized": "file"}}, {"subject": {"text": "the manufacturer", "keywords": [{"text": "manufacturer"}]}, "sentence": " Numerous Actos cancer lawsuit actions were later filed against Asia\u2019s largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "object": {"text": "the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development", "keywords": [{"text": "bladder cancer development"}, {"text": "drug\u2014when"}, {"text": "risk"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "knew", "normalized": "know"}}, {"subject": {"text": "the drug\u2014when", "keywords": [{"text": "drug\u2014when"}]}, "sentence": " Numerous Actos cancer lawsuit actions were later filed against Asia\u2019s largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "object": {"text": "long-term or in higher doses\u2014increased the risk", "keywords": [{"text": "risk"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "the manufacturer", "keywords": [{"text": "manufacturer"}]}, "sentence": " Numerous Actos cancer lawsuit actions were later filed against Asia\u2019s largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "object": {"text": "the risk for bladder cancer development", "keywords": [{"text": "bladder cancer development"}, {"text": "risk"}]}, "action": {"verb": {"text": "doses\u2014increased", "tense": "past"}, "text": "doses\u2014increased", "normalized": "doses\u2014increased"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " According to these Actos cancer lawsuit allegations, Takeda was aware of the associated risks through animal (rat) testing the decade prior to FDA approval.", "object": {"text": "aware of the associated risks through animal (rat) testing the decade prior to FDA approval", "keywords": [{"text": "FDA approval"}, {"text": "associated risks"}, {"text": "decade"}, {"text": "rat"}], "entities": [{"type": "Organization", "text": "U.S. Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "this information", "keywords": [{"text": "information"}]}, "sentence": " Purportedly, this information was hidden when the pharmaceutical company sought market access.", "object": {"text": "hidden"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "this information", "keywords": [{"text": "information"}]}, "sentence": " Purportedly, this information was hidden when the pharmaceutical company sought market access.", "action": {"verb": {"text": "hide", "tense": "past"}, "text": "was hidden", "normalized": "be hide"}}, {"subject": {"text": "the pharmaceutical company", "keywords": [{"text": "pharmaceutical company"}], "entities": []}, "sentence": " Purportedly, this information was hidden when the pharmaceutical company sought market access.", "object": {"text": "market access", "keywords": [{"text": "market access"}]}, "action": {"verb": {"text": "seek", "tense": "past"}, "text": "sought", "normalized": "seek"}}, {"subject": {"text": "Actos", "keywords": [{"text": "Actos"}]}, "sentence": " Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda\u2019s revenue as measured in 2010.", "object": {"text": "insulin resistance", "keywords": [{"text": "insulin resistance"}]}, "action": {"verb": {"text": "decrease", "tense": "present"}, "text": "decreases", "normalized": "decrease"}}, {"subject": {"text": "insulin resistance in patients", "keywords": [{"text": "insulin resistance"}, {"text": "patients"}]}, "sentence": " Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda\u2019s revenue as measured in 2010.", "object": {"text": "with type-2 diabetes", "keywords": [{"text": "type-2 diabetes"}]}, "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "diagnosed", "normalized": "diagnose"}}, {"subject": {"text": "Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes,", "keywords": [{"text": "type-2 diabetes"}, {"text": "insulin resistance"}, {"text": "Actos"}, {"text": "patients"}]}, "sentence": " Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda\u2019s revenue as measured in 2010.", "object": {"text": "a blockbuster medication", "keywords": [{"text": "blockbuster medication"}]}, "action": {"verb": {"text": "become", "tense": "future"}, "text": "to become", "normalized": "to become"}}, {"subject": {"text": "a blockbuster medication", "keywords": [{"text": "blockbuster medication"}]}, "sentence": " Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda\u2019s revenue as measured in 2010.", "object": {"text": "nearly 30 percent of Takeda\u2019s revenue", "keywords": [{"text": "Takeda"}, {"text": "percent"}, {"text": "revenue"}], "entities": [{"type": "Quantity", "text": "30 percent"}]}, "action": {"verb": {"text": "contribute", "tense": "past"}, "text": "contributed", "normalized": "contribute"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda was required to undertake a 10-year post-market clinical trial of the diabetes medication.", "object": {"text": "a 10-year post-market clinical trial of the diabetes medication", "keywords": [{"text": "post-market clinical trial"}, {"text": "diabetes medication"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Quantity", "text": "10-year"}]}, "action": {"verb": {"text": "undertake", "tense": "past"}, "text": "was required to undertake", "normalized": "be require to undertake"}}, {"subject": {"text": "the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "U.S. Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " At the 5-year mark, the FDA had enough data to warrant warning the public that taking it for a year or more or at high doses could radically increase the risk of bladder cancer.", "object": {"text": "enough data to warrant warning the public that taking it for a year or more or at high doses", "keywords": [{"text": "high doses"}, {"text": "data"}, {"text": "public"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "enough data", "keywords": [{"text": "data"}]}, "sentence": " At the 5-year mark, the FDA had enough data to warrant warning the public that taking it for a year or more or at high doses could radically increase the risk of bladder cancer.", "object": {"text": "that taking it for a year or more or at high doses could radically increase the risk of bladder cancer", "keywords": [{"text": "high doses"}, {"text": "bladder cancer"}, {"text": "risk"}], "entities": [{"type": "HealthCondition", "text": "bladder cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Bladder cancer", "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}}]}, "action": {"verb": {"text": "warn", "tense": "past"}, "text": "to warrant warning", "normalized": "to warrant warn"}}, {"subject": {"text": "the public", "keywords": [{"text": "public"}]}, "sentence": " At the 5-year mark, the FDA had enough data to warrant warning the public that taking it for a year or more or at high doses could radically increase the risk of bladder cancer.", "object": {"text": "it"}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "taking", "normalized": "take"}}, {"subject": {"text": "the public that taking it for a year or more or at high doses", "keywords": [{"text": "high doses"}, {"text": "public"}]}, "sentence": " At the 5-year mark, the FDA had enough data to warrant warning the public that taking it for a year or more or at high doses could radically increase the risk of bladder cancer.", "object": {"text": "the risk of bladder cancer", "keywords": [{"text": "bladder cancer"}, {"text": "risk"}], "entities": [{"type": "HealthCondition", "text": "bladder cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Bladder cancer", "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "increase", "normalized": "increase"}}, {"subject": {"text": "the FDA", "keywords": [{"text": "FDA"}], "entities": [{"type": "Organization", "text": "U.S. Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " The warning went out and the FDA requested a label change reflecting these new concerns in 2011.", "object": {"text": "a label change", "keywords": [{"text": "label change"}]}, "action": {"verb": {"text": "request", "tense": "past"}, "text": "requested", "normalized": "request"}}, {"subject": {"text": "these new concerns in 2011", "keywords": [{"text": "new concerns"}]}, "sentence": " The warning went out and the FDA requested a label change reflecting these new concerns in 2011.", "object": {"text": "a label change", "keywords": [{"text": "label change"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflecting", "normalized": "reflect"}}, {"subject": {"text": "the 10-year study", "keywords": [{"text": "10-year study"}], "entities": [{"type": "Quantity", "text": "10-year"}]}, "sentence": " Another concurrent study shored up the data on bladder cancer risk with Actos as well, and when the 10-year study completed in 2016, the FDA without equivocation announced that the drug might be linked to a higher probability of developing bladder cancer.", "action": {"verb": {"text": "complete", "tense": "past"}, "text": "completed", "normalized": "complete"}}, {"subject": {"text": "the FDA without equivocation", "keywords": [{"text": "FDA"}, {"text": "equivocation"}], "entities": [{"type": "Organization", "text": "U.S. Food and Drug Administration", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}]}, "sentence": " Another concurrent study shored up the data on bladder cancer risk with Actos as well, and when the 10-year study completed in 2016, the FDA without equivocation announced that the drug might be linked to a higher probability of developing bladder cancer.", "object": {"text": "that the drug might be linked to a higher probability of developing bladder cancer", "keywords": [{"text": "higher probability"}, {"text": "bladder cancer"}, {"text": "drug"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Actos cancer lawsuits gathered in federal court", "keywords": [{"text": "Actos cancer lawsuits"}, {"text": "federal court"}]}, "sentence": " By this time, there were already 9,000 pending Actos cancer lawsuits gathered in federal court in a class action multidistrict litigation (MDL).", "action": {"verb": {"text": "pending", "tense": "past"}, "text": "pending", "normalized": "pending"}}, {"subject": {"text": "Actos cancer lawsuits", "keywords": [{"text": "Actos cancer lawsuits"}]}, "sentence": " By this time, there were already 9,000 pending Actos cancer lawsuits gathered in federal court in a class action multidistrict litigation (MDL).", "action": {"verb": {"text": "gather", "tense": "past"}, "text": "gathered", "normalized": "gather"}}, {"subject": {"text": "Blue Cross & Blue Shield", "keywords": [{"text": "Blue Shield"}], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"type": "Company", "text": "Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}]}, "sentence": " Blue Cross & Blue Shield opted to join this MDL.", "object": {"text": "to join this MDL", "keywords": [{"text": "MDL"}]}, "action": {"verb": {"text": "opt", "tense": "past"}, "text": "opted", "normalized": "opt"}}, {"subject": {"text": "Blue Cross & Blue Shield", "keywords": [{"text": "Blue Shield"}], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"type": "Company", "text": "Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}]}, "sentence": " Blue Cross & Blue Shield opted to join this MDL.", "object": {"text": "this MDL", "keywords": [{"text": "MDL"}]}, "action": {"verb": {"text": "join", "tense": "future"}, "text": "opted to join", "normalized": "opt to join"}}, {"subject": {"text": "this group", "keywords": [{"text": "group"}]}, "sentence": " When one of the first cases of Actos cancer lawsuit among this group went to \u201cbellwether\u201d trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "object": {"text": "trial phase", "keywords": [{"text": "trial phase"}]}, "action": {"verb": {"text": "bellwether", "tense": "present"}, "text": "bellwether", "normalized": "bellwether"}}, {"subject": {"text": "a jury", "keywords": [{"text": "jury"}]}, "sentence": " When one of the first cases of Actos cancer lawsuit among this group went to \u201cbellwether\u201d trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "object": {"text": "a $9 billion punitive damages fine", "keywords": [{"text": "punitive damages"}], "entities": [{"type": "Quantity", "text": "$9 billion"}]}, "action": {"verb": {"text": "slap", "tense": "past"}, "text": "slapped", "normalized": "slap"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " When one of the first cases of Actos cancer lawsuit among this group went to \u201cbellwether\u201d trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "object": {"text": "later reviewed"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Takeda and Eli Lilly Co., its U.S. distributor,", "keywords": [{"text": "Eli Lilly Co."}, {"text": "Takeda"}, {"text": "U.S. distributor"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Eli Lilly Co."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "object": {"text": "to avoid further court exposure", "keywords": [{"text": "court exposure"}]}, "action": {"verb": {"text": "want", "tense": "past"}, "text": "wanted", "normalized": "want"}}, {"subject": {"text": "Takeda and Eli Lilly Co., its U.S. distributor,", "keywords": [{"text": "Eli Lilly Co."}, {"text": "Takeda"}, {"text": "U.S. distributor"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Eli Lilly Co."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "object": {"text": "further court exposure", "keywords": [{"text": "court exposure"}]}, "action": {"verb": {"text": "avoid", "tense": "future"}, "text": "wanted to avoid", "normalized": "want to avoid"}}, {"subject": {"text": "Takeda and Eli Lilly Co., its U.S. distributor,", "keywords": [{"text": "Eli Lilly Co."}, {"text": "Takeda"}, {"text": "U.S. distributor"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Eli Lilly Co."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "object": {"text": "to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion", "keywords": [{"text": "Actos cancer lawsuit"}, {"text": "leftover cases"}, {"text": "agreement"}, {"text": "payment"}], "entities": [{"type": "Quantity", "text": "$2.4 billion"}]}, "action": {"verb": {"text": "come", "tense": "past"}, "text": "came", "normalized": "come"}}, {"subject": {"text": "Takeda and Eli Lilly Co., its U.S. distributor,", "keywords": [{"text": "Eli Lilly Co."}, {"text": "Takeda"}, {"text": "U.S. distributor"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Eli Lilly Co."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "object": {"text": "most of the leftover cases of Actos cancer lawsuit", "keywords": [{"text": "Actos cancer lawsuit"}, {"text": "leftover cases"}]}, "action": {"verb": {"text": "settle", "tense": "future"}, "text": "to settle", "normalized": "to settle"}}, {"subject": {"text": "Blue Cross & Blue Shield", "keywords": [{"text": "Blue Shield"}], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"type": "Company", "text": "Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}]}, "sentence": " In a separate legal action, Blue Cross & Blue Shield sought to regain the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos.", "action": {"verb": {"text": "seek", "tense": "past"}, "text": "sought to regain", "normalized": "seek to regain"}}, {"subject": {"text": "a separate legal action, Blue Cross & Blue Shield", "keywords": [{"text": "separate legal action"}, {"text": "Blue Shield"}, {"text": "Blue Cross"}], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}, {"type": "Company", "text": "Blue Shield", "disambiguation": {"subtype": [], "name": "Blue Cross Blue Shield Association", "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_Blue_Shield_Association"}}]}, "sentence": " In a separate legal action, Blue Cross & Blue Shield sought to regain the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos.", "object": {"text": "the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos", "keywords": [{"text": "direct consequence"}, {"text": "medical bills"}, {"text": "bladder cancer"}, {"text": "Actos"}], "entities": [{"type": "HealthCondition", "text": "bladder cancer", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Bladder cancer", "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}}]}, "action": {"verb": {"text": "regain", "tense": "future"}, "text": "sought to regain", "normalized": "seek to regain"}}, {"subject": {"text": "it"}, "sentence": " In a separate legal action, Blue Cross & Blue Shield sought to regain the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos.", "object": {"text": "medical bills", "keywords": [{"text": "medical bills"}]}, "action": {"verb": {"text": "pay", "tense": "past"}, "text": "paid", "normalized": "pay"}}, {"subject": {"text": "several hundred people", "keywords": [{"text": "people"}]}, "sentence": " In a separate legal action, Blue Cross & Blue Shield sought to regain the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos.", "object": {"text": "Actos", "keywords": [{"text": "Actos"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "taking", "normalized": "take"}}, {"subject": {"text": "This action", "keywords": [{"text": "action"}]}, "sentence": " This action went into a mediation process, according to a March 2018 report by Law360, that was resolved around the same time.", "object": {"text": "into a mediation process", "keywords": [{"text": "mediation process"}]}, "action": {"verb": {"text": "go", "tense": "past"}, "text": "went", "normalized": "go"}}, {"subject": {"text": "This action", "keywords": [{"text": "action"}]}, "sentence": " This action went into a mediation process, according to a March 2018 report by Law360, that was resolved around the same time.", "object": {"text": "to a March 2018 report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "that"}, "sentence": " This action went into a mediation process, according to a March 2018 report by Law360, that was resolved around the same time.", "object": {"text": "resolved"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a settlement", "keywords": [{"text": "settlement"}]}, "sentence": " While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "object": {"text": "been reached between the parties", "keywords": [{"text": "parties"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a settlement", "keywords": [{"text": "settlement"}]}, "sentence": " While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "object": {"text": "reached between the parties", "keywords": [{"text": "parties"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "a settlement", "keywords": [{"text": "settlement"}]}, "sentence": " While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "action": {"verb": {"text": "reach", "tense": "past"}, "text": "has been reached", "normalized": "have be reach"}}, {"subject": {"text": "counsel comment", "keywords": [{"text": "counsel"}, {"text": "comment"}]}, "sentence": " While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "object": {"text": "not provided by either side"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by either side"}, "sentence": " While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "object": {"text": "counsel comment", "keywords": [{"text": "counsel"}, {"text": "comment"}]}, "action": {"verb": {"text": "provide", "tense": "past", "negated": true}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "A U.S. District Judge in Massachusetts", "keywords": [{"text": "U.S. District Judge"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "sentence": " A U.S. District Judge in Massachusetts dismissed the case because of the non-disclosed but pending deal.", "object": {"text": "the case", "keywords": [{"text": "case"}]}, "action": {"verb": {"text": "dismiss", "tense": "past"}, "text": "dismissed", "normalized": "dismiss"}}, {"subject": {"text": "you or a loved one"}, "sentence": " If you or a loved one took Actos and later developed bladder cancer, you may have a legal claim.", "object": {"text": "Actos", "keywords": [{"text": "Actos"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "you"}, "sentence": " If you or a loved one took Actos and later developed bladder cancer, you may have a legal claim.", "object": {"text": "a legal claim", "keywords": [{"text": "legal claim"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "may have", "normalized": "may have"}}, {"subject": {"text": "you or a loved one"}, "sentence": " If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "object": {"text": "Actos", "keywords": [{"text": "Actos"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "you"}, "sentence": " If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "object": {"text": "to file an Actos lawsuit and for an Actos settlement", "keywords": [{"text": "Actos lawsuit"}, {"text": "Actos settlement"}]}, "action": {"verb": {"text": "qualify", "tense": "future"}, "text": "qualify", "normalized": "qualify"}}], "concepts": [{"text": "Diabetes mellitus", "relevance": 0.952144, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Insulin", "relevance": 0.939941, "dbpedia_resource": "http://dbpedia.org/resource/Insulin"}, {"text": "Metformin", "relevance": 0.914064, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Food and Drug Administration", "relevance": 0.851018, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Obesity", "relevance": 0.804378, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Bladder cancer", "relevance": 0.7578, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}, {"text": "Lawsuit", "relevance": 0.748407, "dbpedia_resource": "http://dbpedia.org/resource/Lawsuit"}, {"text": "Diabetes mellitus type 2", "relevance": 0.746526, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_2"}, {"text": "Pharmaceutical drug", "relevance": 0.736644, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pioglitazone", "relevance": 0.703678, "dbpedia_resource": "http://dbpedia.org/resource/Pioglitazone"}, {"text": "Clinical trial", "relevance": 0.690027, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Eli Lilly and Company", "relevance": 0.664119, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}, {"text": "Insulin resistance", "relevance": 0.654134, "dbpedia_resource": "http://dbpedia.org/resource/Insulin_resistance"}, {"text": "Thiazolidinedione", "relevance": 0.64661, "dbpedia_resource": "http://dbpedia.org/resource/Thiazolidinedione"}, {"text": "Pharmacology", "relevance": 0.617258, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Anti-diabetic drug", "relevance": 0.603098, "dbpedia_resource": "http://dbpedia.org/resource/Anti-diabetic_drug"}, {"text": "Appeal", "relevance": 0.599708, "dbpedia_resource": "http://dbpedia.org/resource/Appeal"}, {"text": "Civil procedure", "relevance": 0.584052, "dbpedia_resource": "http://dbpedia.org/resource/Civil_procedure"}, {"text": "Pleading", "relevance": 0.580868, "dbpedia_resource": "http://dbpedia.org/resource/Pleading"}, {"text": "Metabolic syndrome", "relevance": 0.573179, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Exenatide", "relevance": 0.565754, "dbpedia_resource": "http://dbpedia.org/resource/Exenatide"}, {"text": "Law", "relevance": 0.541844, "dbpedia_resource": "http://dbpedia.org/resource/Law"}, {"text": "Blue Cross and Blue Shield Association", "relevance": 0.534, "dbpedia_resource": "http://dbpedia.org/resource/Blue_Cross_and_Blue_Shield_Association"}, {"text": "Cancer", "relevance": 0.5196, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Urinary bladder", "relevance": 0.51, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Diabetes mellitus type 1", "relevance": 0.50877, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_1"}, {"text": "Diabetes", "relevance": 0.501959, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes"}, {"text": "Multidistrict litigation", "relevance": 0.49326, "dbpedia_resource": "http://dbpedia.org/resource/Multidistrict_litigation"}], "categories": [{"score": 0.723172, "label": "/health and fitness/disease/diabetes"}, {"score": 0.390697, "label": "/law, govt and politics"}, {"score": 0.373819, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "partOf", "sentence": "Actos\u2014a medication for type-2 diabetes manufactured and distributed by the Takeda Corp.\u2014was approved by the U.S. Food and Drug Administration in 1999.", "score": 0.980107, "arguments": [{"text": "Food and Drug Administration", "location": [113, 141], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [108, 112], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Another concurrent study shored up the data on bladder cancer risk with Actos as well, and when the 10-year study completed in 2016, the FDA without equivocation announced that the drug might be linked to a higher probability of developing bladder cancer.", "score": 0.687129, "arguments": [{"text": "FDA", "location": [1408, 1411], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "announced", "location": [1433, 1442], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "By this time, there were already 9,000 pending Actos cancer lawsuits gathered in federal court in a class action multidistrict litigation (MDL).", "score": 0.68354, "arguments": [{"text": "Actos", "location": [1574, 1579], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "MDL", "location": [1666, 1669], "entities": [{"type": "Ticker", "text": "MDL"}]}]}, {"type": "hasAttribute", "sentence": "When one of the first cases of Actos cancer lawsuit among this group went to \"bellwether\" trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "score": 0.648743, "arguments": [{"text": "group", "location": [1784, 1789], "entities": [{"type": "Person", "text": "people"}]}, {"text": "cancer", "location": [1758, 1764], "entities": [{"type": "HealthCondition", "text": "bladder cancer"}]}]}, {"type": "hasAttribute", "sentence": "In a separate legal action, Blue Cross & Blue Shield sought to regain the costs of medical bills it paid out for several hundred people who purportedly developed bladder cancer as a direct consequence of taking Actos.", "score": 0.839073, "arguments": [{"text": "who", "location": [2281, 2284], "entities": [{"type": "Person", "text": "people"}]}, {"text": "bladder cancer", "location": [2307, 2321], "entities": [{"type": "HealthCondition", "text": "bladder cancer"}]}]}, {"type": "affectedBy", "sentence": "When one of the first cases of Actos cancer lawsuit among this group went to \"bellwether\" trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "score": 0.651356, "arguments": [{"text": "group", "location": [1784, 1789], "entities": [{"type": "Person", "text": "people"}]}, {"text": "lawsuit", "location": [1765, 1772], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "hasAttribute", "sentence": "When one of the first cases of Actos cancer lawsuit among this group went to \"bellwether\" trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "score": 0.475637, "arguments": [{"text": "which", "location": [1887, 1892], "entities": [{"type": "Organization", "text": "Takeda Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$38 million", "location": [1927, 1938], "entities": [{"type": "Money", "text": "$38 million"}]}]}, {"type": "partOf", "sentence": "Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "score": 0.966693, "arguments": [{"text": "distributor", "location": [1975, 1986], "entities": [{"type": "Organization", "text": "distributor"}]}, {"text": "U.S.", "location": [1970, 1974], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "While a settlement has been reached between the parties, details were not shared publicly, and counsel comment was not provided by either side.", "score": 0.381241, "arguments": [{"text": "parties", "location": [2538, 2545], "entities": [{"type": "Organization", "text": "parties", "disambiguation": {"subtype": ["Political"]}}]}, {"text": "settlement", "location": [2498, 2508], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "employedBy", "sentence": "A U.S. District Judge in Massachusetts dismissed the case because of the non-disclosed but pending deal.", "score": 0.881057, "arguments": [{"text": "District Judge", "location": [2641, 2655], "entities": [{"type": "Person", "text": "District Judge"}]}, {"text": "U.S.", "location": [2636, 2640], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "A U.S. District Judge in Massachusetts dismissed the case because of the non-disclosed but pending deal.", "score": 0.710395, "arguments": [{"text": "District Judge", "location": [2641, 2655], "entities": [{"type": "Person", "text": "District Judge"}]}, {"text": "Massachusetts", "location": [2659, 2672], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "agentOf", "sentence": "A U.S. District Judge in Massachusetts dismissed the case because of the non-disclosed but pending deal.", "score": 0.848896, "arguments": [{"text": "District Judge", "location": [2641, 2655], "entities": [{"type": "Person", "text": "District Judge"}]}, {"text": "dismissed", "location": [2673, 2682], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "Numerous Actos cancer lawsuit actions were later filed against Asia's largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "score": 0.374109, "arguments": [{"text": "Actos", "location": [160, 165], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [173, 180], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "According to these Actos cancer lawsuit allegations, Takeda was aware of the associated risks through animal (rat) testing the decade prior to FDA approval.", "score": 0.440727, "arguments": [{"text": "Actos", "location": [459, 464], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [472, 479], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "When one of the first cases of Actos cancer lawsuit among this group went to \"bellwether\" trial phase, a jury slapped a $9 billion punitive damages fine upon Takeda, which was later reviewed and reduced to $38 million.", "score": 0.87133, "arguments": [{"text": "Actos", "location": [1752, 1757], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [1765, 1772], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "Takeda and Eli Lilly Co., its U.S. distributor, wanted to avoid further court exposure and came to an agreement to settle most of the leftover cases of Actos cancer lawsuit with a payment of $2.4 billion.", "score": 0.785911, "arguments": [{"text": "Actos", "location": [2092, 2097], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [2105, 2112], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "score": 0.876613, "arguments": [{"text": "Actos", "location": [2926, 2931], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [2932, 2939], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "agentOf", "sentence": "Join this Actos lawsuit investigation by filling out the FREE form on this page.", "score": 0.813782, "arguments": [{"text": "Actos", "location": [2979, 2984], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "lawsuit", "location": [2985, 2992], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "hasAttribute", "sentence": "If you or a loved one took Actos and later developed bladder cancer, you may have a legal claim.", "score": 0.544991, "arguments": [{"text": "you", "location": [2808, 2811], "entities": [{"type": "Person", "text": "you"}]}, {"text": "bladder cancer", "location": [2792, 2806], "entities": [{"type": "HealthCondition", "text": "bladder cancer"}]}]}, {"type": "hasAttribute", "sentence": "If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "score": 0.558041, "arguments": [{"text": "you", "location": [2899, 2902], "entities": [{"type": "Person", "text": "you"}]}, {"text": "bladder cancer", "location": [2883, 2897], "entities": [{"type": "HealthCondition", "text": "bladder cancer"}]}]}, {"type": "affectedBy", "sentence": "If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "score": 0.759766, "arguments": [{"text": "you", "location": [2899, 2902], "entities": [{"type": "Person", "text": "you"}]}, {"text": "lawsuit", "location": [2932, 2939], "entities": [{"type": "EventLegal", "text": "lawsuit"}]}]}, {"type": "affectedBy", "sentence": "If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "score": 0.665949, "arguments": [{"text": "you", "location": [2899, 2902], "entities": [{"type": "Person", "text": "you"}]}, {"text": "settlement", "location": [2957, 2967], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "agentOf", "sentence": "If you or a loved one took Actos and developed bladder cancer, you may qualify to file an Actos lawsuit and for an Actos settlement.", "score": 0.904258, "arguments": [{"text": "Actos", "location": [2951, 2956], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "settlement", "location": [2957, 2967], "entities": [{"type": "EventLegal", "text": "settlement"}]}]}, {"type": "agentOf", "sentence": "Join this Actos lawsuit investigation by filling out the FREE form on this page.", "score": 0.522998, "arguments": [{"text": "Actos", "location": [2979, 2984], "entities": [{"type": "Organization", "text": "Actos"}]}, {"text": "investigation", "location": [2993, 3006], "entities": [{"type": "EventLegal", "text": "investigation"}]}]}, {"type": "basedIn", "sentence": "Numerous Actos cancer lawsuit actions were later filed against Asia's largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "score": 0.881701, "arguments": [{"text": "pharmaceutical company", "location": [229, 251], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "Asia", "location": [214, 218], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Numerous Actos cancer lawsuit actions were later filed against Asia's largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "score": 0.737511, "arguments": [{"text": "pharmaceutical company", "location": [229, 251], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "Blue Cross & Blue Shield of Massachusetts", "location": [255, 296], "entities": [{"type": "Organization", "text": "Blue Cross & Blue Shield of Massachusetts", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Numerous Actos cancer lawsuit actions were later filed against Asia's largest pharmaceutical company by Blue Cross & Blue Shield of Massachusetts, alleging that the manufacturer knew the drug\u2014when either used long-term or in higher doses\u2014increased the risk for bladder cancer development.", "score": 0.483544, "arguments": [{"text": "pharmaceutical company", "location": [229, 251], "entities": [{"type": "Organization", "text": "pharmaceutical company"}]}, {"text": "alleging", "location": [298, 306], "entities": [{"type": "EventCommunication", "text": "alleging"}]}]}, {"type": "employedBy", "sentence": "Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda's revenue as measured in 2010.", "score": 0.309289, "arguments": [{"text": "patients", "location": [737, 745], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "which", "location": [699, 704], "entities": [{"type": "Organization", "text": "Actos"}]}]}, {"type": "hasAttribute", "sentence": "Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda's revenue as measured in 2010.", "score": 0.640396, "arguments": [{"text": "patients", "location": [737, 745], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetes", "location": [768, 776], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "locatedAt", "sentence": "Actos, which decreases insulin resistance in patients diagnosed with type-2 diabetes, went on to become a blockbuster medication which contributed nearly 30 percent of Takeda's revenue as measured in 2010.", "score": 0.497333, "arguments": [{"text": "medication", "location": [810, 820], "entities": [{"type": "Substance", "text": "medication"}]}, {"text": "blockbuster", "location": [798, 809], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "agentOf", "sentence": "The warning went out and the FDA requested a label change reflecting these new concerns in 2011.", "score": 0.98051, "arguments": [{"text": "FDA", "location": [1203, 1206], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "requested", "location": [1207, 1216], "entities": [{"type": "EventCommunication", "text": "requested"}]}]}], "keywords": [{"text": "Actos cancer lawsuit", "sentiment": {"score": -0.543828, "label": "negative"}, "relevance": 0.977543}, {"text": "bladder cancer", "sentiment": {"score": -0.562163, "label": "negative"}, "relevance": 0.845949}, {"text": "Numerous Actos cancer", "sentiment": {"score": -0.618097, "label": "negative"}, "relevance": 0.624561}, {"text": "Actos cancer lawsuits", "sentiment": {"score": -0.487108, "label": "negative"}, "relevance": 0.568889}, {"text": "Actos lawsuit investigation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565494}, {"text": "Actos settlement", "sentiment": {"score": -0.539111, "label": "negative"}, "relevance": 0.465843}, {"text": "Blue Shield", "sentiment": {"score": -0.534753, "label": "negative"}, "relevance": 0.459724}, {"text": "bladder cancer development", "sentiment": {"score": -0.587111, "label": "negative"}, "relevance": 0.451723}, {"text": "Blue Cross", "sentiment": {"score": -0.534753, "label": "negative"}, "relevance": 0.449798}, {"text": "cancer lawsuit allegations", "sentiment": {"score": -0.353244, "label": "negative"}, "relevance": 0.423267}, {"text": "bladder cancer risk", "sentiment": {"score": -0.635903, "label": "negative"}, "relevance": 0.422851}, {"text": "type-2 diabetes", "sentiment": {"score": -0.447617, "label": "negative"}, "relevance": 0.406789}, {"text": "Takeda", "sentiment": {"score": -0.205474, "label": "negative"}, "relevance": 0.391593}, {"text": "pharmaceutical company", "sentiment": {"score": -0.618097, "label": "negative"}, "relevance": 0.384855}, {"text": "largest pharmaceutical company", "sentiment": {"score": -0.618097, "label": "negative"}, "relevance": 0.375095}, {"text": "Takeda Corp.\u2014was", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.370447}, {"text": "post-market clinical trial", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367596}, {"text": "action multidistrict litigation", "sentiment": {"score": -0.487108, "label": "negative"}, "relevance": 0.35456}, {"text": "Takeda\u2019s revenue", "sentiment": {"score": 0.246831, "label": "positive"}, "relevance": 0.353252}, {"text": "Eli Lilly Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351856}, {"text": "separate legal action", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344364}, {"text": "U.S. District Judge", "sentiment": {"score": -0.249664, "label": "negative"}, "relevance": 0.341257}, {"text": "lawsuit actions", "sentiment": {"score": -0.618097, "label": "negative"}, "relevance": 0.334227}, {"text": "Actos\u2014a medication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.304167}, {"text": "FDA approval", "sentiment": {"score": 0.322246, "label": "positive"}, "relevance": 0.301651}, {"text": "U.S. Food", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.297495}, {"text": "blockbuster medication", "sentiment": {"score": 0.246831, "label": "positive"}, "relevance": 0.297084}, {"text": "Drug Administration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.296573}, {"text": "10-year study", "sentiment": {"score": -0.224999, "label": "negative"}, "relevance": 0.296014}, {"text": "diabetes medication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.294895}, {"text": "5-year mark", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292264}, {"text": "market access", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.290545}, {"text": "high doses", "sentiment": {"score": -0.698743, "label": "negative"}, "relevance": 0.290233}, {"text": "associated risks", "sentiment": {"score": -0.35694, "label": "negative"}, "relevance": 0.288866}, {"text": "insulin resistance", "sentiment": {"score": -0.447617, "label": "negative"}, "relevance": 0.28814}, {"text": "punitive damages", "sentiment": {"score": -0.547672, "label": "negative"}, "relevance": 0.287432}, {"text": "label change", "sentiment": {"score": -0.735435, "label": "negative"}, "relevance": 0.287027}, {"text": "concurrent study", "sentiment": {"score": -0.635903, "label": "negative"}, "relevance": 0.284307}, {"text": "new concerns", "sentiment": {"score": -0.735435, "label": "negative"}, "relevance": 0.283954}, {"text": "leftover cases", "sentiment": {"score": -0.679476, "label": "negative"}, "relevance": 0.283944}, {"text": "federal court", "sentiment": {"score": -0.487108, "label": "negative"}, "relevance": 0.283363}, {"text": "direct consequence", "sentiment": {"score": -0.59407, "label": "negative"}, "relevance": 0.282797}, {"text": "U.S. distributor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281537}, {"text": "higher probability", "sentiment": {"score": -0.456951, "label": "negative"}, "relevance": 0.281341}, {"text": "mediation process", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2802}, {"text": "medical bills", "sentiment": {"score": -0.59407, "label": "negative"}, "relevance": 0.280127}, {"text": "FREE form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280101}, {"text": "trial phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279623}, {"text": "court exposure", "sentiment": {"score": -0.679476, "label": "negative"}, "relevance": 0.278639}, {"text": "pending deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.278343}]}, "extracted_metadata": {"sha1": "b3d569f6c9d1713d07da9a4d953e0a539de43881", "filename": "1541033488862.zip-342878e41a2c51b2b9d8b00a8265936b.xml", "file_type": "json"}, "external_links": ["https://www.law360.com/articles/1019553/blue-cross-takeda-settle-actos-cancer-claims"], "title": "Settlement Resolves Actos Cancer Lawsuit Between Takeda and Blue Cross", "forum_title": "Pharma Drugs &amp; Medical Devices Archives - Page 22 of 693 - Top Class Actions"}, {"id": "Hub0GN-kx7noaEq2G-nrIfnDSrvXfMFLb48klHBWMLiwOwRBKvebmjWF09AxCmNr", "result_metadata": {"score": 30.656204}, "author": "CP Wire", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.546888, "label": "/health and fitness/disease"}, {"score": 0.49548, "label": "/health and fitness/disease/asthma"}, {"score": 0.457595, "label": "/health and fitness/disease/allergies"}], "relations": [], "keywords": [{"text": "Ending", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.993594}, {"text": "Microbiome Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.871613}]}, "crawl_date": "2018-10-31T23:06:07Z", "url": "http://www.cafepharma.com/cpwire/article/Microbiome-Report-for-Week-Ending-102718/66279-", "host": "cafepharma.com", "text": "include live microbes ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d).", "main_image_url": "http://www.cafepharma.com/sites/all/themes/metrixx/NCPopengraph.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-10-31T22:41:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.881671, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.59875, "label": "positive"}, "text": "Takeda", "relevance": 0.793802, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.440709, "label": "positive"}, "text": "Life Capital Fund Seventure Partners", "relevance": 0.708062, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.556914, "label": "negative"}, "text": "ENTEROME SA", "relevance": 0.573883, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.570865, "label": "positive"}, "text": "Microbiotica", "relevance": 0.572777, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.59875, "label": "positive"}, "text": "Enterome", "relevance": 0.563667, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambridge Innovation Capital", "relevance": 0.538838, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.634228, "label": "negative"}, "text": "Crohn\u2019s disease", "relevance": 0.519094, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": -0.634228, "label": "negative"}, "text": "Enterome", "relevance": 0.511549, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seventure", "relevance": 0.485745, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IP Group", "relevance": 0.400699, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$50 million", "relevance": 0.400699, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$640", "relevance": 0.400699, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12m", "relevance": 0.400699, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4m", "relevance": 0.400699, "type": "Quantity"}], "sentiment": {"document": {"score": 0.189417, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Enterome", "keywords": [{"text": "Enterome"}], "entities": [{"type": "Person", "text": "Enterome"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "an upfront payment of $50 million end", "keywords": [{"text": "upfront payment"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "$50 million"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "an upfront payment of $50 million end", "keywords": [{"text": "upfront payment"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "$50 million"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "eligible to receive up to $640 in additional paymentsEnterome", "keywords": [{"text": "additional paymentsEnterome"}], "entities": [{"type": "Quantity", "text": "$640"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Enterome", "keywords": [{"text": "Enterome"}], "entities": [{"type": "Person", "text": "Enterome"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "up to $640 in additional paymentsEnterome", "keywords": [{"text": "additional paymentsEnterome"}], "entities": [{"type": "Quantity", "text": "$640"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "to receive", "normalized": "to receive"}}, {"subject": {"text": "agreements", "keywords": [{"text": "agreements"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "multiple other GI conditionsEnterome", "keywords": [{"text": "multiple other GI"}, {"text": "conditionsEnterome"}]}, "action": {"verb": {"text": "target", "tense": "present"}, "text": "targeting", "normalized": "target"}}, {"subject": {"text": "developing treatments", "keywords": [{"text": "treatments"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "from gut microbes", "keywords": [{"text": "gut microbes"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "live microbes", "keywords": [{"text": "live microbes"}]}, "sentence": " Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes", "object": {"text": "gut microbes rather than treatments", "keywords": [{"text": "gut microbes"}, {"text": "treatments"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "10/23/18"}, "sentence": " ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d).", "object": {"text": "it has entered into a global licensing", "keywords": [{"text": "global licensing"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Enterome\u2019s lead investigational drug candidate EB8018 in patients with Crohn\u2019s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases", "keywords": [{"text": "investigational drug candidate"}, {"text": "Crohn\u2019s disease"}, {"text": "liver diseases"}, {"text": "Enterome"}], "entities": [{"type": "Company", "text": "Enterome"}, {"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "sentence": " The agreement covers Enterome\u2019s lead investigational drug candidate EB8018 in patients with Crohn\u2019s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.", "object": {"text": "The agreement", "keywords": [{"text": "agreement"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "Enterome\u2019s", "keywords": [{"text": "Enterome"}], "entities": [{"type": "Company", "text": "Enterome"}]}, "sentence": " The agreement covers Enterome\u2019s lead investigational drug candidate EB8018 in patients with Crohn\u2019s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.", "object": {"text": "investigational drug candidate EB8018 in patients with Crohn\u2019s disease", "keywords": [{"text": "investigational drug candidate"}, {"text": "Crohn"}, {"text": "patients"}, {"text": "disease"}], "entities": [{"type": "HealthCondition", "text": "Crohn\u2019s disease"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "lead", "normalized": "lead"}}, {"subject": {"text": "Microbiotica Attracts Equity Investment from Seventure\u2019s Health for Life Capital Fund Seventure Partners, a specialist investor in the microbiome,", "keywords": [{"text": "Microbiotica Attracts Equity"}, {"text": "Life Capital Fund"}, {"text": "specialist investor"}, {"text": "Seventure\u2019s Health"}], "entities": [{"type": "Company", "text": "Microbiotica"}, {"type": "Company", "text": "Life Capital Fund Seventure Partners"}]}, "sentence": " Microbiotica Attracts Equity Investment from Seventure\u2019s Health for Life Capital Fund Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital\u2122 and strengthens Microbiotica\u2019s Board with microbiome sector expertise and know-how.", "object": {"text": "Microbiotica\u2019s Board", "keywords": [{"text": "Microbiotica"}, {"text": "Board"}], "entities": [{"type": "Company", "text": "Microbiotica"}]}, "action": {"verb": {"text": "strengthen", "tense": "present"}, "text": "strengthens", "normalized": "strengthen"}}, {"subject": {"text": "subscirbe", "keywords": [{"text": "subscirbe"}]}, "sentence": " To see the rest of this week's microbiome report and gain access to our microbiome database, subscirbe to our premium newsletter .", "object": {"text": "the rest of this week's microbiome report and gain access to our microbiome database", "keywords": [{"text": "microbiome database"}, {"text": "rest"}, {"text": "gain"}, {"text": "access"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "To see", "normalized": "To see"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Ownership equity", "relevance": 0.859999, "dbpedia_resource": "http://dbpedia.org/resource/Ownership_equity"}, {"text": "Finance", "relevance": 0.847269, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Contract", "relevance": 0.783899, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}], "categories": [{"score": 0.786491, "label": "/health and fitness/disease"}, {"score": 0.427308, "label": "/health and fitness/disorders"}], "relations": [{"type": "timeOf", "sentence": "Home \u00bb Microbiome Report for Week Ending 10/27/18 Microbiome Report for Week Ending 10/27/18 October 31, 2018 Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (\"Takeda\").", "score": 0.787773, "arguments": [{"text": "10/27/18 Microbiome", "location": [41, 60], "entities": [{"type": "Date", "text": "10/27/18 Microbiome"}]}, {"text": "Report", "location": [61, 67], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Home \u00bb Microbiome Report for Week Ending 10/27/18 Microbiome Report for Week Ending 10/27/18 October 31, 2018 Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (\"Takeda\").", "score": 0.787891, "arguments": [{"text": "10/27/18 October 31, 2018\nEnterome", "location": [84, 118], "entities": [{"type": "Date", "text": "10/27/18 October 31, 2018\nEnterome"}]}, {"text": "Report", "location": [61, 67], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "timeOf", "sentence": "Home \u00bb Microbiome Report for Week Ending 10/27/18 Microbiome Report for Week Ending 10/27/18 October 31, 2018 Enterome will receive an upfront payment of $50 million end is eligible to receive up to $640 in additional paymentsEnterome and Takeda also have agreements targeting multiple other GI conditionsEnterome focuses on developing treatments derived from gut microbes rather than treatments that include live microbes ENTEROME SA, on 10/23/18 announced it has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (\"Takeda\").", "score": 0.663023, "arguments": [{"text": "10/23/18", "location": [439, 447], "entities": [{"type": "Date", "text": "10/23/18"}]}, {"text": "announced", "location": [448, 457], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOfMany", "sentence": "The agreement covers Enterome's lead investigational drug candidate EB8018 in patients with Crohn's disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.", "score": 0.718282, "arguments": [{"text": "EB8018", "location": [663, 669], "entities": [{"type": "Person", "text": "EB8018"}]}, {"text": "patients", "location": [673, 681], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "hasAttribute", "sentence": "The agreement covers Enterome's lead investigational drug candidate EB8018 in patients with Crohn's disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.", "score": 0.555873, "arguments": [{"text": "patients", "location": [673, 681], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "liver diseases", "location": [778, 792], "entities": [{"type": "HealthCondition", "text": "liver diseases"}]}]}, {"type": "partOf", "sentence": "Microbiotica Attracts Equity Investment from Seventure's Health for Life Capital Fund Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life CapitalM and strengthens Microbiotica's Board with microbiome sector expertise and know-how.", "score": 0.839288, "arguments": [{"text": "Health for Life Capital Fund Seventure Partners", "location": [851, 898], "entities": [{"type": "Organization", "text": "Health for Life Capital Fund Seventure Partners"}]}, {"text": "Seventure", "location": [839, 848], "entities": [{"type": "Organization", "text": "Seventure"}]}]}, {"type": "managerOf", "sentence": "Microbiotica Attracts Equity Investment from Seventure's Health for Life Capital Fund Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life CapitalM and strengthens Microbiotica's Board with microbiome sector expertise and know-how.", "score": 0.526981, "arguments": [{"text": "Microbiotica", "location": [1007, 1019], "entities": [{"type": "Person", "text": "Microbiotica"}]}, {"text": "Board", "location": [1022, 1027], "entities": [{"type": "Organization", "text": "Board"}]}]}, {"type": "memberOf", "sentence": "Seventure Joins founding investors, Cambridge Innovation Capital and IP Group, by committing \u00a34m, bringing total equity raised to \u00a312m.", "score": 0.302599, "arguments": [{"text": "investors", "location": [1100, 1109], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "Seventure", "location": [1075, 1084], "entities": [{"type": "Organization", "text": "Seventure"}]}]}, {"type": "agentOf", "sentence": "Seventure Joins founding investors, Cambridge Innovation Capital and IP Group, by committing \u00a34m, bringing total equity raised to \u00a312m.", "score": 0.810344, "arguments": [{"text": "\u00a34m", "location": [1168, 1171], "entities": [{"type": "Person", "text": "\u00a34m"}]}, {"text": "committing", "location": [1157, 1167], "entities": [{"type": "EventCommunication", "text": "committing"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.958382}, {"text": "investigational drug candidate", "sentiment": {"score": -0.634228, "label": "negative"}, "relevance": 0.840341}, {"text": "Attracts Equity Investment", "sentiment": {"score": 0.440709, "label": "positive"}, "relevance": 0.835876}, {"text": "microbiome sector expertise", "sentiment": {"score": 0.70102, "label": "positive"}, "relevance": 0.806238}, {"text": "Microbiome Report", "sentiment": {"score": -0.483282, "label": "negative"}, "relevance": 0.800988}, {"text": "Fund Seventure Partners", "sentiment": {"score": 0.440709, "label": "positive"}, "relevance": 0.797721}, {"text": "Cambridge Innovation Capital", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.780752}, {"text": "gut microbes", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.706998}, {"text": "live microbes", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.685041}, {"text": "multiple other GI", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.68154}, {"text": "Home \u00bb Microbiome", "sentiment": {"score": -0.483282, "label": "negative"}, "relevance": 0.681131}, {"text": "upfront payment", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.662017}, {"text": "co-promotion agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657658}, {"text": "Crohn\u2019s disease", "sentiment": {"score": -0.634228, "label": "negative"}, "relevance": 0.635163}, {"text": "additional paymentsEnterome", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.633836}, {"text": "ENTEROME SA", "sentiment": {"score": -0.556914, "label": "negative"}, "relevance": 0.628037}, {"text": "Seventure Joins", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626236}, {"text": "Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625139}, {"text": "global licensing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622618}, {"text": "microbiome database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621602}, {"text": "liver diseases", "sentiment": {"score": -0.530357, "label": "negative"}, "relevance": 0.620826}, {"text": "total equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619651}, {"text": "Seventure\u2019s Health", "sentiment": {"score": 0.440709, "label": "positive"}, "relevance": 0.618123}, {"text": "specialist investor", "sentiment": {"score": 0.235062, "label": "positive"}, "relevance": 0.611581}, {"text": "Life Capital\u2122", "sentiment": {"score": 0.70102, "label": "positive"}, "relevance": 0.611164}, {"text": "Microbiotica\u2019s Board", "sentiment": {"score": 0.70102, "label": "positive"}, "relevance": 0.610709}, {"text": "new funding", "sentiment": {"score": 0.70102, "label": "positive"}, "relevance": 0.608151}, {"text": "IP Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606236}, {"text": "premium newsletter", "sentiment": {"score": 0.380814, "label": "positive"}, "relevance": 0.599137}, {"text": "Ending", "sentiment": {"score": -0.483282, "label": "negative"}, "relevance": 0.508742}, {"text": "co-development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476818}, {"text": "treatments", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.461059}, {"text": "know-how", "sentiment": {"score": 0.70102, "label": "positive"}, "relevance": 0.449458}, {"text": "agreements", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.442068}, {"text": "end", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.437092}, {"text": "conditionsEnterome", "sentiment": {"score": 0.59875, "label": "positive"}, "relevance": 0.436699}, {"text": "gain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435973}, {"text": "patients", "sentiment": {"score": -0.634228, "label": "negative"}, "relevance": 0.434748}, {"text": "potential", "sentiment": {"score": -0.284603, "label": "negative"}, "relevance": 0.434602}, {"text": "disorders", "sentiment": {"score": -0.530357, "label": "negative"}, "relevance": 0.434438}, {"text": "rest", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433707}, {"text": "Tags", "sentiment": {"score": 0.496811, "label": "positive"}, "relevance": 0.4337}]}, "extracted_metadata": {"sha1": "99efb70cfe58a909f6a2179bc615d980652c1384", "filename": "1541027167045.zip-195e631f79a585fca3f57f608e243d69.xml", "file_type": "json"}, "external_links": ["https://www.microbiotica.com/news/17/58/Microbiotica-Attracts-Equity-Investment-from-Seventures-Health-for-Life-Capital-Fund.html"], "title": "Microbiome Report for Week Ending 10/27/18", "forum_title": "Latest Headlines from Cafepharma"}, {"id": "DubAU4hUtMlea7ERQNmKFDe4mg03jHKrLEMjcCQ2tqAn7LH8YOM2geFUNX7uhFr-", "result_metadata": {"score": 28.864056}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. Andrew Plump", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.591676, "label": "positive"}, "text": "Gilda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.591676, "label": "positive"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.844588, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Dr. Andrew Plump, Takeda And CVS Health", "keywords": [{"text": "CVS Health"}, {"text": "Plump"}, {"text": "Takeda"}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. Andrew Plump"}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "object": {"text": "Honored At Gilda's Club NYC's Benefit Gala", "keywords": [{"text": "Benefit Gala"}, {"text": "Club NYC"}, {"text": "Gilda"}], "entities": [{"type": "Person", "text": "Gilda"}]}, "action": {"verb": {"text": "Be", "tense": "future"}, "text": "Be", "normalized": "Be"}}, {"subject": {"text": "Dr. Andrew Plump, Takeda And CVS Health", "keywords": [{"text": "CVS Health"}, {"text": "Plump"}, {"text": "Takeda"}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. Andrew Plump"}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "action": {"verb": {"text": "Honored", "tense": "past"}, "text": "To Be Honored", "normalized": "To Be Honored"}}], "concepts": [{"text": "Gilda Radner", "relevance": 0.878864, "dbpedia_resource": "http://dbpedia.org/resource/Gilda_Radner"}], "categories": [{"score": 0.236243, "label": "/health and fitness"}, {"score": 0.219719, "label": "/health and fitness/disease/cancer"}, {"score": 0.10617, "label": "/art and entertainment/humor"}], "relations": [{"type": "employedBy", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "score": 0.544321, "arguments": [{"text": "Gilda", "location": [57, 62], "entities": [{"type": "Person", "text": "Gilda"}]}, {"text": "Club NYC", "location": [65, 73], "entities": [{"type": "Organization", "text": "Club NYC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "score": 0.857531, "arguments": [{"text": "Benefit Gala", "location": [76, 88], "entities": [{"type": "Organization", "text": "Benefit Gala", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Club NYC", "location": [65, 73], "entities": [{"type": "Organization", "text": "Club NYC", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Dr. Andrew Plump", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.919556}, {"text": "Takeda And CVS", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.802529}, {"text": "Benefit Gala", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.678419}, {"text": "Club NYC", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.55233}, {"text": "Gilda", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.44588}, {"text": "Health", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.223777}]}, "crawl_date": "2018-10-31T17:36:02Z", "url": "https://www.biospace.com/article/releases/dr-andrew-plump-takeda-and-cvs-health-to-be-honored-at-gilda-s-club-nyc-s-benefit-gala-november-8/", "host": "biospace.com", "text": "Gala Co-Chairs are Laura Bartlett , Chairman, Board of Directors, GCNYC and Mark J.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-10-31T00:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.564771, "label": "positive"}, "text": "Gilda", "relevance": 0.888695, "type": "Person"}, {"count": 4, "sentiment": {"score": 0.564771, "label": "positive"}, "text": "Club NYC", "relevance": 0.77988, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilda\u2019s Club NYC", "relevance": 0.693914, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilda Radner", "relevance": 0.606613, "type": "Person", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "FilmActor", "TheaterActor", "TVActor", "TVWriter"], "name": "Gilda Radner", "dbpedia_resource": "http://dbpedia.org/resource/Gilda_Radner"}}, {"count": 3, "sentiment": {"score": 0.450639, "label": "positive"}, "text": "CVS Health", "relevance": 0.580083, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. Andrew Plump", "relevance": 0.478057, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cancer Research Award", "relevance": 0.398373, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.389892, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Saturday Night Live", "relevance": 0.374824, "type": "TelevisionShow", "disambiguation": {"subtype": ["AwardWinner"], "name": "Saturday Night Live", "dbpedia_resource": "http://dbpedia.org/resource/Saturday_Night_Live"}}, {"count": 1, "sentiment": {"score": -0.405776, "label": "negative"}, "text": "cancer", "relevance": 0.368601, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 1, "sentiment": {"score": 0.342082, "label": "positive"}, "text": "Gotham Hall", "relevance": 0.322895, "type": "Facility", "disambiguation": {"subtype": [], "name": "Greenwich Savings Bank", "dbpedia_resource": "http://dbpedia.org/resource/Greenwich_Savings_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lydia Wickliffe Fenet", "relevance": 0.321881, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.295368, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Medical and Scientific Officer", "relevance": 0.290713, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Laura Bartlett", "relevance": 0.288822, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEW YORK", "relevance": 0.278769, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corporation", "relevance": 0.278543, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0.540967, "label": "positive"}, "text": "Alan Zweibel", "relevance": 0.272992, "type": "Person", "disambiguation": {"subtype": ["Actor", "AwardNominee", "FilmProducer", "TVActor", "FilmWriter", "TVWriter"], "name": "Alan Zweibel", "dbpedia_resource": "http://dbpedia.org/resource/Alan_Zweibel"}}, {"count": 1, "sentiment": {"score": 0.507303, "label": "positive"}, "text": "Slattery Family Foundation", "relevance": 0.27161, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GCNYC", "relevance": 0.271453, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.326631, "label": "positive"}, "text": "West Village Clubhouse", "relevance": 0.26704, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0.206492, "label": "positive"}, "text": "Mandy Patinkin", "relevance": 0.265043, "type": "Person", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "FilmActor", "TheaterActor", "TVActor"], "name": "Mandy Patinkin", "dbpedia_resource": "http://dbpedia.org/resource/Mandy_Patinkin"}}, {"count": 1, "sentiment": {"score": 0.425119, "label": "positive"}, "text": "Joanna Bull", "relevance": 0.261018, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President", "relevance": 0.253372, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GCNYC", "relevance": 0.247441, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark J. Alles", "relevance": 0.245844, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Director of Strategic Partnerships", "relevance": 0.243761, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.241913, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.478538, "label": "positive"}, "text": "Emma Stone", "relevance": 0.241795, "type": "Person", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "FilmActor", "TVActor"], "name": "Emma Stone", "dbpedia_resource": "http://dbpedia.org/resource/Emma_Stone"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.23981, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CHRISTIE", "relevance": 0.237949, "type": "Company", "disambiguation": {"subtype": [], "name": "Christie's", "dbpedia_resource": "http://dbpedia.org/resource/Christie's"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Red Door", "relevance": 0.229789, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai", "relevance": 0.228311, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.540967, "label": "positive"}, "text": "Karen Wilder", "relevance": 0.225026, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.540967, "label": "positive"}, "text": "Robin", "relevance": 0.205301, "type": "Person"}], "sentiment": {"document": {"score": 0.783391, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Dr. Andrew Plump, Takeda And CVS Health", "keywords": [{"text": "CVS Health"}, {"text": "Plump"}, {"text": "Takeda"}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. Andrew Plump"}, {"type": "Company", "text": "CVS Health"}]}, "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "object": {"text": "Honored At Gilda's Club NYC's Benefit Gala", "keywords": [{"text": "Benefit Gala"}, {"text": "Club NYC"}, {"text": "Gilda"}], "entities": [{"type": "Person", "text": "Gilda"}, {"type": "Organization", "text": "Club NYC"}]}, "action": {"verb": {"text": "Be", "tense": "future"}, "text": "Be", "normalized": "Be"}}, {"subject": {"text": "Dr. Andrew Plump, Takeda And CVS Health", "keywords": [{"text": "CVS Health"}, {"text": "Plump"}, {"text": "Takeda"}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. Andrew Plump"}, {"type": "Company", "text": "CVS Health"}]}, "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "action": {"verb": {"text": "Honored", "tense": "past"}, "text": "To Be Honored", "normalized": "To Be Honored"}}, {"subject": {"text": "the founding cancer support organization", "keywords": [{"text": "cancer support organization"}]}, "sentence": " NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "Gilda Radner ,", "keywords": [{"text": "Gilda Radner"}], "entities": [{"type": "Person", "text": "Gilda Radner", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "FilmActor", "TheaterActor", "TVActor", "TVWriter"], "name": "Gilda Radner", "dbpedia_resource": "http://dbpedia.org/resource/Gilda_Radner"}}]}, "sentence": " NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "object": {"text": "its 23 rd Annual Benefit Gala", "keywords": [{"text": "rd Annual Benefit"}, {"text": "Gala"}]}, "action": {"verb": {"text": "host", "tense": "future"}, "text": "will host", "normalized": "will host"}}, {"subject": {"text": "dinner, a silent auction, live auction, award presentation, and an after-party", "keywords": [{"text": "silent auction"}, {"text": "award presentation"}, {"text": "live auction"}, {"text": "dinner"}]}, "sentence": " The evening will include dinner, a silent auction, live auction, award presentation, and an after-party.", "object": {"text": "The evening", "keywords": [{"text": "evening"}]}, "action": {"verb": {"text": "include", "tense": "future"}, "text": "will include", "normalized": "will include"}}, {"subject": {"text": "This year's distinguished honorees", "keywords": [{"text": "distinguished honorees"}]}, "sentence": " This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "object": {"text": "recognized for their impact", "keywords": [{"text": "impact"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "'s distinguished honorees", "keywords": [{"text": "honorees"}]}, "sentence": " This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "object": {"text": "for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer", "keywords": [{"text": "Red Door Award"}, {"text": "quality health care"}, {"text": "CVS Health"}, {"text": "lung cancer"}], "entities": [{"type": "Company", "text": "CVS Health"}]}, "action": {"verb": {"text": "recognize", "tense": "past"}, "text": "are recognized", "normalized": "be recognize"}}, {"subject": {"text": "The Red Door Award for Innovation", "keywords": [{"text": "Red Door Award"}, {"text": "Innovation"}]}, "sentence": " This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "object": {"text": "awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer", "keywords": [{"text": "quality health care"}, {"text": "CVS Health"}, {"text": "lung cancer"}, {"text": "cigarettes"}], "entities": [{"type": "Company", "text": "CVS Health"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Advances in Cancer Research Award", "keywords": [{"text": "Cancer Research Award"}, {"text": "Advances"}], "entities": [{"type": "JobTitle", "text": "Cancer Research Award"}]}, "sentence": " The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "object": {"text": "awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited,", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Andrew Plump"}, {"text": "Chief Medical"}, {"text": "Scientific Officer"}], "entities": [{"type": "Person", "text": "Dr. Andrew Plump"}, {"type": "JobTitle", "text": "Chief Medical and Scientific Officer"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "treatments", "keywords": [{"text": "treatments"}]}, "sentence": " The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "object": {"text": "the lives of cancer patients", "keywords": [{"text": "cancer patients"}, {"text": "lives"}], "entities": [{"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "have helped to improve", "normalized": "have help to improve"}}, {"subject": {"text": "Joanna Bull , Mandy Patinkin , Emma Stone , Karen Wilder and Robin & Alan Zweibel ", "keywords": [{"text": "Mandy Patinkin"}, {"text": "Joanna Bull"}, {"text": "Alan Zweibel"}, {"text": "Emma Stone"}], "entities": [{"type": "Person", "text": "Joanna Bull"}, {"type": "Person", "text": "Mandy Patinkin", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "FilmActor", "TheaterActor", "TVActor"], "name": "Mandy Patinkin", "dbpedia_resource": "http://dbpedia.org/resource/Mandy_Patinkin"}}, {"type": "Person", "text": "Emma Stone", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "FilmActor", "TVActor"], "name": "Emma Stone", "dbpedia_resource": "http://dbpedia.org/resource/Emma_Stone"}}, {"type": "Person", "text": "Karen Wilder"}, {"type": "Person", "text": "Robin"}, {"type": "Person", "text": "Alan Zweibel", "disambiguation": {"subtype": ["Actor", "AwardNominee", "FilmProducer", "TVActor", "FilmWriter", "TVWriter"], "name": "Alan Zweibel", "dbpedia_resource": "http://dbpedia.org/resource/Alan_Zweibel"}}]}, "sentence": " Honorary Chairs include, Joanna Bull , Mandy Patinkin , Emma Stone , Karen Wilder and Robin & Alan Zweibel .", "object": {"text": "Honorary Chairs", "keywords": [{"text": "Honorary Chairs"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Lydia Wickliffe Fenet , Senior Vice President, Global Director of Strategic Partnerships of CHRISTIE'S", "keywords": [{"text": "Lydia Wickliffe Fenet"}, {"text": "Senior Vice President"}, {"text": "Strategic Partnerships"}, {"text": "Global Director"}], "entities": [{"type": "Person", "text": "Lydia Wickliffe Fenet"}, {"type": "JobTitle", "text": "Senior Vice President"}, {"type": "JobTitle", "text": "Global Director of Strategic Partnerships"}, {"type": "Company", "text": "CHRISTIE", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Christie's", "dbpedia_resource": "http://dbpedia.org/resource/Christie's"}}]}, "sentence": " Lydia Wickliffe Fenet , Senior Vice President, Global Director of Strategic Partnerships of CHRISTIE'S will lead the live auction and appeal.", "object": {"text": "the live auction and appeal", "keywords": [{"text": "appeal"}, {"text": "live auction"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "will lead", "normalized": "will lead"}}, {"subject": {"text": "Diamond Benefactor", "keywords": [{"text": "Diamond Benefactor"}]}, "sentence": " Corporate sponsors include Diamond Benefactor: Celgene; Leadership Circle Benefactor: Slattery Family Foundation; Silver Benefactor: Takeda; Red Door Patrons: CVS Health, Eisai; and 18 Bronze Patrons.", "object": {"text": "Corporate sponsors", "keywords": [{"text": "Corporate sponsors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Gilda Radner", "relevance": 0.971875, "dbpedia_resource": "http://dbpedia.org/resource/Gilda_Radner"}, {"text": "Saturday Night Live", "relevance": 0.812789, "dbpedia_resource": "http://dbpedia.org/resource/Saturday_Night_Live"}, {"text": "Cancer", "relevance": 0.648227, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Gene Wilder", "relevance": 0.589883, "dbpedia_resource": "http://dbpedia.org/resource/Gene_Wilder"}, {"text": "Alan Zweibel", "relevance": 0.554239, "dbpedia_resource": "http://dbpedia.org/resource/Alan_Zweibel"}], "categories": [{"score": 0.365055, "label": "/shopping/auctions"}, {"score": 0.356271, "label": "/health and fitness/disease/cancer"}, {"score": 0.349069, "label": "/art and entertainment/humor"}], "relations": [{"type": "employedBy", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8 NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "score": 0.445145, "arguments": [{"text": "Gilda", "location": [57, 62], "entities": [{"type": "Person", "text": "Gilda Radner"}]}, {"text": "Club NYC", "location": [65, 73], "entities": [{"type": "Organization", "text": "Club NYC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.435551, "arguments": [{"text": "Innovation", "location": [549, 559], "entities": [{"type": "Organization", "text": "Innovation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "awarded", "location": [568, 575], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "agentOf", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.590777, "arguments": [{"text": "CVS Health", "location": [579, 589], "entities": [{"type": "Organization", "text": "CVS Health", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "awarded", "location": [568, 575], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "partOf", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.811379, "arguments": [{"text": "customers", "location": [616, 625], "entities": [{"type": "Organization", "text": "customers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "its", "location": [612, 615], "entities": [{"type": "Organization", "text": "CVS Health", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.670363, "arguments": [{"text": "Award", "location": [781, 786], "entities": [{"type": "EntertainmentAward", "text": "Award"}]}, {"text": "Andrew Plump", "location": [806, 818], "entities": [{"type": "Person", "text": "Andrew Plump"}]}]}, {"type": "affectedBy", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.834114, "arguments": [{"text": "Andrew Plump", "location": [806, 818], "entities": [{"type": "Person", "text": "Andrew Plump"}]}, {"text": "awarded", "location": [795, 802], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "agentOf", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.423896, "arguments": [{"text": "Scientific", "location": [852, 862], "entities": [{"type": "Organization", "text": "Scientific"}]}, {"text": "awarded", "location": [795, 802], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "locatedAt", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.944032, "arguments": [{"text": "M.D.", "location": [821, 825], "entities": [{"type": "GeopoliticalEntity", "text": "M.D."}]}, {"text": "Ph.D.", "location": [827, 832], "entities": [{"type": "GeopoliticalEntity", "text": "Ph.D."}]}]}, {"type": "employedBy", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.428396, "arguments": [{"text": "Officer", "location": [863, 870], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Scientific", "location": [852, 862], "entities": [{"type": "Organization", "text": "Scientific"}]}]}, {"type": "managerOf", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.578819, "arguments": [{"text": "Takeda", "location": [872, 878], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Pharmaceutical Company Limited", "location": [879, 909], "entities": [{"type": "Organization", "text": "Pharmaceutical Company Limited"}]}]}, {"type": "hasAttribute", "sentence": "The Advances in Cancer Research Award will be awarded to Andrew Plump , M.D., Ph.D., Chief Medical and Scientific Officer, Takeda Pharmaceutical Company Limited, for his leadership role in the development of treatments that have helped to improve the lives of cancer patients.", "score": 0.861353, "arguments": [{"text": "patients", "location": [1016, 1024], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1009, 1015], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "partOf", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8 NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "score": 0.857531, "arguments": [{"text": "Benefit Gala", "location": [76, 88], "entities": [{"type": "Organization", "text": "Benefit Gala", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Club NYC", "location": [65, 73], "entities": [{"type": "Organization", "text": "Club NYC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Lydia Wickliffe Fenet , Senior Vice President, Global Director of Strategic Partnerships of CHRISTIE'S will lead the live auction and appeal.", "score": 0.843326, "arguments": [{"text": "Global Director", "location": [1425, 1440], "entities": [{"type": "Person", "text": "Lydia Wickliffe Fenet"}]}, {"text": "Strategic Partnerships of CHRISTIE'S", "location": [1444, 1480], "entities": [{"type": "Organization", "text": "Strategic Partnerships of CHRISTIE'S"}]}]}, {"type": "managerOf", "sentence": "Corporate sponsors include Diamond Benefactor: Celgene; Leadership Circle Benefactor: Slattery Family Foundation; Silver Benefactor: Takeda; Red Door Patrons: CVS Health, Eisai; and 18 Bronze Patrons.", "score": 0.690516, "arguments": [{"text": "Benefactor", "location": [1594, 1604], "entities": [{"type": "Person", "text": "Benefactor"}]}, {"text": "Leadership Circle", "location": [1576, 1593], "entities": [{"type": "Organization", "text": "Leadership Circle", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "About Gilda's Club NYC: Gilda's Club NYC's mission is to support, educate, and empower cancer patients and their families free of charge by providing support groups, educational lectures and healthy lifestyle workshops at the West Village Clubhouse or at hospital partners around NYC.", "score": 0.87962, "arguments": [{"text": "patients", "location": [1815, 1823], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1808, 1814], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "locatedAt", "sentence": "About Gilda's Club NYC: Gilda's Club NYC's mission is to support, educate, and empower cancer patients and their families free of charge by providing support groups, educational lectures and healthy lifestyle workshops at the West Village Clubhouse or at hospital partners around NYC.", "score": 0.812675, "arguments": [{"text": "workshops", "location": [1930, 1939], "entities": [{"type": "Location", "text": "workshops"}]}, {"text": "West Village Clubhouse", "location": [1947, 1969], "entities": [{"type": "GeopoliticalEntity", "text": "West Village Clubhouse"}]}]}, {"type": "locatedAt", "sentence": "About Gilda's Club NYC: Gilda's Club NYC's mission is to support, educate, and empower cancer patients and their families free of charge by providing support groups, educational lectures and healthy lifestyle workshops at the West Village Clubhouse or at hospital partners around NYC.", "score": 0.351024, "arguments": [{"text": "partners", "location": [1985, 1993], "entities": [{"type": "Person", "text": "partners"}]}, {"text": "hospital", "location": [1976, 1984], "entities": [{"type": "Organization", "text": "hospital", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "www.gildasclubnyc.org View original content to download multimedia: http://www.prnewswire.com/news-releases/dr-andrew-plump-takeda-and-cvs-health-to-be-honored-at-gildas-club-nycs-benefit-gala-november-8-300741324.html SOURCE Gilda's Club NYC", "score": 0.57842, "arguments": [{"text": "Gilda", "location": [2232, 2237], "entities": [{"type": "Person", "text": "Gilda Radner"}]}, {"text": "Club NYC", "location": [2240, 2248], "entities": [{"type": "Organization", "text": "Club NYC"}]}]}, {"type": "employedBy", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8 NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "score": 0.328781, "arguments": [{"text": "Gilda", "location": [126, 131], "entities": [{"type": "Person", "text": "Gilda Radner"}]}, {"text": "Club NYC", "location": [134, 142], "entities": [{"type": "Organization", "text": "Club NYC"}]}]}, {"type": "employedBy", "sentence": "About Gilda's Club NYC: Gilda's Club NYC's mission is to support, educate, and empower cancer patients and their families free of charge by providing support groups, educational lectures and healthy lifestyle workshops at the West Village Clubhouse or at hospital partners around NYC.", "score": 0.29922, "arguments": [{"text": "Gilda", "location": [1727, 1732], "entities": [{"type": "Person", "text": "Gilda Radner"}]}, {"text": "Club NYC", "location": [1735, 1743], "entities": [{"type": "Organization", "text": "Club NYC"}]}]}, {"type": "hasAttribute", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8 NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "score": 0.839101, "arguments": [{"text": "Club NYC", "location": [134, 142], "entities": [{"type": "Organization", "text": "Club NYC"}]}, {"text": "GCNYC", "location": [144, 149], "entities": [{"type": "Ticker", "text": "GCNYC"}]}]}, {"type": "locatedAt", "sentence": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8 NEW YORK /PRNewswire/ -- Gilda's Club NYC (GCNYC), the founding cancer support organization named in honor of Saturday Night Live comedian, Gilda Radner , will host its 23 rd Annual Benefit Gala on November 8 th at Gotham Hall.", "score": 0.628757, "arguments": [{"text": "Gilda Radner", "location": [241, 253], "entities": [{"type": "Person", "text": "Gilda Radner"}]}, {"text": "Gotham Hall", "location": [316, 327], "entities": [{"type": "Organization", "text": "Gotham Hall", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.685899, "arguments": [{"text": "their", "location": [488, 493], "entities": [{"type": "Person", "text": "their"}]}, {"text": "community", "location": [515, 524], "entities": [{"type": "Person", "text": "community"}]}]}, {"type": "hasAttribute", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.886466, "arguments": [{"text": "community", "location": [515, 524], "entities": [{"type": "Person", "text": "community"}]}, {"text": "cancer", "location": [508, 514], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "awardedBy", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.419084, "arguments": [{"text": "Award", "location": [539, 544], "entities": [{"type": "EntertainmentAward", "text": "Award"}]}, {"text": "Innovation", "location": [549, 559], "entities": [{"type": "Organization", "text": "Innovation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "This year's distinguished honorees are recognized for their impact on the cancer community: The Red Door Award for Innovation will be awarded to CVS Health for its commitment to its customers in quality health care products and services and for discontinuing the sale of cigarettes, a leading cause of lung cancer.", "score": 0.34295, "arguments": [{"text": "Award", "location": [539, 544], "entities": [{"type": "EntertainmentAward", "text": "Award"}]}, {"text": "CVS Health", "location": [579, 589], "entities": [{"type": "Organization", "text": "CVS Health", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Club NYC", "sentiment": {"score": 0.564771, "label": "positive"}, "relevance": 0.974663}, {"text": "CVS Health", "sentiment": {"score": 0.450639, "label": "positive"}, "relevance": 0.791042}, {"text": "Gilda Radner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.788782}, {"text": "Dr. Andrew Plump", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.718119}, {"text": "Benefit Gala", "sentiment": {"score": 0.466879, "label": "positive"}, "relevance": 0.709337}, {"text": "Annual Benefit Gala", "sentiment": {"score": 0.342082, "label": "positive"}, "relevance": 0.707269}, {"text": "SOURCE Gilda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.702916}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.702177}, {"text": "cancer support organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.700734}, {"text": "Leadership Circle Benefactor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68761}, {"text": "Cancer Research Award", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.669735}, {"text": "Takeda And CVS", "sentiment": {"score": 0.591676, "label": "positive"}, "relevance": 0.665147}, {"text": "Night Live comedian", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662059}, {"text": "NEW YORK /PRNewswire/", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655163}, {"text": "Red Door Award", "sentiment": {"score": 0.43383, "label": "positive"}, "relevance": 0.649958}, {"text": "quality health care", "sentiment": {"score": 0.43383, "label": "positive"}, "relevance": 0.649373}, {"text": "Lydia Wickliffe Fenet", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64833}, {"text": "empower cancer patients", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637953}, {"text": "Red Door Patrons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636312}, {"text": "live auction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63454}, {"text": "Slattery Family Foundation", "sentiment": {"score": 0.507303, "label": "positive"}, "relevance": 0.62609}, {"text": "Mark J. Alles", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.615407}, {"text": "View original content", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610825}, {"text": "Senior Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606238}, {"text": "West Village Clubhouse", "sentiment": {"score": 0.326631, "label": "positive"}, "relevance": 0.600327}, {"text": "healthy lifestyle workshops", "sentiment": {"score": 0.326631, "label": "positive"}, "relevance": 0.591806}, {"text": "Diamond Benefactor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588422}, {"text": "Silver Benefactor", "sentiment": {"score": 0.396198, "label": "positive"}, "relevance": 0.587611}, {"text": "Gala Co-Chairs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579114}, {"text": "cancer community", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558275}, {"text": "lung cancer", "sentiment": {"score": -0.421781, "label": "negative"}, "relevance": 0.55372}, {"text": "Gotham Hall", "sentiment": {"score": 0.342082, "label": "positive"}, "relevance": 0.542383}, {"text": "Alan Zweibel", "sentiment": {"score": 0.540967, "label": "positive"}, "relevance": 0.539428}, {"text": "award presentation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5394}, {"text": "Mandy Patinkin", "sentiment": {"score": 0.206492, "label": "positive"}, "relevance": 0.537423}, {"text": "silent auction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534998}, {"text": "Bronze Patrons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529021}, {"text": "leadership role", "sentiment": {"score": -0.405776, "label": "negative"}, "relevance": 0.526853}, {"text": "investment banking", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52076}, {"text": "Celgene Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520705}, {"text": "advertising industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520566}, {"text": "Honorary Chairs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520045}, {"text": "support groups", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520014}, {"text": "Emma Stone", "sentiment": {"score": 0.478538, "label": "positive"}, "relevance": 0.518827}, {"text": "Joanna Bull", "sentiment": {"score": 0.425119, "label": "positive"}, "relevance": 0.517346}, {"text": "Chief Medical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517335}, {"text": "Karen Wilder", "sentiment": {"score": 0.540967, "label": "positive"}, "relevance": 0.51675}, {"text": "Scientific Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516323}, {"text": "Global Director", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515319}, {"text": "Laura Bartlett", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51415}]}, "extracted_metadata": {"sha1": "73fe428c0db3541cabb56abfd48851083b68e3ff", "filename": "1541007362621.zip-e863635c842dcfde6947f30c3ea14269.xml", "file_type": "json"}, "external_links": ["http://www.gildasclubnyc.org/gala2018", "http://www.prnewswire.com/news-releases/dr-andrew-plump-takeda-and-cvs-health-to-be-honored-at-gildas-club-nycs-benefit-gala-november-8-300741324.html", "http://www.gildasclubnyc.org/"], "title": "Dr. Andrew Plump, Takeda And CVS Health To Be Honored At Gilda's Club NYC's Benefit Gala, November 8", "forum_title": "Biotech Conferences & Event Coverage | BioSpace"}]}